<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Calcium channel blockers for primary Raynaud's phenomenon - Ennis, H - 2016 | Cochrane Library</title> <meta content="Calcium channel blockers for primary Raynaud's phenomenon - Ennis, H - 2016 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD002069.pub5/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Calcium channel blockers for primary Raynaud's phenomenon - Ennis, H - 2016 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD002069.pub5/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD002069.pub5" name="dc.identifier" scheme="DOI"/> <meta content="Calcium channel blockers for primary Raynaud's phenomenon" name="citation_title"/> <meta content="Holly Ennis" name="citation_author"/> <meta content="University of Edinburgh" name="citation_author_institution"/> <meta content="Michael Hughes" name="citation_author"/> <meta content="University of Manchester, Manchester Academic Health Science Centre" name="citation_author_institution"/> <meta content="Marina E Anderson" name="citation_author"/> <meta content="University of Liverpool" name="citation_author_institution"/> <meta content="Jack Wilkinson" name="citation_author"/> <meta content="University of Manchester, Manchester Academic Health Science Centre" name="citation_author_institution"/> <meta content="Ariane L Herrick" name="citation_author"/> <meta content="University of Manchester, Manchester Academic Health Science Centre" name="citation_author_institution"/> <meta content="ariane.herrick@manchester.ac.uk" name="citation_author_email"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="2" name="citation_issue"/> <meta content="10.1002/14651858.CD002069.pub5" name="citation_doi"/> <meta content="2016" name="citation_date"/> <meta content="2016/02/25" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD002069.pub5/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD002069.pub5/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD002069.pub5/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Calcium Channel Blockers [*therapeutic use]; Nicardipine [therapeutic use]; Nifedipine [therapeutic use]; Randomized Controlled Trials as Topic; Raynaud Disease [*drug therapy]" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002069.pub5&amp;doi=10.1002/14651858.CD002069.pub5&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002069.pub5&amp;doi=10.1002/14651858.CD002069.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002069.pub5&amp;doi=10.1002/14651858.CD002069.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002069.pub5&amp;doi=10.1002/14651858.CD002069.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002069.pub5&amp;doi=10.1002/14651858.CD002069.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002069.pub5&amp;doi=10.1002/14651858.CD002069.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002069.pub5&amp;doi=10.1002/14651858.CD002069.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002069.pub5&amp;doi=10.1002/14651858.CD002069.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002069.pub5&amp;doi=10.1002/14651858.CD002069.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002069.pub5&amp;doi=10.1002/14651858.CD002069.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002069.pub5&amp;doi=10.1002/14651858.CD002069.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002069.pub5&amp;doi=10.1002/14651858.CD002069.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002069.pub5&amp;doi=10.1002/14651858.CD002069.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002069.pub5&amp;doi=10.1002/14651858.CD002069.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002069.pub5&amp;doi=10.1002/14651858.CD002069.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002069.pub5&amp;doi=10.1002/14651858.CD002069.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002069.pub5&amp;doi=10.1002/14651858.CD002069.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002069.pub5&amp;doi=10.1002/14651858.CD002069.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002069.pub5&amp;doi=10.1002/14651858.CD002069.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002069.pub5&amp;doi=10.1002/14651858.CD002069.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002069.pub5&amp;doi=10.1002/14651858.CD002069.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002069.pub5&amp;doi=10.1002/14651858.CD002069.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002069.pub5&amp;doi=10.1002/14651858.CD002069.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774054000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774081000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000"}};Liferay.authToken="afU96cMv";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD002069\x2epub5\x26doi\x3d10\x2e1002\x2f14651858\x2eCD002069\x2epub5\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD002069\x2epub5\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD002069\x2epub5\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1559916434000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","de","ru","hr","fa","zh_HANS"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD002069.pub5",title:"Calcium channel blockers for primary Raynaud\u0027s phenomenon",firstPublishedDate:"Feb 25, 2016 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Vascular Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738735355000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=afU96cMv&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD002069.pub5&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD002069.pub5';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD002069.pub5/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD002069.pub5/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD002069.pub5%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD002069.pub5/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD002069.pub5/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD002069.pub5/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD002069.pub5/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD002069.PUB5" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;de&quot;,&quot;title&quot;:&quot;Laienverständliche Zusammenfassung&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]},{&quot;param&quot;: &quot;comments&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Comments&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD002069.pub5/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD002069.PUB5" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD002069.pub5/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD002069.pub5/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>2796 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD002069.pub5" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002069.pub5/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002069.pub5/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002069.pub5/full#CD002069-abs-0003"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002069.pub5/full#CD002069-sec-0091"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002069.pub5/full#CD002069-sec-0022"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002069.pub5/full#CD002069-sec-0023"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002069.pub5/full#CD002069-sec-0028"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002069.pub5/full#CD002069-sec-0029"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002069.pub5/full#CD002069-sec-0053"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002069.pub5/full#CD002069-sec-0081"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD002069.pub5/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002069.pub5/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002069.pub5/appendices#CD002069-sec-0096"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002069.pub5/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002069.pub5/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD002069.pub5/media/CDSR/CD002069/table_n/CD002069StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD002069.pub5/media/CDSR/CD002069/table_n/CD002069StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002069.pub5/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002069.pub5/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002069.pub5/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD002069.pub5/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD002069.pub5/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD002069.pub5/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2016 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD002069.pub5/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Calcium channel blockers for primary Raynaud's phenomenon</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD002069.pub5/information#CD002069-cr-0002">Holly Ennis</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD002069.pub5/information#CD002069-cr-0003">Michael Hughes</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD002069.pub5/information#CD002069-cr-0004">Marina E Anderson</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD002069.pub5/information#CD002069-cr-0005">Jack Wilkinson</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD002069.pub5/information#CD002069-cr-0006"><i class="icon corresponding-author fa fa-envelope"></i>Ariane L Herrick</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD002069.pub5/information/en#CD002069-sec-0106">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 25 February 2016 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD002069.pub5/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD002069.pub5">https://doi.org/10.1002/14651858.CD002069.pub5</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD002069-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD002069-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD002069-abs-0002">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD002069-abs-0008">فارسی</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD002069-abs-0010">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD002069-abs-0001" lang="en"> <section id="CD002069-sec-0001"> <h3 class="title" id="CD002069-sec-0001">Background</h3> <p>Calcium channel blockers are the most commonly prescribed drugs for people with primary Raynaud's phenomenon. Primary Raynaud's phenomenon is a common condition characterised by an exaggerated vasospastic response to cold or emotion: classically the digits (fingers and toes) turn white, then blue, then red. This is an update of the review first published in 2014. </p> </section> <section id="CD002069-sec-0002"> <h3 class="title" id="CD002069-sec-0002">Objectives</h3> <p>To assess the effects of different calcium channel blockers for primary Raynaud's phenomenon as determined by attack rates, severity scores, participant‐preference scores and physiological measurements. </p> </section> <section id="CD002069-sec-0003"> <h3 class="title" id="CD002069-sec-0003">Search methods</h3> <p>For this update the Cochrane Vascular Trial Search Co‐ordinator searched the Specialised Register (last searched January 2016) and the Cochrane Register of Studies (CENTRAL) (2015, Issue 12). In addition the TSC searched clinical trials databases. </p> </section> <section id="CD002069-sec-0004"> <h3 class="title" id="CD002069-sec-0004">Selection criteria</h3> <p>Randomised controlled trials evaluating the effects of oral calcium channel blockers for the treatment of primary Raynaud's phenomenon. </p> </section> <section id="CD002069-sec-0005"> <h3 class="title" id="CD002069-sec-0005">Data collection and analysis</h3> <p>Three review authors independently assessed the trials for inclusion and their quality, and extracted the data. Data extraction included adverse events. We contacted trial authors for missing data. </p> </section> <section id="CD002069-sec-0006"> <h3 class="title" id="CD002069-sec-0006">Main results</h3> <p>We included seven randomised trials with 296 participants. Four trials examined nifedipine and the remainder nicardipine. Comparisons were with placebo in six trials and with both dazoxiben and placebo in one trial (only the nifedipine versus placebo data were used within this review). Treatment with oral calcium channel blockers was minimally effective in primary Raynaud's phenomenon at decreasing the frequency of attacks (standardised mean difference of 0.23; 95% confidence interval (CI) 0.08 to 0.38, P = 0.003). This translates to 1.72 (95% CI 0.60 to 2.84) fewer attacks per week on calcium channel blockers compared to placebo. One trial provided details on duration of attacks reporting no statistically significant difference between the nicardipine and placebo groups (no P value reported). Only two trials provided any detail of statistical comparisons of (unvalidated) severity scores between treatment groups: one of these trials (60 participants) reported a mean severity score of 1.55 on placebo and 1.36 on nicardipine, difference 0.2 (95% CI of difference 0 to 0.4, no P value reported) and the other trial (three participants only with primary Raynaud's phenomenon) reported a median severity score of 2 on both nicardipine and placebo treatment (P &gt; 0.999) suggesting little effect on severity. Participant‐preference scores were included in four trials, but in only two were results specific to participants with primary Raynaud's phenomenon, and scoring systems differed between trials: scores differed between treatments in only one trial, in which 33% of participants on placebo and 73% on nifedipine reported improvement in symptoms (P &lt; 0.001). Physiological measurements were included as outcome measures in five trials (different methodologies were used in each): none of these trials found any statistically significant between‐treatment group differences. Treatment with calcium channel blockers appeared to be associated with a number of adverse reactions, including headaches, flushing and oedema (swelling). Overall, the trials were classed as being at low or unclear risk of bias; and the quality of the evidence presented was moderate for number of attacks, very low for duration of attacks, high for severity scores and low for patient preference scores. </p> </section> <section id="CD002069-sec-0007"> <h3 class="title" id="CD002069-sec-0007">Authors' conclusions</h3> <p>The randomised controlled trials included in this review provide moderate quality evidence that oral calcium channel blockers are minimally effective in the treatment of primary Raynaud's phenomenon as measured by the frequency of attacks and high‐quality evidence that they have little effect on severity. We are unable to comment on duration of attacks or on patient preference due to the very low and low quality of evidence as a result of small sample sizes in the included studies and the variable data quality of outcome measures. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD002069-abs-0003" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD002069-abs-0003">English</a> </li> <li class="section-language"> <a class="" href="full/de#CD002069-abs-0004">Deutsch</a> </li> <li class="section-language"> <a class="" href="full/es#CD002069-abs-0007">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD002069-abs-0009">فارسی</a> </li> <li class="section-language"> <a class="" href="full/hr#CD002069-abs-0006">Hrvatski</a> </li> <li class="section-language"> <a class="" href="full/ru#CD002069-abs-0005">Русский</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD002069-abs-0011">简体中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD002069-abs-0003" lang="en"> <h3>Calcium channel blockers for primary Raynaud's phenomenon</h3> <p>Background</p> <p>Raynaud's phenomenon is a disorder whereby blood vessels in the fingers and toes constrict and reduce blood flow, causing pain and discolouration. This is usually in response to cold exposure or emotional stress. In a small number of cases, Raynaud's phenomenon is associated with an underlying disease but, for most people, it is idiopathic (of uncertain cause, or 'primary'). Primary Raynaud's phenomenon is extremely common (especially in women), with one UK study suggesting that over 15% of the population are affected. For people with primary Raynaud's phenomenon who do not respond to conservative measures (e.g. keeping warm), calcium channel blockers represent the first line in drug treatment. Calcium channel blockers (sometimes called calcium antagonists) are drugs that affect the way calcium passes into certain muscle cells and they are the most commonly prescribed medication for primary Raynaud's phenomenon. </p> <p>Study characteristics and key results</p> <p>This review examined seven randomised trials which included 296 participants. Although overall all the trials were classed as being at low or unclear risk of bias, the sample size of the included trials was small and there was unclear reporting of outcomes. Two different calcium channel blockers were included: nifedipine and nicardipine. Comparisons in six trials were with placebo and in one trial with both placebo and another type of drug (although only data relating to the calcium channel blocker and placebo were used in this case). Treatment with oral calcium channel blockers was found to be minimally effective in primary Raynaud's phenomenon, reducing the frequency of attacks by around 1.7 attacks per person per week. One trial provided information on duration of attacks reporting no difference between the calcium channel blocker and placebo groups . Oral calcium channel blockers had no effect on severity scores in the two trials in which these were assessed. Only two trials reported preference scores (whereby participants are asked which treatment they prefer) specifically in those with primary Raynaud's phenomenon, and in only one of these was there a between‐treatment group difference (participants preferred nifedipine to placebo). Physiological measurements (for example measurement of finger blood flow) were performed in five trials, data could not be combined as the methods were too different, no differences found between calcium channel blocker and placebo treatment were seen in any trial. Treatment with calcium channel blockers was associated with a number of adverse events including headaches, flushing and ankle swelling. </p> <p>Quality of the evidence</p> <p>The results of this review were limited by the low number of participants recruited to the studies and by the limitations of currently used outcome measures. This review shows moderate quality evidence that oral calcium channel blockers are minimally effective in the treatment of primary Raynaud's phenomenon, as measured by the frequency of attacks, and high quality evidence that they have little effect on severity. We are unable to comment on duration of attacks and patient preference due to the very low and low quality of evidence provided by the trials in relation to these outcomes<b>.</b> </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD002069-sec-0091" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD002069-sec-0091"></div> <h3 class="title" id="CD002069-sec-0092">Implications for practice</h3> <section id="CD002069-sec-0092"> <p>There is moderate‐quality evidence that oral calcium channel blockers are minimally effective in the treatment of primary Raynaud's phenomenon as measured by the frequency of attacks. Participants experienced 1.72 (95% CI 0.60 to 2.84) fewer attacks per week on calcium channel blockers compared to placebo. This effect size was small, although may be greater with longer duration of treatment. There is high‐quality evidence that calcium channel blockers have little effect on severity. We are unable to comment on duration of attacks or on patient preference due to the very low and low quality of evidence available for these outcomes. The results of this review were limited by small sample size and variable overall data quality. </p> </section> <h3 class="title" id="CD002069-sec-0093">Implications for research</h3> <section id="CD002069-sec-0093"> <p>Given that calcium channel blockers are considered by most clinicians as a first‐line treatment for primary Raynaud's phenomenon (and are likely to be the comparator drug in clinical trials of new therapies), there is a need to better define their efficacy in adequately powered, well‐designed clinical trials. One concern is the current lack of validated, objective outcome measures for the assessment of Raynaud's attacks. The Raynaud's Condition Score (<a href="./references#CD002069-bbs2-0090" title="MerkelPA , HerlynK , MartinRW , AndersonJJ , MayesMD , BellP , et al. Scleroderma Clinical Trials Consortium. Measuring disease activity and functional status in patients with scleroderma and Raynaud's phenomenon. Arthritis and Rheumatism2002;46(9):2410‐20. ">Merkel 2002</a>) has been validated as an outcome measure for Raynaud's phenomenon and future clinical trials should at least include this. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD002069-sec-0022" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD002069-sec-0022"></div> <div class="table" id="CD002069-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Calcium channel blockers for primary Raynauds's phenomenon</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Calcium channel blockers for primary Raynauds's phenomenon</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> primary Raynaud's phenomenon<br/> <b>Setting:</b> hospital and hospital outpatient clinics<br/> <b>Intervention:</b> calcium channel blockers<br/> <b>Comparison:</b> placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with Calcium channel blockers</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number of attacks</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>The mean number of attacks in the intervention group was 0.23 standard deviations more (0.08 more to 0.38 more) than the placebo group. This translates to 1.72 (0.60 to 2.84) fewer attacks per week. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>296<br/> (7 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Duration of attacks</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>One study reported mean attack duration of 11 minutes in placebo group compared to 13 minutes in Nicardipine group. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16</p> <p>(1 RCT)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW <sup>2 3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Severity scores</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>One study reported difference in mean (95% CI) severity score of 0.2 (0 to 0.4) in favour of nicardipine for 60 patients in a crossover study. One study had a median score of 2 for patients taking both placebo and nicardipine. One reported 'no significant difference' with no other information. Unable to make between‐group comparisons using information reported in other studies. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>291</p> <p>(6 RCTs)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> HIGH </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Please see <a href="#CD002069-sec-0084">Quality of the evidence</a> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Patient preference scores</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>One study reported mean improvement score of 0.6 vs 2.2 in favour of nifedipine, P = 0.25. One reported that 73% of patients considered symptoms to have improved on nifedipine compared to 33% on placebo. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>185</p> <p>(4 RCTs)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>4 5</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; <b>OR:</b> Odds ratio; </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate quality:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low quality:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low quality:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Small crossover studies given high weighting due to high correlation between treatment periods. 95% CI for pooled treatment estimate consistent with negligible to moderate treatment effectiveness.<br/> <sup>2</sup> Information from one study of 13 participants.<br/> <sup>3</sup> Only group means provided. No information on variability of response, so unable to establish precision.<br/> <sup>4</sup> Information on variability missing. Substantively different methods of recording prevent pooling.<br/> <sup>5</sup> Two studies did not report separately for primary Raynaud's phenomenon participants. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD002069-sec-0023" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD002069-sec-0023"></div> <section id="CD002069-sec-0024"> <h3 class="title" id="CD002069-sec-0024">Description of the condition</h3> <p>Raynaud's phenomenon (episodic colour changes of the fingers and toes, usually in response to cold exposure or to emotional stress) may be primary (idiopathic); or secondary to a variety of conditions including connective tissue diseases (especially systemic sclerosis‐spectrum disorders), extrinsic vascular compression, use of vibratory equipment (hand‐arm‐vibration‐syndrome), hyperviscosity states, and certain drugs or chemicals (<a href="./references#CD002069-bbs2-0074" title="BlockJA , SequeiraW . Raynaud's phenomenon. Lancet2001;357(9273):2042‐8. ">Block 2001</a>). The classic colour changes are white (ischaemia), blue (deoxygenation) and red (reperfusion). </p> <p>This review of calcium channel blockers is concerned only with primary Raynaud's phenomenon. A key differentiating feature between primary and secondary Raynaud's phenomenon is that in primary Raynaud's phenomenon vasospasm is entirely reversible: irreversible tissue injury does not occur (<a href="./references#CD002069-bbs2-0087" title="LeRoyEC , MedsgerTAJr . Raynaud's phenomenon: a proposal for classification. Clinical and Experimental Rheumatology1992;10(5):458‐8. ">LeRoy 1992</a>). This is in contrast to the situation in systemic sclerosis, for example, when digital ischaemia can be severe and result in ulceration, scarring, and sometimes even gangrene. Although primary Raynaud's phenomenon is therefore often considered 'benign', it can cause considerable discomfort and distress in severely affected people, with a negative impact on perceived quality of life comparable to in patients with secondary Raynaud's (<a href="./references#CD002069-bbs2-0085" title="HughesM , SnapirA , WilkinsonJ , SnapirD , WigleyFM , HerrickAL . Prediction and impact of attacks of Raynaud's phenomenon, as judged by patient perception. Rheumatology (Oxford, England)2015;54(8):1443‐7. [10.1093/rheumatology/kev002. Epub 2015 Mar 9] ">Hughes 2015</a>). </p> <p>The pathogenesis of primary Raynaud's phenomenon is not known but it is likely that abnormalities in the neural control elements of vascular tone play a key role (<a href="./references#CD002069-bbs2-0081" title="HerrickAL . Pathogenesis of Raynaud's phenomenon. Rheumatology2005;44(5):587‐96. ">Herrick 2005</a>). Primary Raynaud's phenomenon is common; its reported prevalence varies, in part related to geography, being less prevalent in warmer climates (<a href="./references#CD002069-bbs2-0089" title="MaricqHR , CarpentierPH , WeinrichMC , KeilJE , PaleschY , BiroC , et al. Geographic variation in the prevalence of Raynaud's phenomenon: a 5 region comparison. Journal of Rheumatology1997;24(5):879‐89. ">Maricq 1997</a>). A UK general practice‐based study suggested that 15% to 19% of the population experience Raynaud's phenomenon (<a href="./references#CD002069-bbs2-0095" title="SilmanA , HolliganS , BrennanP , MaddisonP . Prevalence of symptoms of Raynaud's phenomenon in general practice. British Medical Journal1990;301(6752):590‐2. ">Silman 1990</a>), and of these most will have primary Raynaud's phenomenon. Women are more affected than men. </p> <p>A careful history and examination will usually indicate whether or not a person with Raynaud's phenomenon is likely to have the primary form or whether there is an underlying cause. The key investigations to perform are an erythrocyte sedimentation rate (normal in primary Raynaud's phenomenon), antinuclear antibody (ANA) (negative or only weakly positive in people with primary Raynaud's phenomenon) and nailfold capillaroscopy (normal in people with primary Raynaud's phenomenon) (<a href="./references#CD002069-bbs2-0087" title="LeRoyEC , MedsgerTAJr . Raynaud's phenomenon: a proposal for classification. Clinical and Experimental Rheumatology1992;10(5):458‐8. ">LeRoy 1992</a>; <a href="./references#CD002069-bbs2-0099" title="Wigley FM. Raynaud'sphenomenon . Clinical practice Raynaud's phenomenon. New England Journal of Medicine2002;347(13):1001‐8. ">Wigley 2002</a>). In the person with Raynaud's phenomenon, systemic sclerosis‐specific autoantibodies and nailfold capillaroscopic abnormalities are independent risk factors for systemic sclerosis (<a href="./references#CD002069-bbs2-0086" title="KoenigM , JoyalF , FritzlerMJ , RoussinA , AbrahamowiczM , BoireG , et al. Autoantibodies and microvascular damage are independent predictive factors for the progression of Raynaud's phenomenon to systemic sclerosis: a twenty year prospective study of 586 patients, with validation of proposed criteria for early systemic sclerosis. Arthritis and Rheumatism2008;58(12):3902‐12. ">Koenig 2008</a>). </p> <p>Many people with primary Raynaud's phenomenon are reassured to know that they do not have a serious underlying disease and respond well to conservative measures, including keeping warm and avoiding drugs with vasoconstrictive effects (<a href="./references#CD002069-bbs2-0097" title="SuterLG , MurabitoJM , FelsonDT , FraenkelL . The incidence and natural history of Raynaud's phenomenon in the community. Arthritis and Rheumatism2005;52(4):1259‐63. ">Suter 2005</a>). Smoking cessation should be strongly encouraged. Although smoking has not been proven to adversely affect primary Raynaud's phenomenon, it is likely that Raynaud's could be exacerbated via a variety of possible mechanisms including endothelial injury and increased plasma viscosity. Although some sufferers have reported benefit from temperature biofeedback, this was shown to be ineffective in a large randomised controlled trial of 313 participants with primary Raynaud's phenomenon (<a href="./references#CD002069-bbs2-0004" title="MaricqHR , JenningsJR , ValterI , FrederickM , ThompsonB , SmithEA , et al. Evaluation of treatment efficacy of Raynaud phenomenon by digital blood pressure response to cooling. Raynaud's Treatment Study Investigators. Vascular Medicine2000;5(3):135‐40. MiddaughSJ , HaythornthwaiteJA , ThompsonB , HillR , BrownKM , FreedmanRR , et al. The Raynaud's Treatment Study: biofeedback protocols and acquisition of temperature biofeedback skills. Applied Psychophysiology and Biofeedback2001;26(4):251‐78. Raynaud's Treatment Study Investigators. Comparison of sustained‐release nifedipine and temperature biofeedback for treatment of primary Raynaud phenomenon. Results from a randomized clinical trial with 1‐year follow‐up. Archives of Internal Medicine2000;160(8):1101‐8. ThompsonB , GellerNL , HunsbergerS , FrederickM , HillR , JacobRG , et al. Behavioral and pharmacologic interventions: the Raynaud's Treatment Study. Controlled Clinical Trials1999;20(1):52‐63. ">RTS 2000</a>). </p> <p>For those people with primary Raynaud's phenomenon who do not respond to conservative (i.e. 'non‐drug') measures, drug treatment will often be required. The aim of drug treatment is to prevent vasospasm or to increase vasodilation, or both. Despite the high prevalence of primary Raynaud's phenomenon, there have been relatively few controlled clinical trials, probably reflecting how difficult clinical trials of Raynaud's phenomenon are to set up. These have to be run over the winter months, there is a large placebo effect, and there is a lack of reliable outcome measures which are sensitive to change. The Raynaud's Condition Score, a self‐assessment score (0 to 10) which incorporates frequency, duration and severity of attacks, is increasingly used in clinical trials (<a href="./references#CD002069-bbs2-0090" title="MerkelPA , HerlynK , MartinRW , AndersonJJ , MayesMD , BellP , et al. Scleroderma Clinical Trials Consortium. Measuring disease activity and functional status in patients with scleroderma and Raynaud's phenomenon. Arthritis and Rheumatism2002;46(9):2410‐20. ">Merkel 2002</a>). </p> </section> <section id="CD002069-sec-0025"> <h3 class="title" id="CD002069-sec-0025">Description of the intervention</h3> <p>Calcium channel blockers are generally considered first‐line in the drug treatment of primary Raynaud's phenomenon, and are the group of drugs which have been most researched. A meta‐analysis published in 2005 concluded that calcium channel blockers had some effect in primary Raynaud's phenomenon in reducing the frequency and severity of Raynaud's attacks, but that this was small (2.8 to 5.0 fewer attacks per week with a 33% reduction in severity) (<a href="./references#CD002069-bbs2-0098" title="ThompsonAE , PopeJE . Calcium channel blockers for primary Raynaud's phenomenon: a meta‐analysis. Rheumatology2005;44(2):145‐50. ">Thompson 2005</a>). Other drugs currently used include angiotensin converting enzyme (ACE) inhibitors, angiotensin II receptor antagonists (<a href="./references#CD002069-bbs2-0075" title="DziadzioM , DentonCP , SmithR , HowellK , BlannA , BowersE , et al. Losartan therapy for Raynaud's phenomenon and scleroderma: clinical and biochemical findings in a fifteen‐week, randomized, parallel‐group, controlled trial. Arthritis and Rheumatism1999;42(12):2646‐55. ">Dziadzio 1999</a>) and alpha‐adrenergic blockers (<a href="./references#CD002069-bbs2-0080" title="HardingSE , TingeyPC , PopeJ , FenlonD , FurstD , SheaB , et al. Prazosin for Raynaud's phenomenon in progressive systemic sclerosis. Cochrane Database of Systematic Reviews1998, Issue 2. [DOI: 10.1002/14651858.CD000956] ">Harding 1998</a>). Intravenous prostanoids, used to treat severe exacerbations of digital ischaemia and ulceration in people with systemic sclerosis‐spectrum disorders, are not generally indicated for primary Raynaud's phenomenon. Similarly, surgical intervention, for example digital (palmar) sympathectomy, may be indicated for severe secondary Raynaud's phenomenon but not in people with primary Raynaud's phenomenon. </p> </section> <section id="CD002069-sec-0026"> <h3 class="title" id="CD002069-sec-0026">How the intervention might work</h3> <p>Calcium channel blockers bind to L‐type voltage‐gated calcium channels on cells, preventing influx of extracellular calcium. There are two main categories of calcium channel blocker: the dihydropyridines (these include nifedipine, nicardipine and amlodipine) and the non‐dihydropyridines (these include diltiazem and verapamil) (<a href="./references#CD002069-bbs2-0096" title="SturgillMG , SeiboldJR . Rational use of calcium‐channel antagonists in Raynaud's phenomenon. Current Opinion in Rheumatology1998;10(6):584‐8. ">Sturgill 1998</a>). The dihydropyridines are more selective for vascular smooth muscle than the non‐dihydropyridines: they are potent vasodilators with minimal effect on cardiac contractility or conduction, and can cause reflex tachycardia. In contrast, verapamil and diltiazem are negatively inotropic and can slow cardiac conduction, and are less potent vasodilators than the dihydropyridines. The calcium channel blockers which have been most studied in primary Raynaud's phenomenon, and forming the basis of this review, are dihydropyridines. </p> </section> <section id="CD002069-sec-0027"> <h3 class="title" id="CD002069-sec-0027">Why it is important to do this review</h3> <p>Calcium channel blockers are currently the most commonly prescribed drug treatment for primary Raynaud's phenomenon. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD002069-sec-0028" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD002069-sec-0028"></div> <p>To assess the effects of different calcium channel blockers for primary Raynaud's phenomenon as determined by attack rates, severity scores, participant‐preference scores and physiological measurements. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD002069-sec-0029" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD002069-sec-0029"></div> <section id="CD002069-sec-0030"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD002069-sec-0031"> <h4 class="title">Types of studies</h4> <p>We considered all randomised and blinded trials of the effects of orally‐administered calcium channel blockers compared with placebo, or other drug therapy, in people with primary Raynaud's phenomenon, using any method of randomisation. We included trials not analysed on an intention‐to‐treat basis, provided all randomised participants were accounted for. We included cross‐over trials only if they incorporated (a) a placebo or no‐treatment 'run‐in' of at least one week (or provided baseline data for quantification of the severity of the condition), and (b) a 'wash‐out' period of at least one week between treatment arms for all participants. We identified but did not include in the meta‐analyses studies in which primary and secondary cases could not be resolved. We also excluded open studies and single‐dose studies. There was no restriction on language, with publications in languages other than English translated and assessed for eligibility. </p> </section> <section id="CD002069-sec-0032"> <h4 class="title">Types of participants</h4> <p>Adults, over 18 years of age, with clinical features of primary Raynaud's phenomenon. Trials including a mixture of primary and secondary participants were included if primary participants could be identified and analysed separately. </p> </section> <section id="CD002069-sec-0033"> <h4 class="title">Types of interventions</h4> <p>Experimental intervention</p> <p> <ul id="CD002069-list-0001"> <li> <p>Oral administration of a calcium channel blocker.</p> </li> </ul> </p> <p>Comparator intervention</p> <p> <ul id="CD002069-list-0002"> <li> <p>Placebo</p> </li> <li> <p>Another pharmacological therapy</p> </li> <li> <p>Other treatments</p> </li> </ul> </p> </section> <section id="CD002069-sec-0034"> <h4 class="title">Types of outcome measures</h4> <section id="CD002069-sec-0035"> <h5 class="title">Primary outcomes</h5> <p> <ul id="CD002069-list-0003"> <li> <p>Attack rates of Raynaud's phenomenon</p> </li> <li> <p>Duration of attacks</p> </li> <li> <p>Severity scores</p> </li> <li> <p>Participant‐preference scores</p> </li> </ul> </p> </section> <section id="CD002069-sec-0036"> <h5 class="title">Secondary outcomes</h5> <p> <ul id="CD002069-list-0004"> <li> <p>Physiological measurements (including digital temperature and blood flow response to hand cooling) </p> </li> <li> <p>Adverse reactions (e.g. flushing, headache, tachycardia and ankle swelling), and withdrawal of medication. </p> </li> </ul> </p> </section> </section> </section> <section id="CD002069-sec-0037"> <h3 class="title">Search methods for identification of studies</h3> <p>There were no language or publication status restrictions.</p> <section id="CD002069-sec-0038"> <h4 class="title">Electronic searches</h4> <p>For this update the Cochrane Vascular Trial Search Co‐ordinator (TSC) searched the Specialised Register (January 2016). In addition the TSC searched the Cochrane Central Register of Controlled Trials (CENTRAL) 2015, Issue 12, part of the<i>Cochrane Library</i>, <a href="http://www.cochranelibrary.com/" target="_blank">www.cochranelibrary.com</a>. </p> <p>See <a href="./appendices#CD002069-sec-0097">Appendix 1</a> for details of the search strategy used to search CENTRAL. The Specialised Register is maintained by the TSC and is constructed from weekly electronic searches of MEDLINE, EMBASE, CINAHL, AMED, and through handsearching relevant journals. The full list of the databases, journals and conference proceedings which have been searched, as well as the search strategies used are described in the <a href="http://www.mrw.interscience.wiley.com/cochrane/clabout/articles/PVD/frame.html" target="_blank">Specialised Register</a> section of the Cochrane Vascular module in the<i>Cochrane Library</i> (<a href="http://www.cochranelibrary.com/" target="_blank">www.cochranelibrary.com</a>). </p> <p>The TSC searched the following trial databases (January 2016) for details of ongoing and unpublished studies using the term 'Raynaud'; </p> <p>World Health Organization International Clinical Trials Registry (<a href="http://apps.who.int/trialsearch/" target="_blank">apps.who.int/trialsearch/</a>)<br/> ClinicalTrials.gov (<a href="http://clinicaltrials.gov/" target="_blank">clinicaltrials.gov/</a>)<br/> ISRCTN registry (<a href="http://www.controlled-trials.com/" target="_blank">www.controlled‐trials.com/</a>)<br/> Nederlands Trials Register (<a href="http://www.trialregister.nl/trialreg/admin/rctsearch.asp" target="_blank">www.trialregister.nl/trialreg/admin/rctsearch.asp</a>) </p> </section> <section id="CD002069-sec-0039"> <h4 class="title">Searching other resources</h4> <p>For this update all trials listed under 'channel blockers' on <a href="http://www.trialscentral.org" target="_blank">www.trialscentral.org</a> were checked by the authors for reference to Raynaud's phenomenon (January 2016) with no relevant results found. </p> <p>Reference lists of relevant studies and reviews were also checked for potentially relevant studies. </p> </section> </section> <section id="CD002069-sec-0040"> <h3 class="title" id="CD002069-sec-0040">Data collection and analysis</h3> <section id="CD002069-sec-0041"> <h4 class="title">Selection of studies</h4> <p>We obtained full‐text articles of all the references identified and where necessary translated them. For this update, three review authors (MH, MA, AH) independently assessed the articles identified by the search. For the previous version, three review authors (HE, MA and AH) independently reviewed the articles and resolved disagreements by discussion and consensus. One review author (HE) contacted six trial authors or co‐authors for additional information on articles where data from subgroups could not be identified. We obtained email addresses by searching the relevant article, the author's or co‐author's most recent reference in PubMed, and 'Google'. We received replies from four. </p> </section> <section id="CD002069-sec-0042"> <h4 class="title">Data extraction and management</h4> <p>No new studies were identified for this update. In the previous version, three review authors (HE, MA and AH) independently reviewed each study identified as being eligible for inclusion, and extracted data from included studies using the Cochrane Peripheral Vascular Diseases Group 'Data Extraction Table'. This includes method of allocation, degree of blinding, power calculations, exclusions post‐randomisation, losses to follow‐up, source of funding, number of participants, age and sex of participants, inclusion and exclusion criteria, treatment, control group, duration of study, and outcome measures. We resolved disagreements by discussion and consensus. Where a trial was described in multiple publications, we extracted data from the most complete report. </p> </section> <section id="CD002069-sec-0043"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>No new studies were identified for this update. In the previous version, three review authors (HE, MA, AH) independently assessed trial quality as being at 'low', 'high' or 'unclear' risk of bias across the following areas, with reference to the criteria listed in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD002069-bbs2-0083" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>): </p> <p>1. Adequate sequence generation.<br/> 2. Allocation concealment.<br/> 3. Blinding of participants and personnel, and of outcome assessment.<br/> 4. Incomplete outcome data addressed.<br/> 5. Free of selective reporting.<br/> 6. Free of any other bias: i.e. if no other potential sources of bias were identified. </p> <p>We resolved disagreement about whether or not a trial fulfilled certain quality criteria by consensus, in discussion with the other review authors (HE, JW). All quality criteria ratings and supporting information are listed in the 'Risk of bias' tables (See <a href="./references#CD002069-sec-0112" title="">Characteristics of included studies</a>). </p> </section> <section id="CD002069-sec-0044"> <h4 class="title">Measures of treatment effect</h4> <p>The rate of attacks was the only outcome for which we deemed it appropriate to conduct meta‐analysis. The results of the remaining outcomes were described separately for each study. For attack rate, the measure of treatment effect used was the difference in mean number of Raynaud's attacks in the treatment and placebo groups. Mean numbers of attacks were reported over different time periods across the studies and, in the case of <a href="./references#CD002069-bbs2-0004" title="MaricqHR , JenningsJR , ValterI , FrederickM , ThompsonB , SmithEA , et al. Evaluation of treatment efficacy of Raynaud phenomenon by digital blood pressure response to cooling. Raynaud's Treatment Study Investigators. Vascular Medicine2000;5(3):135‐40. MiddaughSJ , HaythornthwaiteJA , ThompsonB , HillR , BrownKM , FreedmanRR , et al. The Raynaud's Treatment Study: biofeedback protocols and acquisition of temperature biofeedback skills. Applied Psychophysiology and Biofeedback2001;26(4):251‐78. Raynaud's Treatment Study Investigators. Comparison of sustained‐release nifedipine and temperature biofeedback for treatment of primary Raynaud phenomenon. Results from a randomized clinical trial with 1‐year follow‐up. Archives of Internal Medicine2000;160(8):1101‐8. ThompsonB , GellerNL , HunsbergerS , FrederickM , HillR , JacobRG , et al. Behavioral and pharmacologic interventions: the Raynaud's Treatment Study. Controlled Clinical Trials1999;20(1):52‐63. ">RTS 2000</a>, geometric means were reported, requiring log transformation in order to make the comparison. Accordingly, we used a standardised mean difference as the parameterisation of treatment effect, calculated by the difference in means divided by the pooled standard deviation (SD) for each study. We calculated the individual study estimates of treatment effect in R (<a href="./references#CD002069-bbs2-0092" title="R Development Core Team. R: A language and environment for statistical computing. Vienna: R Foundation for Statistical Computing, 2012. ">R Development Core Team 2012</a>). </p> <p>Numbers of attacks were reported on different scales across trials. We calculated standardised mean differences for each trial, in order to provide commensurable estimates of treatment effect. Following data synthesis, we transformed the pooled estimate of treatment effect and its 95% confidence interval to an interpretable scale by multiplying by a typical SD, obtained by pooling the standard deviations of the trials in the analysis (<a href="./references#CD002069-bbs2-0083" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>, section 12.6.4). </p> </section> <section id="CD002069-sec-0045"> <h4 class="title">Unit of analysis issues</h4> <p>The individual participant was the unit of analysis. For cross‐over trials, the calculation of standard errors accounted for the fact that observations were paired (<a href="./references#CD002069-bbs2-0076" title="ElbourneDR , AltmanDG , HigginsJPT , CurtinF , WorthingtonHV , VailA . Meta‐analyses involving cross‐over trials: methodological issues. International Journal of Epidemiology2002;31(1):140–9. ">Elbourne 2002</a>). </p> </section> <section id="CD002069-sec-0046"> <h4 class="title">Dealing with missing data</h4> <p>Five trials had missing data due to participant withdrawal. In three of these (<a href="./references#CD002069-bbs2-0005" title="SarkoziJ , BookmanAA , MahonW , RamsayC , DetskyAS , KeystoneEC . Nifedipine in the treatment of idiopathic Raynaud's syndrome. Journal of Rheumatology1986;13(2):331‐6. ">Sarkozi 1986</a>; <a href="./references#CD002069-bbs2-0006" title="VayssairatM , BoccalonH , GinestetMC , PriolletP , FrancoA , CarpentierP , et al. Controlled multicenter double‐blind trial of nicardipine in the treatment of primary Raynaud phenomenon. American Heart Journal1991;122(1 Suppl 2):352‐5. ">Vayssairat 1991</a>; <a href="./references#CD002069-bbs2-0007" title="WollersheimH , ThienT . Double‐blind placebo‐controlled crossover study of oral nicardipine in the treatment of Raynaud's phenomenon. Journal of Cardiovascular Pharmacology1991;18(6):813‐8. ">Wollersheim 1991</a>), participant‐level data were not reported and no intention‐to‐treat analysis had been attempted. For these studies, we analysed the data as reported based on all participants retained in the study. As such, we assumed missing data to be missing completely at random. In one of the five studies (<a href="./references#CD002069-bbs2-0001" title="EttingerWH , WiseRA , SchaffhauserD , WigleyFM . Controlled double‐blind trial of dazoxiben and nifedipine in the treatment of Raynaud's phenomenon. American Journal of Medicine1984;77(3):451‐6. MalametR , WiseRA , EttingerEH , WigleyFM . Nifedipine in the treatment of Raynaud's phenomenon. Evidence for inhibition of platelet activation. American Journal of Medicine1985;78(4):602‐8. WigleyFM , MalametR , WiseRA . Reproducibility of cold provocation in patients with Raynaud's phenomenon. Journal of Rheumatology1987;14(4):751‐5. ">Ettinger 1984</a>), participant‐level data were reported, but the number of participants with primary Raynaud's phenomenon was too low to permit meaningful imputation of missing values. One study (<a href="./references#CD002069-bbs2-0004" title="MaricqHR , JenningsJR , ValterI , FrederickM , ThompsonB , SmithEA , et al. Evaluation of treatment efficacy of Raynaud phenomenon by digital blood pressure response to cooling. Raynaud's Treatment Study Investigators. Vascular Medicine2000;5(3):135‐40. MiddaughSJ , HaythornthwaiteJA , ThompsonB , HillR , BrownKM , FreedmanRR , et al. The Raynaud's Treatment Study: biofeedback protocols and acquisition of temperature biofeedback skills. Applied Psychophysiology and Biofeedback2001;26(4):251‐78. Raynaud's Treatment Study Investigators. Comparison of sustained‐release nifedipine and temperature biofeedback for treatment of primary Raynaud phenomenon. Results from a randomized clinical trial with 1‐year follow‐up. Archives of Internal Medicine2000;160(8):1101‐8. ThompsonB , GellerNL , HunsbergerS , FrederickM , HillR , JacobRG , et al. Behavioral and pharmacologic interventions: the Raynaud's Treatment Study. Controlled Clinical Trials1999;20(1):52‐63. ">RTS 2000</a>), presented results having conducted multiple imputation to account for missing data. We used these results in the meta‐analysis. We contacted two authors for missing data or if the reporting of data was unclear and, while both responded, no additional data were available. </p> </section> <section id="CD002069-sec-0047"> <h4 class="title">Assessment of heterogeneity</h4> <p>We examined statistical heterogeneity using a Cochrane's Q test and the I² statistic (<a href="./references#CD002069-bbs2-0082" title="HigginsJPT , ThompsonSG , DeeksJJ , AltmanDG . Measuring inconsistency in meta‐analyses. British Medical Journal2003;327(7414):557‐60. ">Higgins 2003</a>). </p> <p>Wherever there appeared to be at least moderate statistical heterogeneity (I² &gt; 30%), we performed a random‐effects analysis to test the robustness of the results derived from the fixed‐effect approach. Assessment of clinical heterogeneity was based on consideration of the protocols of the studies included in the analysis and their individual estimates of effect size. Wherever we suspected clinical heterogeneity, we performed a sensitivity analysis by repeating the meta‐analysis with the clinically heterogeneous trials excluded. </p> </section> <section id="CD002069-sec-0048"> <h4 class="title">Assessment of reporting biases</h4> <p>We entered primary outcome data from all included studies into a funnel plot (trial effect against trial size) to investigate the possibility of publication bias, but the small number of studies (seven) meant that we could reach no definitive conclusion. </p> </section> <section id="CD002069-sec-0049"> <h4 class="title">Data synthesis</h4> <p>We performed statistical analysis according to the statistical guidelines provided for authors by the Cochrane Peripheral Vascular Diseases Group and from the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD002069-bbs2-0083" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>). </p> <p>We combined the results of five cross‐over trials and two parallel‐group trials in a meta‐analysis. These compared the calcium channel blockers nifedipine and nicardipine with placebo for the outcome 'frequency of Raynaud's attacks'. We calculated estimates of treatment effect and standard errors for each of the studies. </p> <p>Two studies did not report SDs for treatment or placebo groups, and did not contain sufficient information to calculate them. This did not, however, prevent the calculation of a standardised mean difference for either study. For one study (<a href="./references#CD002069-bbs2-0007" title="WollersheimH , ThienT . Double‐blind placebo‐controlled crossover study of oral nicardipine in the treatment of Raynaud's phenomenon. Journal of Cardiovascular Pharmacology1991;18(6):813‐8. ">Wollersheim 1991</a>), the mean difference in the number of attacks, and therefore the standardised difference, was zero. We made a conservative assumption that there was no correlation between participants' measurements, resulting in a larger standard error and a relatively low weighting for the study within the meta‐analysis. The other study (<a href="./references#CD002069-bbs2-0004" title="MaricqHR , JenningsJR , ValterI , FrederickM , ThompsonB , SmithEA , et al. Evaluation of treatment efficacy of Raynaud phenomenon by digital blood pressure response to cooling. Raynaud's Treatment Study Investigators. Vascular Medicine2000;5(3):135‐40. MiddaughSJ , HaythornthwaiteJA , ThompsonB , HillR , BrownKM , FreedmanRR , et al. The Raynaud's Treatment Study: biofeedback protocols and acquisition of temperature biofeedback skills. Applied Psychophysiology and Biofeedback2001;26(4):251‐78. Raynaud's Treatment Study Investigators. Comparison of sustained‐release nifedipine and temperature biofeedback for treatment of primary Raynaud phenomenon. Results from a randomized clinical trial with 1‐year follow‐up. Archives of Internal Medicine2000;160(8):1101‐8. ThompsonB , GellerNL , HunsbergerS , FrederickM , HillR , JacobRG , et al. Behavioral and pharmacologic interventions: the Raynaud's Treatment Study. Controlled Clinical Trials1999;20(1):52‐63. ">RTS 2000</a>) reported geometric means for attack rates and adjusted P values. By using the upper limit of the P value and log‐transforming the geometric means, it was possible to calculate a standard error for the difference in means. From this, it was possible to calculate a standardised mean difference and a corresponding standard error. </p> <p>We then pooled the estimates using the generic inverse variance method, whereby each study is weighted according to the precision of its estimate of treatment effect. Following synthesis, we back‐transformed the pooled estimate to an interpretable scale, as described above. </p> <p>We used a forest plot to show individual study estimates and 95% confidence intervals (CI), together with the pooled estimate. We conducted the meta‐analysis using the Review Manager 5 software (<a href="./references#CD002069-bbs2-0093" title="The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">RevMan 2012</a>) provided by The Cochrane Collaboration. </p> </section> <section id="CD002069-sec-0050"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We performed separate subgroup analyses for the nifedipine and nicardipine trials. To investigate the influence of clinically heterogeneous trials, we performed sensitivity analyses with the trials in question excluded. </p> </section> <section id="CD002069-sec-0051"> <h4 class="title">Sensitivity analysis</h4> <p>We conducted sensitivity analyses to examine the robustness of the meta‐analysis as follows: </p> <p> <ol id="CD002069-list-0005"> <li> <p>If a study had a discordant estimate of treatment effect, we repeated the analysis with that study removed. </p> </li> <li> <p>If a study had a weighting that seemed disproportionate to its sample size, we repeated the analysis with that study removed. </p> </li> </ol> </p> <p>If an analysis displayed at least moderate statistical heterogeneity (e.g. I² &gt; 30%) we repeated the analysis using the random‐effects method. </p> <section id="CD002069-sec-0052"> <h5 class="title">Summary of findings</h5> <p>We produced a summary of findings table for the comparison calcium channel blockers versus placebo for patients with primary Raynaud’s phenomenon, using the GRADEpro GDT software. We used the GRADE approach to assess the quality of the evidence for the primary review outcomes of attack rates, duration of attacks, severity and patient preference. We downgraded the evidence from 'high quality' for serious or very serious study limitations (risk of bias, indirectness and inconsistency of evidence, imprecision of effect estimates or potential publication bias) according to the <i>Cochrane Handbook for Systematic Reviews</i> (<a href="https://archie.cochrane.org/sections/documents/view?document=165401092620303738%26format=REVMAN#REF-Higgins-2011" target="_blank">Higgins 2011</a>) and the GRADE Working Group (<a href="./references#CD002069-bbs2-0077" title="GRADE Working Group. Grading quality of evidence and strength of recommendations. British Medical Journal2004;328:1490‐4. ">GRADE Working Group 2004</a>)<i>.</i> </p> <p>To highlight, the number of participants in the summary of findings table does differ from the outcome number of attacks because the participants in the crossover studies are counted twice by <a href="./references#CD002069-bbs2-0093" title="The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">RevMan 2012</a>, due to the fact that each acts as their own control. Our analysis takes this into account, by allowing for the correlation between the paired measurements in the crossover studies. </p> </section> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD002069-sec-0053" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD002069-sec-0053"></div> <section id="CD002069-sec-0054"> <h3 class="title">Description of studies</h3> <p>See: <a href="./references#CD002069-sec-0112" title="">Characteristics of included studies</a>; <a href="./references#CD002069-sec-0113" title="">Characteristics of excluded studies</a>. </p> <section id="CD002069-sec-0055"> <h4 class="title">Results of the search</h4> <p>See <a href="#CD002069-fig-0001">Figure 1</a>. </p> <div class="figure" id="CD002069-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram." data-id="CD002069-fig-0001" src="/cdsr/doi/10.1002/14651858.CD002069.pub5/media/CDSR/CD002069/image_n/nCD002069-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> </div> <p>For this update two additional studies were excluded.</p> </section> <section id="CD002069-sec-0056"> <h4 class="title">Included studies</h4> <p>Seven trials were eligible for inclusion in the review. Three trials had multiple publications (<a href="./references#CD002069-bbs2-0001" title="EttingerWH , WiseRA , SchaffhauserD , WigleyFM . Controlled double‐blind trial of dazoxiben and nifedipine in the treatment of Raynaud's phenomenon. American Journal of Medicine1984;77(3):451‐6. MalametR , WiseRA , EttingerEH , WigleyFM . Nifedipine in the treatment of Raynaud's phenomenon. Evidence for inhibition of platelet activation. American Journal of Medicine1985;78(4):602‐8. WigleyFM , MalametR , WiseRA . Reproducibility of cold provocation in patients with Raynaud's phenomenon. Journal of Rheumatology1987;14(4):751‐5. ">Ettinger 1984</a>; <a href="./references#CD002069-bbs2-0002" title="KahanA , AmorB , MenkesCJ . Nicardipine in the treatment of Raynaud's phenomenon. Revue du Rhumatisme et des Maladies Osteo‐Articulaires1987;54(6):487‐90. KahanA , AmorB , MenkesCJ , WeberS , GuerinF , DegeorgesM . Nicardipine in the treatment of Raynaud's phenomenon: A randomized double‐blind trial. Angiology1987;38(4):333‐7. ">Kahan 1987</a>; <a href="./references#CD002069-bbs2-0004" title="MaricqHR , JenningsJR , ValterI , FrederickM , ThompsonB , SmithEA , et al. Evaluation of treatment efficacy of Raynaud phenomenon by digital blood pressure response to cooling. Raynaud's Treatment Study Investigators. Vascular Medicine2000;5(3):135‐40. MiddaughSJ , HaythornthwaiteJA , ThompsonB , HillR , BrownKM , FreedmanRR , et al. The Raynaud's Treatment Study: biofeedback protocols and acquisition of temperature biofeedback skills. Applied Psychophysiology and Biofeedback2001;26(4):251‐78. Raynaud's Treatment Study Investigators. Comparison of sustained‐release nifedipine and temperature biofeedback for treatment of primary Raynaud phenomenon. Results from a randomized clinical trial with 1‐year follow‐up. Archives of Internal Medicine2000;160(8):1101‐8. ThompsonB , GellerNL , HunsbergerS , FrederickM , HillR , JacobRG , et al. Behavioral and pharmacologic interventions: the Raynaud's Treatment Study. Controlled Clinical Trials1999;20(1):52‐63. ">RTS 2000</a>). In two cases (<a href="./references#CD002069-bbs2-0001" title="EttingerWH , WiseRA , SchaffhauserD , WigleyFM . Controlled double‐blind trial of dazoxiben and nifedipine in the treatment of Raynaud's phenomenon. American Journal of Medicine1984;77(3):451‐6. MalametR , WiseRA , EttingerEH , WigleyFM . Nifedipine in the treatment of Raynaud's phenomenon. Evidence for inhibition of platelet activation. American Journal of Medicine1985;78(4):602‐8. WigleyFM , MalametR , WiseRA . Reproducibility of cold provocation in patients with Raynaud's phenomenon. Journal of Rheumatology1987;14(4):751‐5. ">Ettinger 1984</a>; <a href="./references#CD002069-bbs2-0004" title="MaricqHR , JenningsJR , ValterI , FrederickM , ThompsonB , SmithEA , et al. Evaluation of treatment efficacy of Raynaud phenomenon by digital blood pressure response to cooling. Raynaud's Treatment Study Investigators. Vascular Medicine2000;5(3):135‐40. MiddaughSJ , HaythornthwaiteJA , ThompsonB , HillR , BrownKM , FreedmanRR , et al. The Raynaud's Treatment Study: biofeedback protocols and acquisition of temperature biofeedback skills. Applied Psychophysiology and Biofeedback2001;26(4):251‐78. Raynaud's Treatment Study Investigators. Comparison of sustained‐release nifedipine and temperature biofeedback for treatment of primary Raynaud phenomenon. Results from a randomized clinical trial with 1‐year follow‐up. Archives of Internal Medicine2000;160(8):1101‐8. ThompsonB , GellerNL , HunsbergerS , FrederickM , HillR , JacobRG , et al. Behavioral and pharmacologic interventions: the Raynaud's Treatment Study. Controlled Clinical Trials1999;20(1):52‐63. ">RTS 2000</a>), we extracted data from the main trial report and in one case (<a href="./references#CD002069-bbs2-0002" title="KahanA , AmorB , MenkesCJ . Nicardipine in the treatment of Raynaud's phenomenon. Revue du Rhumatisme et des Maladies Osteo‐Articulaires1987;54(6):487‐90. KahanA , AmorB , MenkesCJ , WeberS , GuerinF , DegeorgesM . Nicardipine in the treatment of Raynaud's phenomenon: A randomized double‐blind trial. Angiology1987;38(4):333‐7. ">Kahan 1987</a>) from the English language publication. See the <a href="./references#CD002069-sec-0112" title="">Characteristics of included studies</a> table. The seven included trials had a total of 296 participants with primary Raynaud's phenomenon. The largest study (<a href="./references#CD002069-bbs2-0004" title="MaricqHR , JenningsJR , ValterI , FrederickM , ThompsonB , SmithEA , et al. Evaluation of treatment efficacy of Raynaud phenomenon by digital blood pressure response to cooling. Raynaud's Treatment Study Investigators. Vascular Medicine2000;5(3):135‐40. MiddaughSJ , HaythornthwaiteJA , ThompsonB , HillR , BrownKM , FreedmanRR , et al. The Raynaud's Treatment Study: biofeedback protocols and acquisition of temperature biofeedback skills. Applied Psychophysiology and Biofeedback2001;26(4):251‐78. Raynaud's Treatment Study Investigators. Comparison of sustained‐release nifedipine and temperature biofeedback for treatment of primary Raynaud phenomenon. Results from a randomized clinical trial with 1‐year follow‐up. Archives of Internal Medicine2000;160(8):1101‐8. ThompsonB , GellerNL , HunsbergerS , FrederickM , HillR , JacobRG , et al. Behavioral and pharmacologic interventions: the Raynaud's Treatment Study. Controlled Clinical Trials1999;20(1):52‐63. ">RTS 2000</a>) involved 158 participants, three (<a href="./references#CD002069-bbs2-0005" title="SarkoziJ , BookmanAA , MahonW , RamsayC , DetskyAS , KeystoneEC . Nifedipine in the treatment of idiopathic Raynaud's syndrome. Journal of Rheumatology1986;13(2):331‐6. ">Sarkozi 1986</a>; <a href="./references#CD002069-bbs2-0006" title="VayssairatM , BoccalonH , GinestetMC , PriolletP , FrancoA , CarpentierP , et al. Controlled multicenter double‐blind trial of nicardipine in the treatment of primary Raynaud phenomenon. American Heart Journal1991;122(1 Suppl 2):352‐5. ">Vayssairat 1991</a>; <a href="./references#CD002069-bbs2-0007" title="WollersheimH , ThienT . Double‐blind placebo‐controlled crossover study of oral nicardipine in the treatment of Raynaud's phenomenon. Journal of Cardiovascular Pharmacology1991;18(6):813‐8. ">Wollersheim 1991</a>) had between 69 and 16 participants and the remaining three studies (<a href="./references#CD002069-bbs2-0003" title="RodehefferRJ , RommerJA , WigleyF , SmithCR . Controlled double‐blind trial of nifedipine in the treatment of Raynaud's phenomenon. New England Journal of Medicine1983;308(15):880‐3. ">Rodeheffer 1983</a>; <a href="./references#CD002069-bbs2-0001" title="EttingerWH , WiseRA , SchaffhauserD , WigleyFM . Controlled double‐blind trial of dazoxiben and nifedipine in the treatment of Raynaud's phenomenon. American Journal of Medicine1984;77(3):451‐6. MalametR , WiseRA , EttingerEH , WigleyFM . Nifedipine in the treatment of Raynaud's phenomenon. Evidence for inhibition of platelet activation. American Journal of Medicine1985;78(4):602‐8. WigleyFM , MalametR , WiseRA . Reproducibility of cold provocation in patients with Raynaud's phenomenon. Journal of Rheumatology1987;14(4):751‐5. ">Ettinger 1984</a>; <a href="./references#CD002069-bbs2-0002" title="KahanA , AmorB , MenkesCJ . Nicardipine in the treatment of Raynaud's phenomenon. Revue du Rhumatisme et des Maladies Osteo‐Articulaires1987;54(6):487‐90. KahanA , AmorB , MenkesCJ , WeberS , GuerinF , DegeorgesM . Nicardipine in the treatment of Raynaud's phenomenon: A randomized double‐blind trial. Angiology1987;38(4):333‐7. ">Kahan 1987</a>) had six or fewer participants. The studies were all published between 1983 and 2000. </p> <p>In the 87 full‐text articles assessed for eligibility, we identified a total of 11 calcium channel blockers (48 studies involved nifedipine, eight nicardipine, five nisoldipine, four diltiazem, three felodipine, three flunarizine, two isradipine, one amlodipine, one verapamil, one phendilin and one drug in development, with some examining more than one calcium channel blocker). The seven included trials represented two different drugs (four nifedipine (<a href="./references#CD002069-bbs2-0003" title="RodehefferRJ , RommerJA , WigleyF , SmithCR . Controlled double‐blind trial of nifedipine in the treatment of Raynaud's phenomenon. New England Journal of Medicine1983;308(15):880‐3. ">Rodeheffer 1983</a>; <a href="./references#CD002069-bbs2-0001" title="EttingerWH , WiseRA , SchaffhauserD , WigleyFM . Controlled double‐blind trial of dazoxiben and nifedipine in the treatment of Raynaud's phenomenon. American Journal of Medicine1984;77(3):451‐6. MalametR , WiseRA , EttingerEH , WigleyFM . Nifedipine in the treatment of Raynaud's phenomenon. Evidence for inhibition of platelet activation. American Journal of Medicine1985;78(4):602‐8. WigleyFM , MalametR , WiseRA . Reproducibility of cold provocation in patients with Raynaud's phenomenon. Journal of Rheumatology1987;14(4):751‐5. ">Ettinger 1984</a>; <a href="./references#CD002069-bbs2-0005" title="SarkoziJ , BookmanAA , MahonW , RamsayC , DetskyAS , KeystoneEC . Nifedipine in the treatment of idiopathic Raynaud's syndrome. Journal of Rheumatology1986;13(2):331‐6. ">Sarkozi 1986</a>; <a href="./references#CD002069-bbs2-0004" title="MaricqHR , JenningsJR , ValterI , FrederickM , ThompsonB , SmithEA , et al. Evaluation of treatment efficacy of Raynaud phenomenon by digital blood pressure response to cooling. Raynaud's Treatment Study Investigators. Vascular Medicine2000;5(3):135‐40. MiddaughSJ , HaythornthwaiteJA , ThompsonB , HillR , BrownKM , FreedmanRR , et al. The Raynaud's Treatment Study: biofeedback protocols and acquisition of temperature biofeedback skills. Applied Psychophysiology and Biofeedback2001;26(4):251‐78. Raynaud's Treatment Study Investigators. Comparison of sustained‐release nifedipine and temperature biofeedback for treatment of primary Raynaud phenomenon. Results from a randomized clinical trial with 1‐year follow‐up. Archives of Internal Medicine2000;160(8):1101‐8. ThompsonB , GellerNL , HunsbergerS , FrederickM , HillR , JacobRG , et al. Behavioral and pharmacologic interventions: the Raynaud's Treatment Study. Controlled Clinical Trials1999;20(1):52‐63. ">RTS 2000</a>) and three nicardipine (<a href="./references#CD002069-bbs2-0002" title="KahanA , AmorB , MenkesCJ . Nicardipine in the treatment of Raynaud's phenomenon. Revue du Rhumatisme et des Maladies Osteo‐Articulaires1987;54(6):487‐90. KahanA , AmorB , MenkesCJ , WeberS , GuerinF , DegeorgesM . Nicardipine in the treatment of Raynaud's phenomenon: A randomized double‐blind trial. Angiology1987;38(4):333‐7. ">Kahan 1987</a>; <a href="./references#CD002069-bbs2-0006" title="VayssairatM , BoccalonH , GinestetMC , PriolletP , FrancoA , CarpentierP , et al. Controlled multicenter double‐blind trial of nicardipine in the treatment of primary Raynaud phenomenon. American Heart Journal1991;122(1 Suppl 2):352‐5. ">Vayssairat 1991</a>; <a href="./references#CD002069-bbs2-0007" title="WollersheimH , ThienT . Double‐blind placebo‐controlled crossover study of oral nicardipine in the treatment of Raynaud's phenomenon. Journal of Cardiovascular Pharmacology1991;18(6):813‐8. ">Wollersheim 1991</a>)). </p> <section id="CD002069-sec-0057"> <h5 class="title">Types of participants</h5> <p>Four trials had a mixture of participants with primary and secondary Raynaud's phenomenon (<a href="./references#CD002069-bbs2-0003" title="RodehefferRJ , RommerJA , WigleyF , SmithCR . Controlled double‐blind trial of nifedipine in the treatment of Raynaud's phenomenon. New England Journal of Medicine1983;308(15):880‐3. ">Rodeheffer 1983</a>; <a href="./references#CD002069-bbs2-0001" title="EttingerWH , WiseRA , SchaffhauserD , WigleyFM . Controlled double‐blind trial of dazoxiben and nifedipine in the treatment of Raynaud's phenomenon. American Journal of Medicine1984;77(3):451‐6. MalametR , WiseRA , EttingerEH , WigleyFM . Nifedipine in the treatment of Raynaud's phenomenon. Evidence for inhibition of platelet activation. American Journal of Medicine1985;78(4):602‐8. WigleyFM , MalametR , WiseRA . Reproducibility of cold provocation in patients with Raynaud's phenomenon. Journal of Rheumatology1987;14(4):751‐5. ">Ettinger 1984</a>; <a href="./references#CD002069-bbs2-0002" title="KahanA , AmorB , MenkesCJ . Nicardipine in the treatment of Raynaud's phenomenon. Revue du Rhumatisme et des Maladies Osteo‐Articulaires1987;54(6):487‐90. KahanA , AmorB , MenkesCJ , WeberS , GuerinF , DegeorgesM . Nicardipine in the treatment of Raynaud's phenomenon: A randomized double‐blind trial. Angiology1987;38(4):333‐7. ">Kahan 1987</a>; <a href="./references#CD002069-bbs2-0007" title="WollersheimH , ThienT . Double‐blind placebo‐controlled crossover study of oral nicardipine in the treatment of Raynaud's phenomenon. Journal of Cardiovascular Pharmacology1991;18(6):813‐8. ">Wollersheim 1991</a>). However, results were presented separately for the two groups. The remaining trials included only participants with primary Raynaud's phenomenon. The definitions of primary Raynaud's phenomenon used within the seven trials varied substantially: two referenced specific criteria (<a href="./references#CD002069-bbs2-0007" title="WollersheimH , ThienT . Double‐blind placebo‐controlled crossover study of oral nicardipine in the treatment of Raynaud's phenomenon. Journal of Cardiovascular Pharmacology1991;18(6):813‐8. ">Wollersheim 1991</a> used <a href="./references#CD002069-bbs2-0072" title="AllenEV , BrownGE . Raynaud's disease: a critical review of minimal requisites for diagnosis. American Journal of Medical Science1932;183(2):187‐200. ">Allen 1932</a>; <a href="./references#CD002069-bbs2-0006" title="VayssairatM , BoccalonH , GinestetMC , PriolletP , FrancoA , CarpentierP , et al. Controlled multicenter double‐blind trial of nicardipine in the treatment of primary Raynaud phenomenon. American Heart Journal1991;122(1 Suppl 2):352‐5. ">Vayssairat 1991</a> used <a href="./references#CD002069-bbs2-0091" title="PriolletP , VayssairatM , HoussetE . How to classify Raynaud's phenomenon. Long‐term follow up study of 73 cases. American Journal of Medicine1987;83(3):494‐8. ">Priollet 1987</a>), four provided descriptions only (<a href="./references#CD002069-bbs2-0003" title="RodehefferRJ , RommerJA , WigleyF , SmithCR . Controlled double‐blind trial of nifedipine in the treatment of Raynaud's phenomenon. New England Journal of Medicine1983;308(15):880‐3. ">Rodeheffer 1983</a>: symptomatic Raynaud's phenomenon relating to cold or stress without demonstrable systemic disease; <a href="./references#CD002069-bbs2-0001" title="EttingerWH , WiseRA , SchaffhauserD , WigleyFM . Controlled double‐blind trial of dazoxiben and nifedipine in the treatment of Raynaud's phenomenon. American Journal of Medicine1984;77(3):451‐6. MalametR , WiseRA , EttingerEH , WigleyFM . Nifedipine in the treatment of Raynaud's phenomenon. Evidence for inhibition of platelet activation. American Journal of Medicine1985;78(4):602‐8. WigleyFM , MalametR , WiseRA . Reproducibility of cold provocation in patients with Raynaud's phenomenon. Journal of Rheumatology1987;14(4):751‐5. ">Ettinger 1984</a>: episodic digital pallor and cyanosis on cold exposure without associated demonstrable disease; <a href="./references#CD002069-bbs2-0005" title="SarkoziJ , BookmanAA , MahonW , RamsayC , DetskyAS , KeystoneEC . Nifedipine in the treatment of idiopathic Raynaud's syndrome. Journal of Rheumatology1986;13(2):331‐6. ">Sarkozi 1986</a>: episodic, well‐demarcated, digital pallor or cyanosis in response to cold or emotional stimuli, episodes associated with numbness and pain and no clinical evidence of primary disease; and <a href="./references#CD002069-bbs2-0002" title="KahanA , AmorB , MenkesCJ . Nicardipine in the treatment of Raynaud's phenomenon. Revue du Rhumatisme et des Maladies Osteo‐Articulaires1987;54(6):487‐90. KahanA , AmorB , MenkesCJ , WeberS , GuerinF , DegeorgesM . Nicardipine in the treatment of Raynaud's phenomenon: A randomized double‐blind trial. Angiology1987;38(4):333‐7. ">Kahan 1987</a>: symptomatic, bilateral Raynaud's without secondary disease) while <a href="./references#CD002069-bbs2-0004" title="MaricqHR , JenningsJR , ValterI , FrederickM , ThompsonB , SmithEA , et al. Evaluation of treatment efficacy of Raynaud phenomenon by digital blood pressure response to cooling. Raynaud's Treatment Study Investigators. Vascular Medicine2000;5(3):135‐40. MiddaughSJ , HaythornthwaiteJA , ThompsonB , HillR , BrownKM , FreedmanRR , et al. The Raynaud's Treatment Study: biofeedback protocols and acquisition of temperature biofeedback skills. Applied Psychophysiology and Biofeedback2001;26(4):251‐78. Raynaud's Treatment Study Investigators. Comparison of sustained‐release nifedipine and temperature biofeedback for treatment of primary Raynaud phenomenon. Results from a randomized clinical trial with 1‐year follow‐up. Archives of Internal Medicine2000;160(8):1101‐8. ThompsonB , GellerNL , HunsbergerS , FrederickM , HillR , JacobRG , et al. Behavioral and pharmacologic interventions: the Raynaud's Treatment Study. Controlled Clinical Trials1999;20(1):52‐63. ">RTS 2000</a> screened participants for primary Raynaud's using colour charts (<a href="./references#CD002069-bbs2-0088" title="MaricqHR , WeinrichMC . Diagnosis of Raynaud's phenomenon assisted by colour charts. Journal of Rheumatology1988;15(3):454‐9. ">Maricq 1988</a>) and, along with <a href="./references#CD002069-bbs2-0006" title="VayssairatM , BoccalonH , GinestetMC , PriolletP , FrancoA , CarpentierP , et al. Controlled multicenter double‐blind trial of nicardipine in the treatment of primary Raynaud phenomenon. American Heart Journal1991;122(1 Suppl 2):352‐5. ">Vayssairat 1991</a>, used nailfold capillaroscopy, antinuclear antibody (ANA) testing and physical examinations to rule out secondary Raynaud's. In two trials (<a href="./references#CD002069-bbs2-0003" title="RodehefferRJ , RommerJA , WigleyF , SmithCR . Controlled double‐blind trial of nifedipine in the treatment of Raynaud's phenomenon. New England Journal of Medicine1983;308(15):880‐3. ">Rodeheffer 1983</a>; <a href="./references#CD002069-bbs2-0005" title="SarkoziJ , BookmanAA , MahonW , RamsayC , DetskyAS , KeystoneEC . Nifedipine in the treatment of idiopathic Raynaud's syndrome. Journal of Rheumatology1986;13(2):331‐6. ">Sarkozi 1986</a>), references to positive ANA titres or the development of digital gangrene amongst trial participants indicate that some participants diagnosed as primary Raynaud's phenomenon may not have fulfilled what are now the generally accepted criteria. </p> <p>Major exclusion criteria were secondary Raynaud's phenomenon in three trials (<a href="./references#CD002069-bbs2-0005" title="SarkoziJ , BookmanAA , MahonW , RamsayC , DetskyAS , KeystoneEC . Nifedipine in the treatment of idiopathic Raynaud's syndrome. Journal of Rheumatology1986;13(2):331‐6. ">Sarkozi 1986</a>; <a href="./references#CD002069-bbs2-0006" title="VayssairatM , BoccalonH , GinestetMC , PriolletP , FrancoA , CarpentierP , et al. Controlled multicenter double‐blind trial of nicardipine in the treatment of primary Raynaud phenomenon. American Heart Journal1991;122(1 Suppl 2):352‐5. ">Vayssairat 1991</a>; <a href="./references#CD002069-bbs2-0004" title="MaricqHR , JenningsJR , ValterI , FrederickM , ThompsonB , SmithEA , et al. Evaluation of treatment efficacy of Raynaud phenomenon by digital blood pressure response to cooling. Raynaud's Treatment Study Investigators. Vascular Medicine2000;5(3):135‐40. MiddaughSJ , HaythornthwaiteJA , ThompsonB , HillR , BrownKM , FreedmanRR , et al. The Raynaud's Treatment Study: biofeedback protocols and acquisition of temperature biofeedback skills. Applied Psychophysiology and Biofeedback2001;26(4):251‐78. Raynaud's Treatment Study Investigators. Comparison of sustained‐release nifedipine and temperature biofeedback for treatment of primary Raynaud phenomenon. Results from a randomized clinical trial with 1‐year follow‐up. Archives of Internal Medicine2000;160(8):1101‐8. ThompsonB , GellerNL , HunsbergerS , FrederickM , HillR , JacobRG , et al. Behavioral and pharmacologic interventions: the Raynaud's Treatment Study. Controlled Clinical Trials1999;20(1):52‐63. ">RTS 2000</a>) although, as above, there were concerns that some participants with secondary Raynaud's phenomenon may have been included in one of these studies (<a href="./references#CD002069-bbs2-0005" title="SarkoziJ , BookmanAA , MahonW , RamsayC , DetskyAS , KeystoneEC . Nifedipine in the treatment of idiopathic Raynaud's syndrome. Journal of Rheumatology1986;13(2):331‐6. ">Sarkozi 1986</a>). Participants were required to be free of vasoactive medications one week prior in one case (<a href="./references#CD002069-bbs2-0005" title="SarkoziJ , BookmanAA , MahonW , RamsayC , DetskyAS , KeystoneEC . Nifedipine in the treatment of idiopathic Raynaud's syndrome. Journal of Rheumatology1986;13(2):331‐6. ">Sarkozi 1986</a>), four weeks prior in one case (<a href="./references#CD002069-bbs2-0007" title="WollersheimH , ThienT . Double‐blind placebo‐controlled crossover study of oral nicardipine in the treatment of Raynaud's phenomenon. Journal of Cardiovascular Pharmacology1991;18(6):813‐8. ">Wollersheim 1991</a>), and at the start of the trial in four cases (<a href="./references#CD002069-bbs2-0003" title="RodehefferRJ , RommerJA , WigleyF , SmithCR . Controlled double‐blind trial of nifedipine in the treatment of Raynaud's phenomenon. New England Journal of Medicine1983;308(15):880‐3. ">Rodeheffer 1983</a>; <a href="./references#CD002069-bbs2-0001" title="EttingerWH , WiseRA , SchaffhauserD , WigleyFM . Controlled double‐blind trial of dazoxiben and nifedipine in the treatment of Raynaud's phenomenon. American Journal of Medicine1984;77(3):451‐6. MalametR , WiseRA , EttingerEH , WigleyFM . Nifedipine in the treatment of Raynaud's phenomenon. Evidence for inhibition of platelet activation. American Journal of Medicine1985;78(4):602‐8. WigleyFM , MalametR , WiseRA . Reproducibility of cold provocation in patients with Raynaud's phenomenon. Journal of Rheumatology1987;14(4):751‐5. ">Ettinger 1984</a>; <a href="./references#CD002069-bbs2-0002" title="KahanA , AmorB , MenkesCJ . Nicardipine in the treatment of Raynaud's phenomenon. Revue du Rhumatisme et des Maladies Osteo‐Articulaires1987;54(6):487‐90. KahanA , AmorB , MenkesCJ , WeberS , GuerinF , DegeorgesM . Nicardipine in the treatment of Raynaud's phenomenon: A randomized double‐blind trial. Angiology1987;38(4):333‐7. ">Kahan 1987</a>; <a href="./references#CD002069-bbs2-0006" title="VayssairatM , BoccalonH , GinestetMC , PriolletP , FrancoA , CarpentierP , et al. Controlled multicenter double‐blind trial of nicardipine in the treatment of primary Raynaud phenomenon. American Heart Journal1991;122(1 Suppl 2):352‐5. ">Vayssairat 1991</a>). <a href="./references#CD002069-bbs2-0001" title="EttingerWH , WiseRA , SchaffhauserD , WigleyFM . Controlled double‐blind trial of dazoxiben and nifedipine in the treatment of Raynaud's phenomenon. American Journal of Medicine1984;77(3):451‐6. MalametR , WiseRA , EttingerEH , WigleyFM . Nifedipine in the treatment of Raynaud's phenomenon. Evidence for inhibition of platelet activation. American Journal of Medicine1985;78(4):602‐8. WigleyFM , MalametR , WiseRA . Reproducibility of cold provocation in patients with Raynaud's phenomenon. Journal of Rheumatology1987;14(4):751‐5. ">Ettinger 1984</a> also required participants not to take non‐steroidal anti‐inflammatory drugs (NSAIDS), aspirin and drugs affecting the nervous system. One trial did not list medications as exclusion criteria (<a href="./references#CD002069-bbs2-0004" title="MaricqHR , JenningsJR , ValterI , FrederickM , ThompsonB , SmithEA , et al. Evaluation of treatment efficacy of Raynaud phenomenon by digital blood pressure response to cooling. Raynaud's Treatment Study Investigators. Vascular Medicine2000;5(3):135‐40. MiddaughSJ , HaythornthwaiteJA , ThompsonB , HillR , BrownKM , FreedmanRR , et al. The Raynaud's Treatment Study: biofeedback protocols and acquisition of temperature biofeedback skills. Applied Psychophysiology and Biofeedback2001;26(4):251‐78. Raynaud's Treatment Study Investigators. Comparison of sustained‐release nifedipine and temperature biofeedback for treatment of primary Raynaud phenomenon. Results from a randomized clinical trial with 1‐year follow‐up. Archives of Internal Medicine2000;160(8):1101‐8. ThompsonB , GellerNL , HunsbergerS , FrederickM , HillR , JacobRG , et al. Behavioral and pharmacologic interventions: the Raynaud's Treatment Study. Controlled Clinical Trials1999;20(1):52‐63. ">RTS 2000</a>). </p> <p>Baseline frequency of Raynaud's attacks was provided in only one trial (<a href="./references#CD002069-bbs2-0004" title="MaricqHR , JenningsJR , ValterI , FrederickM , ThompsonB , SmithEA , et al. Evaluation of treatment efficacy of Raynaud phenomenon by digital blood pressure response to cooling. Raynaud's Treatment Study Investigators. Vascular Medicine2000;5(3):135‐40. MiddaughSJ , HaythornthwaiteJA , ThompsonB , HillR , BrownKM , FreedmanRR , et al. The Raynaud's Treatment Study: biofeedback protocols and acquisition of temperature biofeedback skills. Applied Psychophysiology and Biofeedback2001;26(4):251‐78. Raynaud's Treatment Study Investigators. Comparison of sustained‐release nifedipine and temperature biofeedback for treatment of primary Raynaud phenomenon. Results from a randomized clinical trial with 1‐year follow‐up. Archives of Internal Medicine2000;160(8):1101‐8. ThompsonB , GellerNL , HunsbergerS , FrederickM , HillR , JacobRG , et al. Behavioral and pharmacologic interventions: the Raynaud's Treatment Study. Controlled Clinical Trials1999;20(1):52‐63. ">RTS 2000</a>; as an average daily attack rate during the previous cold season) and five trials had a minimum attack rate as an inclusion criterion. Participants were required to have at least two attacks per day during the previous cold season in one trial (<a href="./references#CD002069-bbs2-0004" title="MaricqHR , JenningsJR , ValterI , FrederickM , ThompsonB , SmithEA , et al. Evaluation of treatment efficacy of Raynaud phenomenon by digital blood pressure response to cooling. Raynaud's Treatment Study Investigators. Vascular Medicine2000;5(3):135‐40. MiddaughSJ , HaythornthwaiteJA , ThompsonB , HillR , BrownKM , FreedmanRR , et al. The Raynaud's Treatment Study: biofeedback protocols and acquisition of temperature biofeedback skills. Applied Psychophysiology and Biofeedback2001;26(4):251‐78. Raynaud's Treatment Study Investigators. Comparison of sustained‐release nifedipine and temperature biofeedback for treatment of primary Raynaud phenomenon. Results from a randomized clinical trial with 1‐year follow‐up. Archives of Internal Medicine2000;160(8):1101‐8. ThompsonB , GellerNL , HunsbergerS , FrederickM , HillR , JacobRG , et al. Behavioral and pharmacologic interventions: the Raynaud's Treatment Study. Controlled Clinical Trials1999;20(1):52‐63. ">RTS 2000</a>), one attack per day in two trials (<a href="./references#CD002069-bbs2-0001" title="EttingerWH , WiseRA , SchaffhauserD , WigleyFM . Controlled double‐blind trial of dazoxiben and nifedipine in the treatment of Raynaud's phenomenon. American Journal of Medicine1984;77(3):451‐6. MalametR , WiseRA , EttingerEH , WigleyFM . Nifedipine in the treatment of Raynaud's phenomenon. Evidence for inhibition of platelet activation. American Journal of Medicine1985;78(4):602‐8. WigleyFM , MalametR , WiseRA . Reproducibility of cold provocation in patients with Raynaud's phenomenon. Journal of Rheumatology1987;14(4):751‐5. ">Ettinger 1984</a>; <a href="./references#CD002069-bbs2-0007" title="WollersheimH , ThienT . Double‐blind placebo‐controlled crossover study of oral nicardipine in the treatment of Raynaud's phenomenon. Journal of Cardiovascular Pharmacology1991;18(6):813‐8. ">Wollersheim 1991</a>), two per week in one trial (<a href="./references#CD002069-bbs2-0005" title="SarkoziJ , BookmanAA , MahonW , RamsayC , DetskyAS , KeystoneEC . Nifedipine in the treatment of idiopathic Raynaud's syndrome. Journal of Rheumatology1986;13(2):331‐6. ">Sarkozi 1986</a>) and three per week in one trial (<a href="./references#CD002069-bbs2-0006" title="VayssairatM , BoccalonH , GinestetMC , PriolletP , FrancoA , CarpentierP , et al. Controlled multicenter double‐blind trial of nicardipine in the treatment of primary Raynaud phenomenon. American Heart Journal1991;122(1 Suppl 2):352‐5. ">Vayssairat 1991</a>). Two trials (<a href="./references#CD002069-bbs2-0003" title="RodehefferRJ , RommerJA , WigleyF , SmithCR . Controlled double‐blind trial of nifedipine in the treatment of Raynaud's phenomenon. New England Journal of Medicine1983;308(15):880‐3. ">Rodeheffer 1983</a>; <a href="./references#CD002069-bbs2-0002" title="KahanA , AmorB , MenkesCJ . Nicardipine in the treatment of Raynaud's phenomenon. Revue du Rhumatisme et des Maladies Osteo‐Articulaires1987;54(6):487‐90. KahanA , AmorB , MenkesCJ , WeberS , GuerinF , DegeorgesM . Nicardipine in the treatment of Raynaud's phenomenon: A randomized double‐blind trial. Angiology1987;38(4):333‐7. ">Kahan 1987</a>) did not stipulate a minimum attack rate. </p> <p>One study (<a href="./references#CD002069-bbs2-0003" title="RodehefferRJ , RommerJA , WigleyF , SmithCR . Controlled double‐blind trial of nifedipine in the treatment of Raynaud's phenomenon. New England Journal of Medicine1983;308(15):880‐3. ">Rodeheffer 1983</a>) had only female participants and four trials had more female than male participants (<a href="./references#CD002069-bbs2-0001" title="EttingerWH , WiseRA , SchaffhauserD , WigleyFM . Controlled double‐blind trial of dazoxiben and nifedipine in the treatment of Raynaud's phenomenon. American Journal of Medicine1984;77(3):451‐6. MalametR , WiseRA , EttingerEH , WigleyFM . Nifedipine in the treatment of Raynaud's phenomenon. Evidence for inhibition of platelet activation. American Journal of Medicine1985;78(4):602‐8. WigleyFM , MalametR , WiseRA . Reproducibility of cold provocation in patients with Raynaud's phenomenon. Journal of Rheumatology1987;14(4):751‐5. ">Ettinger 1984</a>; <a href="./references#CD002069-bbs2-0005" title="SarkoziJ , BookmanAA , MahonW , RamsayC , DetskyAS , KeystoneEC . Nifedipine in the treatment of idiopathic Raynaud's syndrome. Journal of Rheumatology1986;13(2):331‐6. ">Sarkozi 1986</a>; <a href="./references#CD002069-bbs2-0006" title="VayssairatM , BoccalonH , GinestetMC , PriolletP , FrancoA , CarpentierP , et al. Controlled multicenter double‐blind trial of nicardipine in the treatment of primary Raynaud phenomenon. American Heart Journal1991;122(1 Suppl 2):352‐5. ">Vayssairat 1991</a>; <a href="./references#CD002069-bbs2-0004" title="MaricqHR , JenningsJR , ValterI , FrederickM , ThompsonB , SmithEA , et al. Evaluation of treatment efficacy of Raynaud phenomenon by digital blood pressure response to cooling. Raynaud's Treatment Study Investigators. Vascular Medicine2000;5(3):135‐40. MiddaughSJ , HaythornthwaiteJA , ThompsonB , HillR , BrownKM , FreedmanRR , et al. The Raynaud's Treatment Study: biofeedback protocols and acquisition of temperature biofeedback skills. Applied Psychophysiology and Biofeedback2001;26(4):251‐78. Raynaud's Treatment Study Investigators. Comparison of sustained‐release nifedipine and temperature biofeedback for treatment of primary Raynaud phenomenon. Results from a randomized clinical trial with 1‐year follow‐up. Archives of Internal Medicine2000;160(8):1101‐8. ThompsonB , GellerNL , HunsbergerS , FrederickM , HillR , JacobRG , et al. Behavioral and pharmacologic interventions: the Raynaud's Treatment Study. Controlled Clinical Trials1999;20(1):52‐63. ">RTS 2000</a>), which would reflect the prevalence of primary Raynaud's phenomenon in the population. In two trials (<a href="./references#CD002069-bbs2-0002" title="KahanA , AmorB , MenkesCJ . Nicardipine in the treatment of Raynaud's phenomenon. Revue du Rhumatisme et des Maladies Osteo‐Articulaires1987;54(6):487‐90. KahanA , AmorB , MenkesCJ , WeberS , GuerinF , DegeorgesM . Nicardipine in the treatment of Raynaud's phenomenon: A randomized double‐blind trial. Angiology1987;38(4):333‐7. ">Kahan 1987</a>; <a href="./references#CD002069-bbs2-0007" title="WollersheimH , ThienT . Double‐blind placebo‐controlled crossover study of oral nicardipine in the treatment of Raynaud's phenomenon. Journal of Cardiovascular Pharmacology1991;18(6):813‐8. ">Wollersheim 1991</a>), no breakdown by gender was available for participants with primary Raynaud's phenomenon. The age range across the studies also reflected the age distribution of Raynaud's phenomenon in the population by including both young and older participants: three trials included participants aged 18 to 65 years, one trial 18 to 68 years, one trial 20 to 49 years and in two cases the mean age was 39 and 45 years. Ethnicity data were provided in only one trial (<a href="./references#CD002069-bbs2-0004" title="MaricqHR , JenningsJR , ValterI , FrederickM , ThompsonB , SmithEA , et al. Evaluation of treatment efficacy of Raynaud phenomenon by digital blood pressure response to cooling. Raynaud's Treatment Study Investigators. Vascular Medicine2000;5(3):135‐40. MiddaughSJ , HaythornthwaiteJA , ThompsonB , HillR , BrownKM , FreedmanRR , et al. The Raynaud's Treatment Study: biofeedback protocols and acquisition of temperature biofeedback skills. Applied Psychophysiology and Biofeedback2001;26(4):251‐78. Raynaud's Treatment Study Investigators. Comparison of sustained‐release nifedipine and temperature biofeedback for treatment of primary Raynaud phenomenon. Results from a randomized clinical trial with 1‐year follow‐up. Archives of Internal Medicine2000;160(8):1101‐8. ThompsonB , GellerNL , HunsbergerS , FrederickM , HillR , JacobRG , et al. Behavioral and pharmacologic interventions: the Raynaud's Treatment Study. Controlled Clinical Trials1999;20(1):52‐63. ">RTS 2000</a>). All seven trials were based within a hospital setting: three in the USA, two in France, one in Canada and one in the Netherlands. Five trials were conducted during the cold season, one trial ran from January to June (<a href="./references#CD002069-bbs2-0002" title="KahanA , AmorB , MenkesCJ . Nicardipine in the treatment of Raynaud's phenomenon. Revue du Rhumatisme et des Maladies Osteo‐Articulaires1987;54(6):487‐90. KahanA , AmorB , MenkesCJ , WeberS , GuerinF , DegeorgesM . Nicardipine in the treatment of Raynaud's phenomenon: A randomized double‐blind trial. Angiology1987;38(4):333‐7. ">Kahan 1987</a>) and in one trial (<a href="./references#CD002069-bbs2-0007" title="WollersheimH , ThienT . Double‐blind placebo‐controlled crossover study of oral nicardipine in the treatment of Raynaud's phenomenon. Journal of Cardiovascular Pharmacology1991;18(6):813‐8. ">Wollersheim 1991</a>) the timing was not specified. Data on smoking habits were provided in only one trial (<a href="./references#CD002069-bbs2-0005" title="SarkoziJ , BookmanAA , MahonW , RamsayC , DetskyAS , KeystoneEC . Nifedipine in the treatment of idiopathic Raynaud's syndrome. Journal of Rheumatology1986;13(2):331‐6. ">Sarkozi 1986</a>). </p> </section> <section id="CD002069-sec-0058"> <h5 class="title">Interventions</h5> <p>The included trials represented two different drugs: four trials with nifedipine and three with nicardipine. Four trials compared a calcium channel blocker with placebo using a cross‐over design, two trials compared a calcium channel blocker with placebo using a parallel design and one study compared a calcium channel blocker with another active drug (dazoxiben) and with placebo using a cross‐over design (<a href="./references#CD002069-bbs2-0001" title="EttingerWH , WiseRA , SchaffhauserD , WigleyFM . Controlled double‐blind trial of dazoxiben and nifedipine in the treatment of Raynaud's phenomenon. American Journal of Medicine1984;77(3):451‐6. MalametR , WiseRA , EttingerEH , WigleyFM . Nifedipine in the treatment of Raynaud's phenomenon. Evidence for inhibition of platelet activation. American Journal of Medicine1985;78(4):602‐8. WigleyFM , MalametR , WiseRA . Reproducibility of cold provocation in patients with Raynaud's phenomenon. Journal of Rheumatology1987;14(4):751‐5. ">Ettinger 1984</a>). </p> </section> <section id="CD002069-sec-0059"> <h5 class="title">Length of studies</h5> <p>The duration of the treatment periods varied between studies: two weeks (<a href="./references#CD002069-bbs2-0003" title="RodehefferRJ , RommerJA , WigleyF , SmithCR . Controlled double‐blind trial of nifedipine in the treatment of Raynaud's phenomenon. New England Journal of Medicine1983;308(15):880‐3. ">Rodeheffer 1983</a>; <a href="./references#CD002069-bbs2-0001" title="EttingerWH , WiseRA , SchaffhauserD , WigleyFM . Controlled double‐blind trial of dazoxiben and nifedipine in the treatment of Raynaud's phenomenon. American Journal of Medicine1984;77(3):451‐6. MalametR , WiseRA , EttingerEH , WigleyFM . Nifedipine in the treatment of Raynaud's phenomenon. Evidence for inhibition of platelet activation. American Journal of Medicine1985;78(4):602‐8. WigleyFM , MalametR , WiseRA . Reproducibility of cold provocation in patients with Raynaud's phenomenon. Journal of Rheumatology1987;14(4):751‐5. ">Ettinger 1984</a>; <a href="./references#CD002069-bbs2-0002" title="KahanA , AmorB , MenkesCJ . Nicardipine in the treatment of Raynaud's phenomenon. Revue du Rhumatisme et des Maladies Osteo‐Articulaires1987;54(6):487‐90. KahanA , AmorB , MenkesCJ , WeberS , GuerinF , DegeorgesM . Nicardipine in the treatment of Raynaud's phenomenon: A randomized double‐blind trial. Angiology1987;38(4):333‐7. ">Kahan 1987</a>; <a href="./references#CD002069-bbs2-0006" title="VayssairatM , BoccalonH , GinestetMC , PriolletP , FrancoA , CarpentierP , et al. Controlled multicenter double‐blind trial of nicardipine in the treatment of primary Raynaud phenomenon. American Heart Journal1991;122(1 Suppl 2):352‐5. ">Vayssairat 1991</a>), three weeks (<a href="./references#CD002069-bbs2-0007" title="WollersheimH , ThienT . Double‐blind placebo‐controlled crossover study of oral nicardipine in the treatment of Raynaud's phenomenon. Journal of Cardiovascular Pharmacology1991;18(6):813‐8. ">Wollersheim 1991</a>), 10 weeks (<a href="./references#CD002069-bbs2-0005" title="SarkoziJ , BookmanAA , MahonW , RamsayC , DetskyAS , KeystoneEC . Nifedipine in the treatment of idiopathic Raynaud's syndrome. Journal of Rheumatology1986;13(2):331‐6. ">Sarkozi 1986</a>) and 12 to 13 months (<a href="./references#CD002069-bbs2-0004" title="MaricqHR , JenningsJR , ValterI , FrederickM , ThompsonB , SmithEA , et al. Evaluation of treatment efficacy of Raynaud phenomenon by digital blood pressure response to cooling. Raynaud's Treatment Study Investigators. Vascular Medicine2000;5(3):135‐40. MiddaughSJ , HaythornthwaiteJA , ThompsonB , HillR , BrownKM , FreedmanRR , et al. The Raynaud's Treatment Study: biofeedback protocols and acquisition of temperature biofeedback skills. Applied Psychophysiology and Biofeedback2001;26(4):251‐78. Raynaud's Treatment Study Investigators. Comparison of sustained‐release nifedipine and temperature biofeedback for treatment of primary Raynaud phenomenon. Results from a randomized clinical trial with 1‐year follow‐up. Archives of Internal Medicine2000;160(8):1101‐8. ThompsonB , GellerNL , HunsbergerS , FrederickM , HillR , JacobRG , et al. Behavioral and pharmacologic interventions: the Raynaud's Treatment Study. Controlled Clinical Trials1999;20(1):52‐63. ">RTS 2000</a>). Three trials had a run‐in period on no medication lasting either one week (<a href="./references#CD002069-bbs2-0005" title="SarkoziJ , BookmanAA , MahonW , RamsayC , DetskyAS , KeystoneEC . Nifedipine in the treatment of idiopathic Raynaud's syndrome. Journal of Rheumatology1986;13(2):331‐6. ">Sarkozi 1986</a>; <a href="./references#CD002069-bbs2-0002" title="KahanA , AmorB , MenkesCJ . Nicardipine in the treatment of Raynaud's phenomenon. Revue du Rhumatisme et des Maladies Osteo‐Articulaires1987;54(6):487‐90. KahanA , AmorB , MenkesCJ , WeberS , GuerinF , DegeorgesM . Nicardipine in the treatment of Raynaud's phenomenon: A randomized double‐blind trial. Angiology1987;38(4):333‐7. ">Kahan 1987</a>) or three weeks (<a href="./references#CD002069-bbs2-0007" title="WollersheimH , ThienT . Double‐blind placebo‐controlled crossover study of oral nicardipine in the treatment of Raynaud's phenomenon. Journal of Cardiovascular Pharmacology1991;18(6):813‐8. ">Wollersheim 1991</a>). One trial had a one‐week run‐in period with single‐blind placebo treatment (<a href="./references#CD002069-bbs2-0006" title="VayssairatM , BoccalonH , GinestetMC , PriolletP , FrancoA , CarpentierP , et al. Controlled multicenter double‐blind trial of nicardipine in the treatment of primary Raynaud phenomenon. American Heart Journal1991;122(1 Suppl 2):352‐5. ">Vayssairat 1991</a>) and two trials had a two‐week run‐in period with single‐blind placebo treatment (<a href="./references#CD002069-bbs2-0003" title="RodehefferRJ , RommerJA , WigleyF , SmithCR . Controlled double‐blind trial of nifedipine in the treatment of Raynaud's phenomenon. New England Journal of Medicine1983;308(15):880‐3. ">Rodeheffer 1983</a>; <a href="./references#CD002069-bbs2-0001" title="EttingerWH , WiseRA , SchaffhauserD , WigleyFM . Controlled double‐blind trial of dazoxiben and nifedipine in the treatment of Raynaud's phenomenon. American Journal of Medicine1984;77(3):451‐6. MalametR , WiseRA , EttingerEH , WigleyFM . Nifedipine in the treatment of Raynaud's phenomenon. Evidence for inhibition of platelet activation. American Journal of Medicine1985;78(4):602‐8. WigleyFM , MalametR , WiseRA . Reproducibility of cold provocation in patients with Raynaud's phenomenon. Journal of Rheumatology1987;14(4):751‐5. ">Ettinger 1984</a>). In one trial, there was a one‐month baseline observation period but it was not clear if participants were required to be off medication (<a href="./references#CD002069-bbs2-0004" title="MaricqHR , JenningsJR , ValterI , FrederickM , ThompsonB , SmithEA , et al. Evaluation of treatment efficacy of Raynaud phenomenon by digital blood pressure response to cooling. Raynaud's Treatment Study Investigators. Vascular Medicine2000;5(3):135‐40. MiddaughSJ , HaythornthwaiteJA , ThompsonB , HillR , BrownKM , FreedmanRR , et al. The Raynaud's Treatment Study: biofeedback protocols and acquisition of temperature biofeedback skills. Applied Psychophysiology and Biofeedback2001;26(4):251‐78. Raynaud's Treatment Study Investigators. Comparison of sustained‐release nifedipine and temperature biofeedback for treatment of primary Raynaud phenomenon. Results from a randomized clinical trial with 1‐year follow‐up. Archives of Internal Medicine2000;160(8):1101‐8. ThompsonB , GellerNL , HunsbergerS , FrederickM , HillR , JacobRG , et al. Behavioral and pharmacologic interventions: the Raynaud's Treatment Study. Controlled Clinical Trials1999;20(1):52‐63. ">RTS 2000</a>). </p> </section> <section id="CD002069-sec-0060"> <h5 class="title">Outcomes</h5> <p>All the trials were published prior to 2001 and so predated the use of the Raynaud's Condition Score (<a href="./references#CD002069-bbs2-0090" title="MerkelPA , HerlynK , MartinRW , AndersonJJ , MayesMD , BellP , et al. Scleroderma Clinical Trials Consortium. Measuring disease activity and functional status in patients with scleroderma and Raynaud's phenomenon. Arthritis and Rheumatism2002;46(9):2410‐20. ">Merkel 2002</a>). Frequency of Raynaud's attacks was recorded in all seven trials using participant diaries. In one trial (<a href="./references#CD002069-bbs2-0004" title="MaricqHR , JenningsJR , ValterI , FrederickM , ThompsonB , SmithEA , et al. Evaluation of treatment efficacy of Raynaud phenomenon by digital blood pressure response to cooling. Raynaud's Treatment Study Investigators. Vascular Medicine2000;5(3):135‐40. MiddaughSJ , HaythornthwaiteJA , ThompsonB , HillR , BrownKM , FreedmanRR , et al. The Raynaud's Treatment Study: biofeedback protocols and acquisition of temperature biofeedback skills. Applied Psychophysiology and Biofeedback2001;26(4):251‐78. Raynaud's Treatment Study Investigators. Comparison of sustained‐release nifedipine and temperature biofeedback for treatment of primary Raynaud phenomenon. Results from a randomized clinical trial with 1‐year follow‐up. Archives of Internal Medicine2000;160(8):1101‐8. ThompsonB , GellerNL , HunsbergerS , FrederickM , HillR , JacobRG , et al. Behavioral and pharmacologic interventions: the Raynaud's Treatment Study. Controlled Clinical Trials1999;20(1):52‐63. ">RTS 2000</a>) participants were provided with a colour chart and each verified attack had to be at least 30 minutes apart. </p> <p>Duration of attacks was recorded in only one trial (<a href="./references#CD002069-bbs2-0007" title="WollersheimH , ThienT . Double‐blind placebo‐controlled crossover study of oral nicardipine in the treatment of Raynaud's phenomenon. Journal of Cardiovascular Pharmacology1991;18(6):813‐8. ">Wollersheim 1991</a>). </p> <p>Severity of Raynaud's attacks was recorded in six of the seven trials (<a href="./references#CD002069-bbs2-0001" title="EttingerWH , WiseRA , SchaffhauserD , WigleyFM . Controlled double‐blind trial of dazoxiben and nifedipine in the treatment of Raynaud's phenomenon. American Journal of Medicine1984;77(3):451‐6. MalametR , WiseRA , EttingerEH , WigleyFM . Nifedipine in the treatment of Raynaud's phenomenon. Evidence for inhibition of platelet activation. American Journal of Medicine1985;78(4):602‐8. WigleyFM , MalametR , WiseRA . Reproducibility of cold provocation in patients with Raynaud's phenomenon. Journal of Rheumatology1987;14(4):751‐5. ">Ettinger 1984</a>; <a href="./references#CD002069-bbs2-0005" title="SarkoziJ , BookmanAA , MahonW , RamsayC , DetskyAS , KeystoneEC . Nifedipine in the treatment of idiopathic Raynaud's syndrome. Journal of Rheumatology1986;13(2):331‐6. ">Sarkozi 1986</a>; <a href="./references#CD002069-bbs2-0002" title="KahanA , AmorB , MenkesCJ . Nicardipine in the treatment of Raynaud's phenomenon. Revue du Rhumatisme et des Maladies Osteo‐Articulaires1987;54(6):487‐90. KahanA , AmorB , MenkesCJ , WeberS , GuerinF , DegeorgesM . Nicardipine in the treatment of Raynaud's phenomenon: A randomized double‐blind trial. Angiology1987;38(4):333‐7. ">Kahan 1987</a>; <a href="./references#CD002069-bbs2-0006" title="VayssairatM , BoccalonH , GinestetMC , PriolletP , FrancoA , CarpentierP , et al. Controlled multicenter double‐blind trial of nicardipine in the treatment of primary Raynaud phenomenon. American Heart Journal1991;122(1 Suppl 2):352‐5. ">Vayssairat 1991</a>; <a href="./references#CD002069-bbs2-0007" title="WollersheimH , ThienT . Double‐blind placebo‐controlled crossover study of oral nicardipine in the treatment of Raynaud's phenomenon. Journal of Cardiovascular Pharmacology1991;18(6):813‐8. ">Wollersheim 1991</a>; <a href="./references#CD002069-bbs2-0004" title="MaricqHR , JenningsJR , ValterI , FrederickM , ThompsonB , SmithEA , et al. Evaluation of treatment efficacy of Raynaud phenomenon by digital blood pressure response to cooling. Raynaud's Treatment Study Investigators. Vascular Medicine2000;5(3):135‐40. MiddaughSJ , HaythornthwaiteJA , ThompsonB , HillR , BrownKM , FreedmanRR , et al. The Raynaud's Treatment Study: biofeedback protocols and acquisition of temperature biofeedback skills. Applied Psychophysiology and Biofeedback2001;26(4):251‐78. Raynaud's Treatment Study Investigators. Comparison of sustained‐release nifedipine and temperature biofeedback for treatment of primary Raynaud phenomenon. Results from a randomized clinical trial with 1‐year follow‐up. Archives of Internal Medicine2000;160(8):1101‐8. ThompsonB , GellerNL , HunsbergerS , FrederickM , HillR , JacobRG , et al. Behavioral and pharmacologic interventions: the Raynaud's Treatment Study. Controlled Clinical Trials1999;20(1):52‐63. ">RTS 2000</a>). Severity was recorded in five trials using participant diaries whereby each attack was rated according to a scale, although the scales used differed: mild, moderate or severe (<a href="./references#CD002069-bbs2-0001" title="EttingerWH , WiseRA , SchaffhauserD , WigleyFM . Controlled double‐blind trial of dazoxiben and nifedipine in the treatment of Raynaud's phenomenon. American Journal of Medicine1984;77(3):451‐6. MalametR , WiseRA , EttingerEH , WigleyFM . Nifedipine in the treatment of Raynaud's phenomenon. Evidence for inhibition of platelet activation. American Journal of Medicine1985;78(4):602‐8. WigleyFM , MalametR , WiseRA . Reproducibility of cold provocation in patients with Raynaud's phenomenon. Journal of Rheumatology1987;14(4):751‐5. ">Ettinger 1984</a>), 0 to 3 with 0 = mild and 3 = severe (<a href="./references#CD002069-bbs2-0005" title="SarkoziJ , BookmanAA , MahonW , RamsayC , DetskyAS , KeystoneEC . Nifedipine in the treatment of idiopathic Raynaud's syndrome. Journal of Rheumatology1986;13(2):331‐6. ">Sarkozi 1986</a>), 0 to 10 scale (<a href="./references#CD002069-bbs2-0007" title="WollersheimH , ThienT . Double‐blind placebo‐controlled crossover study of oral nicardipine in the treatment of Raynaud's phenomenon. Journal of Cardiovascular Pharmacology1991;18(6):813‐8. ">Wollersheim 1991</a>), 1 to 4 scale with 1 = mild and 4 = highly severe (<a href="./references#CD002069-bbs2-0006" title="VayssairatM , BoccalonH , GinestetMC , PriolletP , FrancoA , CarpentierP , et al. Controlled multicenter double‐blind trial of nicardipine in the treatment of primary Raynaud phenomenon. American Heart Journal1991;122(1 Suppl 2):352‐5. ">Vayssairat 1991</a>) and a four‐point scale (<a href="./references#CD002069-bbs2-0004" title="MaricqHR , JenningsJR , ValterI , FrederickM , ThompsonB , SmithEA , et al. Evaluation of treatment efficacy of Raynaud phenomenon by digital blood pressure response to cooling. Raynaud's Treatment Study Investigators. Vascular Medicine2000;5(3):135‐40. MiddaughSJ , HaythornthwaiteJA , ThompsonB , HillR , BrownKM , FreedmanRR , et al. The Raynaud's Treatment Study: biofeedback protocols and acquisition of temperature biofeedback skills. Applied Psychophysiology and Biofeedback2001;26(4):251‐78. Raynaud's Treatment Study Investigators. Comparison of sustained‐release nifedipine and temperature biofeedback for treatment of primary Raynaud phenomenon. Results from a randomized clinical trial with 1‐year follow‐up. Archives of Internal Medicine2000;160(8):1101‐8. ThompsonB , GellerNL , HunsbergerS , FrederickM , HillR , JacobRG , et al. Behavioral and pharmacologic interventions: the Raynaud's Treatment Study. Controlled Clinical Trials1999;20(1):52‐63. ">RTS 2000</a>). In one trial, severity of attacks was graded at the end of each treatment period using a single scale of 1 to 4 with 1 = slight to 4 = very severe (<a href="./references#CD002069-bbs2-0002" title="KahanA , AmorB , MenkesCJ . Nicardipine in the treatment of Raynaud's phenomenon. Revue du Rhumatisme et des Maladies Osteo‐Articulaires1987;54(6):487‐90. KahanA , AmorB , MenkesCJ , WeberS , GuerinF , DegeorgesM . Nicardipine in the treatment of Raynaud's phenomenon: A randomized double‐blind trial. Angiology1987;38(4):333‐7. ">Kahan 1987</a>). One trial (<a href="./references#CD002069-bbs2-0003" title="RodehefferRJ , RommerJA , WigleyF , SmithCR . Controlled double‐blind trial of nifedipine in the treatment of Raynaud's phenomenon. New England Journal of Medicine1983;308(15):880‐3. ">Rodeheffer 1983</a>) did not record severity of Raynaud's attacks. </p> <p>Four trials (<a href="./references#CD002069-bbs2-0003" title="RodehefferRJ , RommerJA , WigleyF , SmithCR . Controlled double‐blind trial of nifedipine in the treatment of Raynaud's phenomenon. New England Journal of Medicine1983;308(15):880‐3. ">Rodeheffer 1983</a>; <a href="./references#CD002069-bbs2-0001" title="EttingerWH , WiseRA , SchaffhauserD , WigleyFM . Controlled double‐blind trial of dazoxiben and nifedipine in the treatment of Raynaud's phenomenon. American Journal of Medicine1984;77(3):451‐6. MalametR , WiseRA , EttingerEH , WigleyFM . Nifedipine in the treatment of Raynaud's phenomenon. Evidence for inhibition of platelet activation. American Journal of Medicine1985;78(4):602‐8. WigleyFM , MalametR , WiseRA . Reproducibility of cold provocation in patients with Raynaud's phenomenon. Journal of Rheumatology1987;14(4):751‐5. ">Ettinger 1984</a>; <a href="./references#CD002069-bbs2-0007" title="WollersheimH , ThienT . Double‐blind placebo‐controlled crossover study of oral nicardipine in the treatment of Raynaud's phenomenon. Journal of Cardiovascular Pharmacology1991;18(6):813‐8. ">Wollersheim 1991</a>; <a href="./references#CD002069-bbs2-0004" title="MaricqHR , JenningsJR , ValterI , FrederickM , ThompsonB , SmithEA , et al. Evaluation of treatment efficacy of Raynaud phenomenon by digital blood pressure response to cooling. Raynaud's Treatment Study Investigators. Vascular Medicine2000;5(3):135‐40. MiddaughSJ , HaythornthwaiteJA , ThompsonB , HillR , BrownKM , FreedmanRR , et al. The Raynaud's Treatment Study: biofeedback protocols and acquisition of temperature biofeedback skills. Applied Psychophysiology and Biofeedback2001;26(4):251‐78. Raynaud's Treatment Study Investigators. Comparison of sustained‐release nifedipine and temperature biofeedback for treatment of primary Raynaud phenomenon. Results from a randomized clinical trial with 1‐year follow‐up. Archives of Internal Medicine2000;160(8):1101‐8. ThompsonB , GellerNL , HunsbergerS , FrederickM , HillR , JacobRG , et al. Behavioral and pharmacologic interventions: the Raynaud's Treatment Study. Controlled Clinical Trials1999;20(1):52‐63. ">RTS 2000</a>) used some form of participant‐preference scores although again scales used differed substantially across trials. <a href="./references#CD002069-bbs2-0003" title="RodehefferRJ , RommerJA , WigleyF , SmithCR . Controlled double‐blind trial of nifedipine in the treatment of Raynaud's phenomenon. New England Journal of Medicine1983;308(15):880‐3. ">Rodeheffer 1983</a> asked participants to rate the overall effectiveness of treatment at the end of each treatment period on a five‐point scale (marked improvement, moderate improvement, minimal improvement, no change, worse). <a href="./references#CD002069-bbs2-0001" title="EttingerWH , WiseRA , SchaffhauserD , WigleyFM . Controlled double‐blind trial of dazoxiben and nifedipine in the treatment of Raynaud's phenomenon. American Journal of Medicine1984;77(3):451‐6. MalametR , WiseRA , EttingerEH , WigleyFM . Nifedipine in the treatment of Raynaud's phenomenon. Evidence for inhibition of platelet activation. American Journal of Medicine1985;78(4):602‐8. WigleyFM , MalametR , WiseRA . Reproducibility of cold provocation in patients with Raynaud's phenomenon. Journal of Rheumatology1987;14(4):751‐5. ">Ettinger 1984</a> asked participants to rate overall response to treatment and side effects at the end of each treatment period on a four‐point scale (worse or no change, slight change, moderate change, marked change). <a href="./references#CD002069-bbs2-0007" title="WollersheimH , ThienT . Double‐blind placebo‐controlled crossover study of oral nicardipine in the treatment of Raynaud's phenomenon. Journal of Cardiovascular Pharmacology1991;18(6):813‐8. ">Wollersheim 1991</a> asked participants to rate drug effectiveness relative to baseline at the end of each treatment period on a five‐point scale (much worse, worse, no difference, better, much better). Finally, <a href="./references#CD002069-bbs2-0004" title="MaricqHR , JenningsJR , ValterI , FrederickM , ThompsonB , SmithEA , et al. Evaluation of treatment efficacy of Raynaud phenomenon by digital blood pressure response to cooling. Raynaud's Treatment Study Investigators. Vascular Medicine2000;5(3):135‐40. MiddaughSJ , HaythornthwaiteJA , ThompsonB , HillR , BrownKM , FreedmanRR , et al. The Raynaud's Treatment Study: biofeedback protocols and acquisition of temperature biofeedback skills. Applied Psychophysiology and Biofeedback2001;26(4):251‐78. Raynaud's Treatment Study Investigators. Comparison of sustained‐release nifedipine and temperature biofeedback for treatment of primary Raynaud phenomenon. Results from a randomized clinical trial with 1‐year follow‐up. Archives of Internal Medicine2000;160(8):1101‐8. ThompsonB , GellerNL , HunsbergerS , FrederickM , HillR , JacobRG , et al. Behavioral and pharmacologic interventions: the Raynaud's Treatment Study. Controlled Clinical Trials1999;20(1):52‐63. ">RTS 2000</a> asked participants to rate improvement compared to baseline at quarterly visits. </p> <p>Two trials (<a href="./references#CD002069-bbs2-0006" title="VayssairatM , BoccalonH , GinestetMC , PriolletP , FrancoA , CarpentierP , et al. Controlled multicenter double‐blind trial of nicardipine in the treatment of primary Raynaud phenomenon. American Heart Journal1991;122(1 Suppl 2):352‐5. ">Vayssairat 1991</a>; <a href="./references#CD002069-bbs2-0004" title="MaricqHR , JenningsJR , ValterI , FrederickM , ThompsonB , SmithEA , et al. Evaluation of treatment efficacy of Raynaud phenomenon by digital blood pressure response to cooling. Raynaud's Treatment Study Investigators. Vascular Medicine2000;5(3):135‐40. MiddaughSJ , HaythornthwaiteJA , ThompsonB , HillR , BrownKM , FreedmanRR , et al. The Raynaud's Treatment Study: biofeedback protocols and acquisition of temperature biofeedback skills. Applied Psychophysiology and Biofeedback2001;26(4):251‐78. Raynaud's Treatment Study Investigators. Comparison of sustained‐release nifedipine and temperature biofeedback for treatment of primary Raynaud phenomenon. Results from a randomized clinical trial with 1‐year follow‐up. Archives of Internal Medicine2000;160(8):1101‐8. ThompsonB , GellerNL , HunsbergerS , FrederickM , HillR , JacobRG , et al. Behavioral and pharmacologic interventions: the Raynaud's Treatment Study. Controlled Clinical Trials1999;20(1):52‐63. ">RTS 2000</a>) included quality of life measures, although data were reported only in one (<a href="./references#CD002069-bbs2-0006" title="VayssairatM , BoccalonH , GinestetMC , PriolletP , FrancoA , CarpentierP , et al. Controlled multicenter double‐blind trial of nicardipine in the treatment of primary Raynaud phenomenon. American Heart Journal1991;122(1 Suppl 2):352‐5. ">Vayssairat 1991</a>). </p> <p>Physiological measurements were used in five trials (<a href="./references#CD002069-bbs2-0003" title="RodehefferRJ , RommerJA , WigleyF , SmithCR . Controlled double‐blind trial of nifedipine in the treatment of Raynaud's phenomenon. New England Journal of Medicine1983;308(15):880‐3. ">Rodeheffer 1983</a>; <a href="./references#CD002069-bbs2-0001" title="EttingerWH , WiseRA , SchaffhauserD , WigleyFM . Controlled double‐blind trial of dazoxiben and nifedipine in the treatment of Raynaud's phenomenon. American Journal of Medicine1984;77(3):451‐6. MalametR , WiseRA , EttingerEH , WigleyFM . Nifedipine in the treatment of Raynaud's phenomenon. Evidence for inhibition of platelet activation. American Journal of Medicine1985;78(4):602‐8. WigleyFM , MalametR , WiseRA . Reproducibility of cold provocation in patients with Raynaud's phenomenon. Journal of Rheumatology1987;14(4):751‐5. ">Ettinger 1984</a>; <a href="./references#CD002069-bbs2-0005" title="SarkoziJ , BookmanAA , MahonW , RamsayC , DetskyAS , KeystoneEC . Nifedipine in the treatment of idiopathic Raynaud's syndrome. Journal of Rheumatology1986;13(2):331‐6. ">Sarkozi 1986</a>; <a href="./references#CD002069-bbs2-0006" title="VayssairatM , BoccalonH , GinestetMC , PriolletP , FrancoA , CarpentierP , et al. Controlled multicenter double‐blind trial of nicardipine in the treatment of primary Raynaud phenomenon. American Heart Journal1991;122(1 Suppl 2):352‐5. ">Vayssairat 1991</a>; <a href="./references#CD002069-bbs2-0007" title="WollersheimH , ThienT . Double‐blind placebo‐controlled crossover study of oral nicardipine in the treatment of Raynaud's phenomenon. Journal of Cardiovascular Pharmacology1991;18(6):813‐8. ">Wollersheim 1991</a>). <a href="./references#CD002069-bbs2-0001" title="EttingerWH , WiseRA , SchaffhauserD , WigleyFM . Controlled double‐blind trial of dazoxiben and nifedipine in the treatment of Raynaud's phenomenon. American Journal of Medicine1984;77(3):451‐6. MalametR , WiseRA , EttingerEH , WigleyFM . Nifedipine in the treatment of Raynaud's phenomenon. Evidence for inhibition of platelet activation. American Journal of Medicine1985;78(4):602‐8. WigleyFM , MalametR , WiseRA . Reproducibility of cold provocation in patients with Raynaud's phenomenon. Journal of Rheumatology1987;14(4):751‐5. ">Ettinger 1984</a> examined finger systolic pressure after local cooling at the end of each treatment period but no data were available specifically for participants with primary Raynaud's phenomenon. <a href="./references#CD002069-bbs2-0003" title="RodehefferRJ , RommerJA , WigleyF , SmithCR . Controlled double‐blind trial of nifedipine in the treatment of Raynaud's phenomenon. New England Journal of Medicine1983;308(15):880‐3. ">Rodeheffer 1983</a> assessed digital‐artery systolic pressure at 30 and 15 degrees C. <a href="./references#CD002069-bbs2-0005" title="SarkoziJ , BookmanAA , MahonW , RamsayC , DetskyAS , KeystoneEC . Nifedipine in the treatment of idiopathic Raynaud's syndrome. Journal of Rheumatology1986;13(2):331‐6. ">Sarkozi 1986</a> assessed pulse amplitude of digital blood flow (assessed by photoplethysmography) and time to return to baseline pulse amplitude following cold pressor challenge at baseline and on the last day of treatment. <a href="./references#CD002069-bbs2-0006" title="VayssairatM , BoccalonH , GinestetMC , PriolletP , FrancoA , CarpentierP , et al. Controlled multicenter double‐blind trial of nicardipine in the treatment of primary Raynaud phenomenon. American Heart Journal1991;122(1 Suppl 2):352‐5. ">Vayssairat 1991</a> assessed cold‐reactive hyperaemia as measured by skin temperature using cold challenge tests at each visit with the exception of the 'wash‐out' period. <a href="./references#CD002069-bbs2-0007" title="WollersheimH , ThienT . Double‐blind placebo‐controlled crossover study of oral nicardipine in the treatment of Raynaud's phenomenon. Journal of Cardiovascular Pharmacology1991;18(6):813‐8. ">Wollersheim 1991</a> examined response to a finger‐cooling test as measured by finger skin temperature, laser Doppler flux and transcutaneous oxygen tension. </p> </section> </section> <section id="CD002069-sec-0061"> <h4 class="title">Excluded studies</h4> <p>See: <a href="./references#CD002069-sec-0113" title="">Characteristics of excluded studies</a> and <a href="#CD002069-fig-0001">Figure 1</a>. </p> <p>For this update two additional studies were excluded (<a href="./references#CD002069-bbs2-0029" title="FontenelleSM , KayserC , PucinelliML , AndradeLE . Cold stimulus fingertip lacticemy test ‐ an effective method to monitor acute therapeutic intervention on primary Raynaud's phenomenon and systemic sclerosis. Rheumatology (Oxford, England)2008;47(1):80‐3. ">Fontenelle 2008</a>; <a href="./references#CD002069-bbs2-0043" title="LeeEY , ParkJK , LeeW , KimYK , ParkCS‐Y , GilesJT , et al. Head‐to‐head comparison of udenafil vs amlodipine in the treatment of secondary raynaud's phenomenon: A double‐blind, randomized, cross‐over study. Rheumatology (Oxford, England)2014;53(4):658‐64. ">Lee 2014</a>), making a total of sixty‐four excluded studies. Of these, twenty‐three were excluded because they did not meet the review inclusion criteria of a minimum one week wash‐out within cross‐over designs and a minimum one week run‐in at baseline or baseline data on the severity of Raynaud's phenomenon (<a href="./references#CD002069-bbs2-0060" title="SmithCD , McKendryRJ . Controlled trial of nifedipine in the treatment of Raynaud's phenomenon. Lancet1982;2(8311):1299‐301. SmithD , McKendryR . Treatment of Raynaud's phenomenon with nifedipine. Annals of the Royal College of Physicians and Surgeons of Canada1982;15(4):Abstract 282. ">Smith 1982</a>; <a href="./references#CD002069-bbs2-0010" title="BaadsgaardO , SchmidtJF , IronmannL . The effect of nifedipin (adalat) on Raynaud's phenomenon. Ugeskrift for Laeger1983;145(49):3814‐6. ">Baadsgaard 1983</a>; <a href="./references#CD002069-bbs2-0035" title="KahanA , WeberS , AmorB , MenkesCJ , HodaraM , DegeorgesM . Nifedipine and Raynaud's phenomenon associated with connective tissue diseases. International Angiology1985;4(2):221‐3. KahanA , WeberS , AmorB , MenkesCJ , SaportaL , HodaraM , et al. Calcium entry blocking agents in digital vasospasm (Raynaud's phenomenon). European Heart Journal1983;4(Suppl C):123‐9. KahanA , WeberS , AmorB , SaportaL , HodaraM , DegeorgesM . Controlled study of nifedipine in the treatment of Raynaud's phenomenon. Revue du Rhumatisme et des Maladies Osteo‐Articulaires1982;49(5):337‐43. ">Kahan 1983a</a>; <a href="./references#CD002069-bbs2-0036" title="KahanA , WeberS , AmorB , GuerinF , DegeorgesM . Nifedipine in the treatment of migraine in patients with Raynaud's phenomenon. New England Journal of Medicine1983;308(18):1102‐3. ">Kahan 1983b</a>; <a href="./references#CD002069-bbs2-0069" title="WinstonEL , PariserKM , MillerKB , SalemDN , CreagerMA . Nifedipine as a therapeutic modality for Raynaud's phenomenon. Arthritis and Rheumatism1983;26(10):1177‐80. ">Winston 1983</a>; <a href="./references#CD002069-bbs2-0008" title="AgnelliG , PariseP , ColangeliC . Pilot evaluation of flunarizine in Raynaud's disease: A placebo‐ controlled, double blind cross‐over study. Acta Therapeutica1984;10(2):153‐62. ">Agnelli 1984</a>; <a href="./references#CD002069-bbs2-0037" title="KahanA , AmorB , MenkesCJ . A randomised double‐blind trial of diltiazem in the treatment of Raynaud's phenomenon. Annals of the Rheumatic Diseases1985;44(1):30‐3. ">Kahan 1985a</a>; <a href="./references#CD002069-bbs2-0038" title="KahanA , FoultJM , WeberS , AmorB , MenkesCJ , DegeorgesM . Nifedipine and alpha1‐adrenergic blockade in Raynaud's phenomenon. European Heart Journal1985;6(8):702‐5. ">Kahan 1985b</a>; <a href="./references#CD002069-bbs2-0018" title="CorbinDO , WoodDA , MacintyreCC , HousleyE . A randomized double blind cross‐over trial of nifedipine in the treatment of primary Raynaud's phenomenon. European Heart Journal1986;7(2):165‐70. CorbinDOC , WoodDA , MacintyreCCA , HousleyEl . A randomised double blind cross‐over trial of nifedipine in the treatment of primary Raynaud's phenomenon [abstract]. Clinical Science1985; Vol. 69, issue Suppl 12:21P. ">Corbin 1986</a>; <a href="./references#CD002069-bbs2-0027" title="FinchMB , JohnstonGD , DawsonJ . The peripheral vascular effects of nifedipine in Raynaud's disease. British Journal of Clinical Pharmacology1985; Vol. 21:100P‐1P. FinchMB , JohnstonGD , DawsonJ . The peripheral vascular effects of nifedipine in Raynaud's disease associated with scleroderma: a double blind crossover study. Clinical Rheumatology1986; Vol. 5, issue 4:493‐8. ">Finch 1986</a>; <a href="./references#CD002069-bbs2-0030" title="GjorupT , KelbaekH , HartlingOJ , NielsenSL . Controlled double‐blind trial of the clinical effect of nifedipine in the treatment of idiopathic Raynaud's phenomenon. American Heart Journal1986;111(4):742‐5. ">Gjorup 1986a</a>; <a href="./references#CD002069-bbs2-0031" title="GjorupT , HartlingOJ , KelbaekH , NielsenSL . Controlled double blind trial of nisoldipine in the treatment of idiopathic Raynaud's phenomenon. European Journal of Clinical Pharmacology1986;31(4):387‐9. ">Gjorup 1986b</a>; <a href="./references#CD002069-bbs2-0033" title="HawkinsSJ , BlackCM , HallND , McGregorA , RingEF , MaddisonPJ . Clinical and laboratory effects of nifedipine in Raynaud's phenomenon. Rheumatology International1986;6(2):85‐8. ">Hawkins 1986</a>; <a href="./references#CD002069-bbs2-0039" title="KahanA , AmorB , MenkesCJ , WeberS , GuerinF , DegeorgesM . Controlled double‐blind trial of nicardipine in the treatment of Raynaud's phenomenon. International Journal of Clinical Pharmacology and Therapeutics1986; Vol. 39, issue 2:202. ">Kahan 1986</a>; <a href="./references#CD002069-bbs2-0053" title="Rivera RedondoJ , Noguerado AsensioA , López BoteJP , Alvaro‐Gracia AlvaroJM , Ossorio CastellanosC . Nifedipine treatment of Raynaud's phenomenon: a double blind controlled clinical study. Revista Espanola de Reumatologia1986;13:121‐3. ">Redondo 1986</a>; <a href="./references#CD002069-bbs2-0067" title="WhiteCJ , PhillipsWA , AbrahamsLA , WatsonTD , SingletonPTJr . Objective benefit of nifedipine in the treatment of Raynaud's phenomenon. American Journal of Medicine1986;80(4):623‐5. ">White 1986</a>; <a href="./references#CD002069-bbs2-0013" title="ChallenorVF , WallerDG , FrancisDA , FrancisJL , ManiR , RoathS . Nisoldipine in primary Raynaud's phenomenon. European Journal of Clinical Pharmacology1987;33(1):27‐30. FrancisJL , RoathOS , ChallenorVF , WallerDG . The effect of nisoldipine on whole blood platelet aggregation in patients with Raynaud's phenomenon. British Journal of Clinical Pharmacology1988;25(6):751‐4. ">Challenor 1987</a>; <a href="./references#CD002069-bbs2-0040" title="KallenbergCG , WoudaAA , KuitertJJ , TijssenJ , WesselingH . Nifedipine in Raynaud's phenomenon: Relationship between immediate, short term and longterm effects. Journal of Rheumatology1987;14(2):284‐90. KallenbergCG , WoudaAA , KuitertJJ , TijssenJ , WesselingH . Treatment of Raynaud's phenomenon with nifedipine short‐term and long‐term effects. Vasa Supplementum1987;18:68‐70. ">Kallenberg 1987</a>; <a href="./references#CD002069-bbs2-0055" title="RuppPA , MellingerS , KohlerJ , DorseyJK , FurstDE . Nicardipine for the treatment of Raynaud's phenomena: A double blind crossover trial of a new calcium entry blocker. Journal of Rheumatology1987;14(4):745‐50. ">Rupp 1987</a>; <a href="./references#CD002069-bbs2-0068" title="WigleyFM , WiseRA , MalametR , ScottTE . Nicardipine in the treatment of Raynaud's phenomenon. Dissociation of platelet activation from vasospasm. Arthritis and Rheumatism1987;30(3):281‐6. ">Wigley 1987a</a>; <a href="./references#CD002069-bbs2-0070" title="WiseRA , MalametR , WigleyFM . Acute effects of nifedipine on digital blood flow in human subjects with Raynaud's phenomenon: a double blind placebo controlled trial. Journal of Rheumatology1987;14(2):278‐83. ">Wise 1987</a>; <a href="./references#CD002069-bbs2-0062" title="VanHeereveldH , WollersheimH , GoughK , ThienT . Intravenous nicardipine in Raynaud's phenomenon: A controlled trial. Journal of Cardiovascular Pharmacology1988;11(1):68‐74. ">Van Heereveld 1988</a>; <a href="./references#CD002069-bbs2-0014" title="ChallenorVF , WallerDG , HaywardRA , GriffinMJ , RoathOS . Vibrotactile sensation and response to nifedipine dose titration in primary Raynaud's phenomenon. Angiology1989;40(2):122‐8. ">Challenor 1989</a>). Ten trials included participants with both primary and secondary Raynaud's phenomenon and did not present data which allowed data extraction for the primary group (and no additional data could be obtained) (<a href="./references#CD002069-bbs2-0050" title="DiehmC , Müller‐BühlU , MörlH , SchettlerG . Calcium antagonists in Raynaud's phenomenon [Calciumantagonistum beim Raynaud‐phanomen]. Zeitschrift fur Kardiologie1982; Vol. 71, issue 9:Abstract 86. Müller‐BühlU , DiehmC , ScheuermannW , MörlH . Calcium antagonists for the treatment of Raynaud's phenomenon. Deutsche Medizinische Wochenschrift1983;108(47):1795‐7. ">Müller‐Bühl 1983</a>; <a href="./references#CD002069-bbs2-0054" title="RheddaA , McCansJ , WillanAR , FordPM . A double blind placebo controlled crossover randomized trial of diltiazem in Raynaud's phenomenon. Journal of Rheumatology1985;12(4):724‐7. ">Rhedda 1985</a>; <a href="./references#CD002069-bbs2-0009" title="AldooriM , CampbellWB , DieppePA . Nifedipine in the treatment of Raynaud's syndrome. Cardiovascular Research1986;20(6):466‐70. ">Aldoori 1986</a>; <a href="./references#CD002069-bbs2-0064" title="FrancisDA , WallerDG , ChallenorVF , RoathOS . Red cell deformability in patients with Raynaud's phenomenon treated with nifedipine. Clinical Hemorheology1985; Vol. 5, issue 5:742. WallerDG , ChallenorVF , FrancisDA , RoathOS . Clinical and rheological effects of nifedipine in Raynaud's phenomenon. British Journal of Clinical Pharmacology1986;22(4):449‐54. ">Waller 1986</a>; <a href="./references#CD002069-bbs2-0019" title="CostantiniA , MartelliE , BaveraP , AgusGB . Slow release nifedipine in the treatment of Raynaud's phenomenon. International Angiology1987;6(4):359‐63. ">Costantini 1987</a>; <a href="./references#CD002069-bbs2-0028" title="FinchMB , CopelandS , PassmoreAP , JohnstonGD . A double‐blind cross‐over study of nifedipine retard in patients with Raynaud's phenomenon. Clinical Rheumatology1988;7(3):359‐65. ">Finch 1988</a>; <a href="./references#CD002069-bbs2-0026" title="FerriC , CecchettiR , CiniG , GambiniI , LaCivitaL , BerniniL , et al. Slow‐releasing nicardipine in the treatment of Raynaud's phenomena without underlying diseases. Clinical Rheumatology1992;11(1):76‐80. ">Ferri 1992</a>; <a href="./references#CD002069-bbs2-0041" title="LaCivitaL , PitaroN , RossiM , GambiniI , GiuggioliD , CiniG , et al. Amlodipine in the treatment of Raynaud's phenomenon. British Journal of Rheumatology1993;32(6):524‐5. LaCivitaL , PitaroN , RossiM , GiuggioliD , GambiniI , CiniG , et al. Amlodipine in the treatment of Raynaud's phenomenon. A double‐blind placebo‐controlled crossover study. Clinical Drug Investigation1997;13(Suppl 1):126‐31. ">La Civita 1993</a>; <a href="./references#CD002069-bbs2-0042" title="LaCivitaL , GiuggioliD , DelChiccaMG , LongombardoG , PaseroG , FerriC . Effect of isradipine on endothelin‐1 plasma concentrations in patients with Raynaud's phenomenon [letter]. Annals of the Rheumatic Diseases1996;55(5):331‐2. ">La Civita 1996</a>; <a href="./references#CD002069-bbs2-0046" title="MartinezS , LozanoP , PallaresL , JuliaJ , ArtiguesI , PlazaA , et al. Usefulness of photoplethysmography and indexes of digital pressure in Raynaud phenomenon. Medicina Clinica1999;113(9):327‐30. ">Martinez 1999</a>). In eight trials the drug was administered only once (single‐dose trials) (<a href="./references#CD002069-bbs2-0034" title="KahanA , WeberS , AmorB , SaportaL , HodaraM , DegoergesM . Nifedipine and Raynaud's phenomenon. Annals of Internal Medicine1981;94(41):546. ">Kahan 1981</a>; <a href="./references#CD002069-bbs2-0032" title="GushRJ , TaylorLJ , JaysonMI . Acute effects of sublingual nifedipine in patients with Raynaud's phenomenon. Journal of Cardiovascular Pharmacology1987;9(5):628‐31. ">Gush 1987</a>; <a href="./references#CD002069-bbs2-0045" title="LewisP , PsailaJV , MorganRH , DaviesWT , WoodcockJP . Nifedipine in patients with Raynaud's syndrome ‐ effects on radial artery flow. European Heart Journal1987;8(Suppl K):83‐6. ">Lewis 1987</a>; <a href="./references#CD002069-bbs2-0048" title="MorganRH , PsailaJV , DaviesWT , CarolanG , WoodcockJP . Digital and radial artery blood flow in patients with Raynaud's phenomenon in response to nifedipine. European Journal of Vascular Surgery1987;1(6):403‐8. ">Morgan 1987</a>; <a href="./references#CD002069-bbs2-0071" title="WollersheimH , ThienT , Van't LaarA . Acute and chronic effects of nifedipine in Raynaud's phenomenon. European Journal of Clinical Investigation1986;16(Suppl):A16. WollersheimH , ThienT , Van't LaarA . Nifedipine in primary Raynaud's phenomenon and in scleroderma: oral versus sublingual hemodynamic effects. Journal of Clinical Pharmacology1987;27(11):907‐13. ">Wollersheim 1987</a>; <a href="./references#CD002069-bbs2-0066" title="WeberA , BounameauxH . Effects of low‐dose nifedipine on a cold provocation test in patients with Raynaud's disease. Journal of Cardiovascular Pharmacology1990;15(5):853‐5. ">Weber 1990</a>; <a href="./references#CD002069-bbs2-0024" title="DompelingEC , SmitAJ . Assessment of pinacidil in patients with primary Raynaud's phenomenon. Vasa Supplementum1992;34:34‐7. ">Dompeling 1992</a>; <a href="./references#CD002069-bbs2-0029" title="FontenelleSM , KayserC , PucinelliML , AndradeLE . Cold stimulus fingertip lacticemy test ‐ an effective method to monitor acute therapeutic intervention on primary Raynaud's phenomenon and systemic sclerosis. Rheumatology (Oxford, England)2008;47(1):80‐3. ">Fontenelle 2008</a>), six trials were open studies (<a href="./references#CD002069-bbs2-0059" title="ShcherbakovAB , GusevaNG , MachES . Treatment of Raynaud's syndrome with calcium entry blockers. Terapevticheskii Arkhiv1987;59(4):89‐92. ">Shcherbakov 1987</a>; <a href="./references#CD002069-bbs2-0016" title="CodellaO , CaramaschiP , OlivieriO , PerbelliniL , PerbelliniA , BambaraLM , et al. Controlled comparison of ketanserin and nifedipine in Raynaud's phenomenon. Angiology1989;40(2):114‐21. ">Codella 1989</a>; <a href="./references#CD002069-bbs2-0023" title="DentonCP , BunceTD , DoradoMB , RobertsZ , WilsonH , HowellK , et al. Probucol improves symptoms and reduces lipoprotein oxidation susceptibility in patients with Raynaud's phenomenon. Rheumatology1999;38(4):309‐15. ">Denton 1999</a>; <a href="./references#CD002069-bbs2-0025" title="DziadzioM , DentonCP , SmithR , HowellK , BlannA , BowersE , et al. Losartan therapy for Raynaud's phenomenon and scleroderma: clinical and biochemical findings in a fifteen‐week, randomized, parallel‐group, controlled trial. Arthritis and Rheumatism1999;42(12):2646‐55. ">Dziadzio 1999a</a>; <a href="./references#CD002069-bbs2-0017" title="ColeiroB , MarshallSE , DentonCP , HowellK , BlannA , WelshKI , et al. Treatment of Raynaud's phenomenon with the selective serotonin reuptake inhibitor fluoxetine. Rheumatology2001;40(9):1038‐43. ">Coleiro 2001</a>; <a href="./references#CD002069-bbs2-0015" title="ChoiWS , ChoiCJ , KimKS , LeeJH , SongCH , ChungJH , et al. To compare the efficacy and safety of nifedipine sustained release with Ginkgo biloba extract to treat patients with primary Raynaud's phenomenon in South Korea; Korean Raynaud study (KOARA study). Clinical Rheumatology2009;28(5):553‐9. ">Choi 2009</a>) and participants within seven trials did not have primary Raynaud's phenomenon (<a href="./references#CD002069-bbs2-0056" title="SauzaJ , KrausA , González‐AmaroR , Alarcón‐SegoviaD . Effect of the calcium channel blocker nifedipine on Raynaud's Phenomenon. A controlled double blind trial. Journal of Rheumatology1984;11(3):362‐4. ">Sauza 1984</a>; <a href="./references#CD002069-bbs2-0022" title="DaCostaJ , GomesJA , Espirito SantoJ , QueirosM . Inefficacy of diltiazem in the treatment of Raynaud's Phenomenon with associated connective tissue disease: a double blind placebo controlled study. Journal of Rheumatology1987;14(4):858‐9. ">Da Costa 1987</a>; <a href="./references#CD002069-bbs2-0057" title="SchmidtJF , ValentinN , NielsenSL . The clinical effect of felodipine and nifedipine in Raynaud's phenomenon. European Journal of Clinical Pharmacology1989;37(2):191‐2. ">Schmidt 1989</a>; <a href="./references#CD002069-bbs2-0047" title="MascagniB , SardinaM , AlvinoS , BerrutiV , BazziS , ScorzaR . Effects of iloprost in comparison to nifedipine in patients with Raynaud's phenomenon secondary to progressive systemic sclerosis. International Angiology1994; Vol. 13, issue Suppl 1:81. ">Mascagni 1994</a>; <a href="./references#CD002069-bbs2-0063" title="Varela‐AguilarJM , Sanchez‐RomanJ , Talegon MelendezA , Castillo PalmaMJ . [Comparative study of misoprostol and nifedipine in the treatment of Raynaud's phenomenon secondary to systemic diseases. Hemodynamic assessment with Doppler duplex]. Revista Clinica Espanola1997;197(2):77‐83. ">Varela‐Aguilar 1997</a>; <a href="./references#CD002069-bbs2-0058" title="ScorzaR , CaronniM , MascagniB , BerrutiV , BazziS , MicallefE , et al. Effects of long‐term cyclic iloprost therapy in systemic sclerosis with Raynaud's phenomenon. A randomized, controlled study. Clinical and Experimental Rheumatology2001;19(5):503‐8. ">Scorza 2001</a>; <a href="./references#CD002069-bbs2-0043" title="LeeEY , ParkJK , LeeW , KimYK , ParkCS‐Y , GilesJT , et al. Head‐to‐head comparison of udenafil vs amlodipine in the treatment of secondary raynaud's phenomenon: A double‐blind, randomized, cross‐over study. Rheumatology (Oxford, England)2014;53(4):658‐64. ">Lee 2014</a>). In four trials the active drug was not a calcium channel blocker, or a calcium channel blocker was used in combination with another therapy (<a href="./references#CD002069-bbs2-0011" title="BrotzuG , FalchiS , MannuB , MontisciR , PetruzzoP , StaicoR . The importance of presynaptic beta receptors in Raynaud's disease. Journal of Vascular Surgery1989;9(6):767‐71. ">Brotzu 1989</a>; <a href="./references#CD002069-bbs2-0049" title="MoriauM , Lavenne‐PardongeE , CrasbornL , VonFrenckellR , Col‐DebeysC . Treatment of Raynaud's phenomenon with piracetam. Arzneimittel‐Forschung1993;43(5):526‐35. ">Moriau 1993</a>; <a href="./references#CD002069-bbs2-0021" title="CsikiZ , GaraiI , ShemiraniAH , PappG , ZsoriKS , AndrasC , et al. The effect of metoprolol alone and combined metoprolol‐felodipin on the digital microcirculation of patients with primary Raynaud's syndrome. Microvascular Research2011;82(1):84‐7. ">Csiki 2011</a>; <a href="./references#CD002069-bbs2-0012" title="CaglayanE , AxmannS , HellmichM , MoinzadehP , RosenkranzS . Vardenafil for the treatment of Raynaud phenomenon: A randomized, double‐blind, placebo‐controlled crossover study. Archives of Internal Medicine2012;172(15):1182‐4. ">Caglayan 2012</a>). Four trials were not randomised (<a href="./references#CD002069-bbs2-0020" title="CreagerMA , PariserKM , WinstonEM , RasmussenHM , MillerKB , CoffmanJD . Nifedipine‐induced fingertip vasodilation in patients with Raynaud's phenomenon. American Heart Journal1984;108(2):370‐3. ">Creager 1984</a>; <a href="./references#CD002069-bbs2-0052" title="PisentiL , HartLL . DIAS Rounds. Nifedipine and prazosin in Raynaud's phenomenon. Drug Intelligence and Clinical Pharmacy1984;18(3):213‐4. ">Pisenti 1984</a>; <a href="./references#CD002069-bbs2-0061" title="StefenelliT , SilberbauerK , GlogarD . Pentoxifylline/placebo/nifedipine in patients with Raynaud's phenomenon: influence on frequency of attacks and rewarming time. Klinische Wochenschrift1986;64:1155‐6. ">Stefenelli 1986</a>; <a href="./references#CD002069-bbs2-0044" title="LeppertJ , JonassonT , NilssonH , RingqvistI . The effect of isradipine, a new calcium‐channel antagonist, in patients with primary Raynaud's phenomenon: A single‐blind dose‐response study. Cardiovascular Drugs Therapy1989;3(3):397‐401. ">Leppert 1989</a>). In two trials, the definition of the outcome and description of the data collection were lacking (<a href="./references#CD002069-bbs2-0051" title="NilssonH , JonasonT , LeppertJ , RingqvistI . The effect of the calcium‐entry blocker nifedipine on cold‐induced digital vasospasm. A double‐blind crossover study versus placebo. Acta Medica Scandinavica1987;221(1):53‐60. ">Nilsson 1987</a>; <a href="./references#CD002069-bbs2-0065" title="WasirHS , SinghG , KaulR , SachdevaU , KhanWA , ChhinaGS , et al. A comparative study of trifluoperazine a calmodulin inhibitor, nifedipine, dipyridamole and intraarterial reserpine in the treatment of Raynaud's phenomenon: A double blind randomised controlled trial. Indian Heart Journal1983; Vol. 35, issue 5:306. ">Wasir 1983</a>). Many trials had more than one reason for exclusion. The principle reasons for exclusion only are listed in <a href="./references#CD002069-sec-0113" title="">Characteristics of excluded studies</a>. </p> </section> </section> <section id="CD002069-sec-0062"> <h3 class="title">Risk of bias in included studies</h3> <p>See: <a href="#CD002069-fig-0002">Figure 2</a>. All included studies were described as randomised and double‐blinded. No studies were classed as being at high risk of bias. </p> <div class="figure" id="CD002069-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD002069-fig-0002" src="/cdsr/doi/10.1002/14651858.CD002069.pub5/media/CDSR/CD002069/image_n/nCD002069-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <section id="CD002069-sec-0063"> <h4 class="title">Allocation</h4> <p>Six of the seven included trials (<a href="./references#CD002069-bbs2-0003" title="RodehefferRJ , RommerJA , WigleyF , SmithCR . Controlled double‐blind trial of nifedipine in the treatment of Raynaud's phenomenon. New England Journal of Medicine1983;308(15):880‐3. ">Rodeheffer 1983</a>; <a href="./references#CD002069-bbs2-0001" title="EttingerWH , WiseRA , SchaffhauserD , WigleyFM . Controlled double‐blind trial of dazoxiben and nifedipine in the treatment of Raynaud's phenomenon. American Journal of Medicine1984;77(3):451‐6. MalametR , WiseRA , EttingerEH , WigleyFM . Nifedipine in the treatment of Raynaud's phenomenon. Evidence for inhibition of platelet activation. American Journal of Medicine1985;78(4):602‐8. WigleyFM , MalametR , WiseRA . Reproducibility of cold provocation in patients with Raynaud's phenomenon. Journal of Rheumatology1987;14(4):751‐5. ">Ettinger 1984</a>; <a href="./references#CD002069-bbs2-0005" title="SarkoziJ , BookmanAA , MahonW , RamsayC , DetskyAS , KeystoneEC . Nifedipine in the treatment of idiopathic Raynaud's syndrome. Journal of Rheumatology1986;13(2):331‐6. ">Sarkozi 1986</a>; <a href="./references#CD002069-bbs2-0002" title="KahanA , AmorB , MenkesCJ . Nicardipine in the treatment of Raynaud's phenomenon. Revue du Rhumatisme et des Maladies Osteo‐Articulaires1987;54(6):487‐90. KahanA , AmorB , MenkesCJ , WeberS , GuerinF , DegeorgesM . Nicardipine in the treatment of Raynaud's phenomenon: A randomized double‐blind trial. Angiology1987;38(4):333‐7. ">Kahan 1987</a>; <a href="./references#CD002069-bbs2-0006" title="VayssairatM , BoccalonH , GinestetMC , PriolletP , FrancoA , CarpentierP , et al. Controlled multicenter double‐blind trial of nicardipine in the treatment of primary Raynaud phenomenon. American Heart Journal1991;122(1 Suppl 2):352‐5. ">Vayssairat 1991</a>; <a href="./references#CD002069-bbs2-0007" title="WollersheimH , ThienT . Double‐blind placebo‐controlled crossover study of oral nicardipine in the treatment of Raynaud's phenomenon. Journal of Cardiovascular Pharmacology1991;18(6):813‐8. ">Wollersheim 1991</a>), did not provide full details of the method of allocation and, as a result, these were classed as having an unclear risk of bias. </p> </section> <section id="CD002069-sec-0064"> <h4 class="title">Blinding</h4> <p>All included studies were described as being double‐blind with both participants and personnel unaware of the treatment allocation. Data regarding Raynaud's attack frequency, severity and duration were all collected from participant diaries. Overall, from the descriptions provided by authors, the blinding appeared to be adequate. </p> </section> <section id="CD002069-sec-0065"> <h4 class="title">Incomplete outcome data</h4> <p>In two trials (<a href="./references#CD002069-bbs2-0007" title="WollersheimH , ThienT . Double‐blind placebo‐controlled crossover study of oral nicardipine in the treatment of Raynaud's phenomenon. Journal of Cardiovascular Pharmacology1991;18(6):813‐8. ">Wollersheim 1991</a>; <a href="./references#CD002069-bbs2-0004" title="MaricqHR , JenningsJR , ValterI , FrederickM , ThompsonB , SmithEA , et al. Evaluation of treatment efficacy of Raynaud phenomenon by digital blood pressure response to cooling. Raynaud's Treatment Study Investigators. Vascular Medicine2000;5(3):135‐40. MiddaughSJ , HaythornthwaiteJA , ThompsonB , HillR , BrownKM , FreedmanRR , et al. The Raynaud's Treatment Study: biofeedback protocols and acquisition of temperature biofeedback skills. Applied Psychophysiology and Biofeedback2001;26(4):251‐78. Raynaud's Treatment Study Investigators. Comparison of sustained‐release nifedipine and temperature biofeedback for treatment of primary Raynaud phenomenon. Results from a randomized clinical trial with 1‐year follow‐up. Archives of Internal Medicine2000;160(8):1101‐8. ThompsonB , GellerNL , HunsbergerS , FrederickM , HillR , JacobRG , et al. Behavioral and pharmacologic interventions: the Raynaud's Treatment Study. Controlled Clinical Trials1999;20(1):52‐63. ">RTS 2000</a>), the reporting of outcome data and side effects associated with treatment was difficult to interpret. </p> </section> <section id="CD002069-sec-0066"> <h4 class="title">Selective reporting</h4> <p>In <a href="./references#CD002069-bbs2-0004" title="MaricqHR , JenningsJR , ValterI , FrederickM , ThompsonB , SmithEA , et al. Evaluation of treatment efficacy of Raynaud phenomenon by digital blood pressure response to cooling. Raynaud's Treatment Study Investigators. Vascular Medicine2000;5(3):135‐40. MiddaughSJ , HaythornthwaiteJA , ThompsonB , HillR , BrownKM , FreedmanRR , et al. The Raynaud's Treatment Study: biofeedback protocols and acquisition of temperature biofeedback skills. Applied Psychophysiology and Biofeedback2001;26(4):251‐78. Raynaud's Treatment Study Investigators. Comparison of sustained‐release nifedipine and temperature biofeedback for treatment of primary Raynaud phenomenon. Results from a randomized clinical trial with 1‐year follow‐up. Archives of Internal Medicine2000;160(8):1101‐8. ThompsonB , GellerNL , HunsbergerS , FrederickM , HillR , JacobRG , et al. Behavioral and pharmacologic interventions: the Raynaud's Treatment Study. Controlled Clinical Trials1999;20(1):52‐63. ">RTS 2000</a>, participant progress through the study was not clear. In both <a href="./references#CD002069-bbs2-0007" title="WollersheimH , ThienT . Double‐blind placebo‐controlled crossover study of oral nicardipine in the treatment of Raynaud's phenomenon. Journal of Cardiovascular Pharmacology1991;18(6):813‐8. ">Wollersheim 1991</a> and <a href="./references#CD002069-bbs2-0004" title="MaricqHR , JenningsJR , ValterI , FrederickM , ThompsonB , SmithEA , et al. Evaluation of treatment efficacy of Raynaud phenomenon by digital blood pressure response to cooling. Raynaud's Treatment Study Investigators. Vascular Medicine2000;5(3):135‐40. MiddaughSJ , HaythornthwaiteJA , ThompsonB , HillR , BrownKM , FreedmanRR , et al. The Raynaud's Treatment Study: biofeedback protocols and acquisition of temperature biofeedback skills. Applied Psychophysiology and Biofeedback2001;26(4):251‐78. Raynaud's Treatment Study Investigators. Comparison of sustained‐release nifedipine and temperature biofeedback for treatment of primary Raynaud phenomenon. Results from a randomized clinical trial with 1‐year follow‐up. Archives of Internal Medicine2000;160(8):1101‐8. ThompsonB , GellerNL , HunsbergerS , FrederickM , HillR , JacobRG , et al. Behavioral and pharmacologic interventions: the Raynaud's Treatment Study. Controlled Clinical Trials1999;20(1):52‐63. ">RTS 2000</a> not all outcomes described in the methods were reported in full. </p> </section> <section id="CD002069-sec-0067"> <h4 class="title">Other potential sources of bias</h4> <p>We identified no other potential sources of bias.</p> <section id="CD002069-sec-0068"> <h5 class="title">Follow‐up and exclusions</h5> <p>Only one trial (<a href="./references#CD002069-bbs2-0004" title="MaricqHR , JenningsJR , ValterI , FrederickM , ThompsonB , SmithEA , et al. Evaluation of treatment efficacy of Raynaud phenomenon by digital blood pressure response to cooling. Raynaud's Treatment Study Investigators. Vascular Medicine2000;5(3):135‐40. MiddaughSJ , HaythornthwaiteJA , ThompsonB , HillR , BrownKM , FreedmanRR , et al. The Raynaud's Treatment Study: biofeedback protocols and acquisition of temperature biofeedback skills. Applied Psychophysiology and Biofeedback2001;26(4):251‐78. Raynaud's Treatment Study Investigators. Comparison of sustained‐release nifedipine and temperature biofeedback for treatment of primary Raynaud phenomenon. Results from a randomized clinical trial with 1‐year follow‐up. Archives of Internal Medicine2000;160(8):1101‐8. ThompsonB , GellerNL , HunsbergerS , FrederickM , HillR , JacobRG , et al. Behavioral and pharmacologic interventions: the Raynaud's Treatment Study. Controlled Clinical Trials1999;20(1):52‐63. ">RTS 2000</a>) discussed intention‐to‐treat analysis. This study had forty‐three drop‐outs after randomisation (27%). Two trials (<a href="./references#CD002069-bbs2-0003" title="RodehefferRJ , RommerJA , WigleyF , SmithCR . Controlled double‐blind trial of nifedipine in the treatment of Raynaud's phenomenon. New England Journal of Medicine1983;308(15):880‐3. ">Rodeheffer 1983</a>; <a href="./references#CD002069-bbs2-0002" title="KahanA , AmorB , MenkesCJ . Nicardipine in the treatment of Raynaud's phenomenon. Revue du Rhumatisme et des Maladies Osteo‐Articulaires1987;54(6):487‐90. KahanA , AmorB , MenkesCJ , WeberS , GuerinF , DegeorgesM . Nicardipine in the treatment of Raynaud's phenomenon: A randomized double‐blind trial. Angiology1987;38(4):333‐7. ">Kahan 1987</a>) had no drop‐outs or exclusions. Four trials reported loss to follow‐up. <a href="./references#CD002069-bbs2-0001" title="EttingerWH , WiseRA , SchaffhauserD , WigleyFM . Controlled double‐blind trial of dazoxiben and nifedipine in the treatment of Raynaud's phenomenon. American Journal of Medicine1984;77(3):451‐6. MalametR , WiseRA , EttingerEH , WigleyFM . Nifedipine in the treatment of Raynaud's phenomenon. Evidence for inhibition of platelet activation. American Journal of Medicine1985;78(4):602‐8. WigleyFM , MalametR , WiseRA . Reproducibility of cold provocation in patients with Raynaud's phenomenon. Journal of Rheumatology1987;14(4):751‐5. ">Ettinger 1984</a> had three withdrawals (50%) which, in all cases, were due to symptomatic orthostatic hypotension while on nifedipine. <a href="./references#CD002069-bbs2-0005" title="SarkoziJ , BookmanAA , MahonW , RamsayC , DetskyAS , KeystoneEC . Nifedipine in the treatment of idiopathic Raynaud's syndrome. Journal of Rheumatology1986;13(2):331‐6. ">Sarkozi 1986</a> had seven withdrawals (18%), of which five were on nifedipine (two for digital gangrene, two for non‐compliance and one for severe flushing) and two were on placebo (one for pregnancy and one for non‐compliance). <a href="./references#CD002069-bbs2-0006" title="VayssairatM , BoccalonH , GinestetMC , PriolletP , FrancoA , CarpentierP , et al. Controlled multicenter double‐blind trial of nicardipine in the treatment of primary Raynaud phenomenon. American Heart Journal1991;122(1 Suppl 2):352‐5. ">Vayssairat 1991</a> had nine withdrawals (13%), of which two were for personal reasons and seven due to side effects (five on placebo and two on nicardipine for headache/nausea and malaise/vertigo). <a href="./references#CD002069-bbs2-0007" title="WollersheimH , ThienT . Double‐blind placebo‐controlled crossover study of oral nicardipine in the treatment of Raynaud's phenomenon. Journal of Cardiovascular Pharmacology1991;18(6):813‐8. ">Wollersheim 1991</a> had three (18%) withdrawals due to side effects (one on placebo and two on nicardipine) although the reasons were not recorded. </p> </section> <section id="CD002069-sec-0069"> <h5 class="title">Power calculations</h5> <p>Power calculations for a comparison of a calcium channel blocker with a placebo for participants with primary Raynaud's phenomenon were given by only one trial (<a href="./references#CD002069-bbs2-0006" title="VayssairatM , BoccalonH , GinestetMC , PriolletP , FrancoA , CarpentierP , et al. Controlled multicenter double‐blind trial of nicardipine in the treatment of primary Raynaud phenomenon. American Heart Journal1991;122(1 Suppl 2):352‐5. ">Vayssairat 1991</a>). Overall, the sample sizes in the included trials were small. </p> </section> <section id="CD002069-sec-0070"> <h5 class="title">Cross‐over, carry‐over and period effect</h5> <p>All five cross‐over studies included in the review (<a href="./references#CD002069-bbs2-0003" title="RodehefferRJ , RommerJA , WigleyF , SmithCR . Controlled double‐blind trial of nifedipine in the treatment of Raynaud's phenomenon. New England Journal of Medicine1983;308(15):880‐3. ">Rodeheffer 1983</a>; <a href="./references#CD002069-bbs2-0001" title="EttingerWH , WiseRA , SchaffhauserD , WigleyFM . Controlled double‐blind trial of dazoxiben and nifedipine in the treatment of Raynaud's phenomenon. American Journal of Medicine1984;77(3):451‐6. MalametR , WiseRA , EttingerEH , WigleyFM . Nifedipine in the treatment of Raynaud's phenomenon. Evidence for inhibition of platelet activation. American Journal of Medicine1985;78(4):602‐8. WigleyFM , MalametR , WiseRA . Reproducibility of cold provocation in patients with Raynaud's phenomenon. Journal of Rheumatology1987;14(4):751‐5. ">Ettinger 1984</a>; <a href="./references#CD002069-bbs2-0002" title="KahanA , AmorB , MenkesCJ . Nicardipine in the treatment of Raynaud's phenomenon. Revue du Rhumatisme et des Maladies Osteo‐Articulaires1987;54(6):487‐90. KahanA , AmorB , MenkesCJ , WeberS , GuerinF , DegeorgesM . Nicardipine in the treatment of Raynaud's phenomenon: A randomized double‐blind trial. Angiology1987;38(4):333‐7. ">Kahan 1987</a>; <a href="./references#CD002069-bbs2-0006" title="VayssairatM , BoccalonH , GinestetMC , PriolletP , FrancoA , CarpentierP , et al. Controlled multicenter double‐blind trial of nicardipine in the treatment of primary Raynaud phenomenon. American Heart Journal1991;122(1 Suppl 2):352‐5. ">Vayssairat 1991</a>; <a href="./references#CD002069-bbs2-0007" title="WollersheimH , ThienT . Double‐blind placebo‐controlled crossover study of oral nicardipine in the treatment of Raynaud's phenomenon. Journal of Cardiovascular Pharmacology1991;18(6):813‐8. ">Wollersheim 1991</a>) incorporated a wash‐out period of at least one week. In three cases (<a href="./references#CD002069-bbs2-0003" title="RodehefferRJ , RommerJA , WigleyF , SmithCR . Controlled double‐blind trial of nifedipine in the treatment of Raynaud's phenomenon. New England Journal of Medicine1983;308(15):880‐3. ">Rodeheffer 1983</a>; <a href="./references#CD002069-bbs2-0001" title="EttingerWH , WiseRA , SchaffhauserD , WigleyFM . Controlled double‐blind trial of dazoxiben and nifedipine in the treatment of Raynaud's phenomenon. American Journal of Medicine1984;77(3):451‐6. MalametR , WiseRA , EttingerEH , WigleyFM . Nifedipine in the treatment of Raynaud's phenomenon. Evidence for inhibition of platelet activation. American Journal of Medicine1985;78(4):602‐8. WigleyFM , MalametR , WiseRA . Reproducibility of cold provocation in patients with Raynaud's phenomenon. Journal of Rheumatology1987;14(4):751‐5. ">Ettinger 1984</a>; <a href="./references#CD002069-bbs2-0006" title="VayssairatM , BoccalonH , GinestetMC , PriolletP , FrancoA , CarpentierP , et al. Controlled multicenter double‐blind trial of nicardipine in the treatment of primary Raynaud phenomenon. American Heart Journal1991;122(1 Suppl 2):352‐5. ">Vayssairat 1991</a>), this involved single‐blind treatment with placebo and in the remaining two cases (<a href="./references#CD002069-bbs2-0002" title="KahanA , AmorB , MenkesCJ . Nicardipine in the treatment of Raynaud's phenomenon. Revue du Rhumatisme et des Maladies Osteo‐Articulaires1987;54(6):487‐90. KahanA , AmorB , MenkesCJ , WeberS , GuerinF , DegeorgesM . Nicardipine in the treatment of Raynaud's phenomenon: A randomized double‐blind trial. Angiology1987;38(4):333‐7. ">Kahan 1987</a>; <a href="./references#CD002069-bbs2-0007" title="WollersheimH , ThienT . Double‐blind placebo‐controlled crossover study of oral nicardipine in the treatment of Raynaud's phenomenon. Journal of Cardiovascular Pharmacology1991;18(6):813‐8. ">Wollersheim 1991</a>) it involved no vasoactive treatment. One study reported that there was no observed order effect (<a href="./references#CD002069-bbs2-0002" title="KahanA , AmorB , MenkesCJ . Nicardipine in the treatment of Raynaud's phenomenon. Revue du Rhumatisme et des Maladies Osteo‐Articulaires1987;54(6):487‐90. KahanA , AmorB , MenkesCJ , WeberS , GuerinF , DegeorgesM . Nicardipine in the treatment of Raynaud's phenomenon: A randomized double‐blind trial. Angiology1987;38(4):333‐7. ">Kahan 1987</a>). In the remaining studies, no testing for period and carry‐over effect was reported. </p> </section> <section id="CD002069-sec-0071"> <h5 class="title">Funding</h5> <p>Five trials (<a href="./references#CD002069-bbs2-0003" title="RodehefferRJ , RommerJA , WigleyF , SmithCR . Controlled double‐blind trial of nifedipine in the treatment of Raynaud's phenomenon. New England Journal of Medicine1983;308(15):880‐3. ">Rodeheffer 1983</a>; <a href="./references#CD002069-bbs2-0001" title="EttingerWH , WiseRA , SchaffhauserD , WigleyFM . Controlled double‐blind trial of dazoxiben and nifedipine in the treatment of Raynaud's phenomenon. American Journal of Medicine1984;77(3):451‐6. MalametR , WiseRA , EttingerEH , WigleyFM . Nifedipine in the treatment of Raynaud's phenomenon. Evidence for inhibition of platelet activation. American Journal of Medicine1985;78(4):602‐8. WigleyFM , MalametR , WiseRA . Reproducibility of cold provocation in patients with Raynaud's phenomenon. Journal of Rheumatology1987;14(4):751‐5. ">Ettinger 1984</a>; <a href="./references#CD002069-bbs2-0006" title="VayssairatM , BoccalonH , GinestetMC , PriolletP , FrancoA , CarpentierP , et al. Controlled multicenter double‐blind trial of nicardipine in the treatment of primary Raynaud phenomenon. American Heart Journal1991;122(1 Suppl 2):352‐5. ">Vayssairat 1991</a>; <a href="./references#CD002069-bbs2-0007" title="WollersheimH , ThienT . Double‐blind placebo‐controlled crossover study of oral nicardipine in the treatment of Raynaud's phenomenon. Journal of Cardiovascular Pharmacology1991;18(6):813‐8. ">Wollersheim 1991</a>; <a href="./references#CD002069-bbs2-0004" title="MaricqHR , JenningsJR , ValterI , FrederickM , ThompsonB , SmithEA , et al. Evaluation of treatment efficacy of Raynaud phenomenon by digital blood pressure response to cooling. Raynaud's Treatment Study Investigators. Vascular Medicine2000;5(3):135‐40. MiddaughSJ , HaythornthwaiteJA , ThompsonB , HillR , BrownKM , FreedmanRR , et al. The Raynaud's Treatment Study: biofeedback protocols and acquisition of temperature biofeedback skills. Applied Psychophysiology and Biofeedback2001;26(4):251‐78. Raynaud's Treatment Study Investigators. Comparison of sustained‐release nifedipine and temperature biofeedback for treatment of primary Raynaud phenomenon. Results from a randomized clinical trial with 1‐year follow‐up. Archives of Internal Medicine2000;160(8):1101‐8. ThompsonB , GellerNL , HunsbergerS , FrederickM , HillR , JacobRG , et al. Behavioral and pharmacologic interventions: the Raynaud's Treatment Study. Controlled Clinical Trials1999;20(1):52‐63. ">RTS 2000</a>) had support from a pharmaceutical company (two (<a href="./references#CD002069-bbs2-0006" title="VayssairatM , BoccalonH , GinestetMC , PriolletP , FrancoA , CarpentierP , et al. Controlled multicenter double‐blind trial of nicardipine in the treatment of primary Raynaud phenomenon. American Heart Journal1991;122(1 Suppl 2):352‐5. ">Vayssairat 1991</a>; <a href="./references#CD002069-bbs2-0007" title="WollersheimH , ThienT . Double‐blind placebo‐controlled crossover study of oral nicardipine in the treatment of Raynaud's phenomenon. Journal of Cardiovascular Pharmacology1991;18(6):813‐8. ">Wollersheim 1991</a>) received financial support and three (<a href="./references#CD002069-bbs2-0003" title="RodehefferRJ , RommerJA , WigleyF , SmithCR . Controlled double‐blind trial of nifedipine in the treatment of Raynaud's phenomenon. New England Journal of Medicine1983;308(15):880‐3. ">Rodeheffer 1983</a>; <a href="./references#CD002069-bbs2-0001" title="EttingerWH , WiseRA , SchaffhauserD , WigleyFM . Controlled double‐blind trial of dazoxiben and nifedipine in the treatment of Raynaud's phenomenon. American Journal of Medicine1984;77(3):451‐6. MalametR , WiseRA , EttingerEH , WigleyFM . Nifedipine in the treatment of Raynaud's phenomenon. Evidence for inhibition of platelet activation. American Journal of Medicine1985;78(4):602‐8. WigleyFM , MalametR , WiseRA . Reproducibility of cold provocation in patients with Raynaud's phenomenon. Journal of Rheumatology1987;14(4):751‐5. ">Ettinger 1984</a>; <a href="./references#CD002069-bbs2-0004" title="MaricqHR , JenningsJR , ValterI , FrederickM , ThompsonB , SmithEA , et al. Evaluation of treatment efficacy of Raynaud phenomenon by digital blood pressure response to cooling. Raynaud's Treatment Study Investigators. Vascular Medicine2000;5(3):135‐40. MiddaughSJ , HaythornthwaiteJA , ThompsonB , HillR , BrownKM , FreedmanRR , et al. The Raynaud's Treatment Study: biofeedback protocols and acquisition of temperature biofeedback skills. Applied Psychophysiology and Biofeedback2001;26(4):251‐78. Raynaud's Treatment Study Investigators. Comparison of sustained‐release nifedipine and temperature biofeedback for treatment of primary Raynaud phenomenon. Results from a randomized clinical trial with 1‐year follow‐up. Archives of Internal Medicine2000;160(8):1101‐8. ThompsonB , GellerNL , HunsbergerS , FrederickM , HillR , JacobRG , et al. Behavioral and pharmacologic interventions: the Raynaud's Treatment Study. Controlled Clinical Trials1999;20(1):52‐63. ">RTS 2000</a>) received donations of the active drug), three trials also had support from charitable bodies (<a href="./references#CD002069-bbs2-0003" title="RodehefferRJ , RommerJA , WigleyF , SmithCR . Controlled double‐blind trial of nifedipine in the treatment of Raynaud's phenomenon. New England Journal of Medicine1983;308(15):880‐3. ">Rodeheffer 1983</a>; <a href="./references#CD002069-bbs2-0007" title="WollersheimH , ThienT . Double‐blind placebo‐controlled crossover study of oral nicardipine in the treatment of Raynaud's phenomenon. Journal of Cardiovascular Pharmacology1991;18(6):813‐8. ">Wollersheim 1991</a>; <a href="./references#CD002069-bbs2-0004" title="MaricqHR , JenningsJR , ValterI , FrederickM , ThompsonB , SmithEA , et al. Evaluation of treatment efficacy of Raynaud phenomenon by digital blood pressure response to cooling. Raynaud's Treatment Study Investigators. Vascular Medicine2000;5(3):135‐40. MiddaughSJ , HaythornthwaiteJA , ThompsonB , HillR , BrownKM , FreedmanRR , et al. The Raynaud's Treatment Study: biofeedback protocols and acquisition of temperature biofeedback skills. Applied Psychophysiology and Biofeedback2001;26(4):251‐78. Raynaud's Treatment Study Investigators. Comparison of sustained‐release nifedipine and temperature biofeedback for treatment of primary Raynaud phenomenon. Results from a randomized clinical trial with 1‐year follow‐up. Archives of Internal Medicine2000;160(8):1101‐8. ThompsonB , GellerNL , HunsbergerS , FrederickM , HillR , JacobRG , et al. Behavioral and pharmacologic interventions: the Raynaud's Treatment Study. Controlled Clinical Trials1999;20(1):52‐63. ">RTS 2000</a>) and the remaining two (<a href="./references#CD002069-bbs2-0005" title="SarkoziJ , BookmanAA , MahonW , RamsayC , DetskyAS , KeystoneEC . Nifedipine in the treatment of idiopathic Raynaud's syndrome. Journal of Rheumatology1986;13(2):331‐6. ">Sarkozi 1986</a>; <a href="./references#CD002069-bbs2-0002" title="KahanA , AmorB , MenkesCJ . Nicardipine in the treatment of Raynaud's phenomenon. Revue du Rhumatisme et des Maladies Osteo‐Articulaires1987;54(6):487‐90. KahanA , AmorB , MenkesCJ , WeberS , GuerinF , DegeorgesM . Nicardipine in the treatment of Raynaud's phenomenon: A randomized double‐blind trial. Angiology1987;38(4):333‐7. ">Kahan 1987</a>) did not state their source of funding. </p> </section> </section> </section> <section id="CD002069-sec-0072"> <h3 class="title" id="CD002069-sec-0072">Effects of interventions</h3> <p>See: <a href="./full#CD002069-tbl-0001"><b>Summary of findings for the main comparison</b> Calcium channel blockers for primary Raynauds's phenomenon</a> </p> <section id="CD002069-sec-0073"> <h4 class="title">Attack rates of Raynaud's phenomenon</h4> <p>The meta‐analysis suggested a statistically significant advantage of treatment with calcium channel blockers compared to placebo as measured by the number of Raynaud's attacks (standardised mean difference (SMD) of 0.23; 95% confidence interval (CI) 0.08 to 0.38, P = 0.003) although the effect size was small and the 95% CI indicated that the actual treatment effect may be very small to moderate (<a href="#CD002069-fig-0003">Figure 3</a>; <a href="./references#CD002069-fig-0007" title="">Analysis 1.1</a>). The transformed results, using a pooled SD of 7.48, indicated a decrease in the number of Raynaud's attacks per week on calcium channel blockers as compared to placebo (1.72; 95% CI 0.60 to 2.84). Calcium channel blockers, therefore, could reduce the weekly number of attacks by as few as 0.6, or as many as 2.8. </p> <div class="figure" id="CD002069-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Comparison 1 Calcium channel blockers versus placebo, Outcome: 1 Number of attacks." data-id="CD002069-fig-0003" src="/cdsr/doi/10.1002/14651858.CD002069.pub5/media/CDSR/CD002069/image_n/nCD002069-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 1 Calcium channel blockers versus placebo, Outcome: 1 Number of attacks.</p> </div> </div> </div> <p>Within the meta‐analysis, <a href="./references#CD002069-bbs2-0001" title="EttingerWH , WiseRA , SchaffhauserD , WigleyFM . Controlled double‐blind trial of dazoxiben and nifedipine in the treatment of Raynaud's phenomenon. American Journal of Medicine1984;77(3):451‐6. MalametR , WiseRA , EttingerEH , WigleyFM . Nifedipine in the treatment of Raynaud's phenomenon. Evidence for inhibition of platelet activation. American Journal of Medicine1985;78(4):602‐8. WigleyFM , MalametR , WiseRA . Reproducibility of cold provocation in patients with Raynaud's phenomenon. Journal of Rheumatology1987;14(4):751‐5. ">Ettinger 1984</a> received a high weighting inconsistent with the number of participants but when we conducted a sensitivity analysis the effect of excluding this study made little difference to the overall results (<a href="./references#CD002069-fig-0008" title="">Analysis 1.2</a>). <a href="./references#CD002069-bbs2-0004" title="MaricqHR , JenningsJR , ValterI , FrederickM , ThompsonB , SmithEA , et al. Evaluation of treatment efficacy of Raynaud phenomenon by digital blood pressure response to cooling. Raynaud's Treatment Study Investigators. Vascular Medicine2000;5(3):135‐40. MiddaughSJ , HaythornthwaiteJA , ThompsonB , HillR , BrownKM , FreedmanRR , et al. The Raynaud's Treatment Study: biofeedback protocols and acquisition of temperature biofeedback skills. Applied Psychophysiology and Biofeedback2001;26(4):251‐78. Raynaud's Treatment Study Investigators. Comparison of sustained‐release nifedipine and temperature biofeedback for treatment of primary Raynaud phenomenon. Results from a randomized clinical trial with 1‐year follow‐up. Archives of Internal Medicine2000;160(8):1101‐8. ThompsonB , GellerNL , HunsbergerS , FrederickM , HillR , JacobRG , et al. Behavioral and pharmacologic interventions: the Raynaud's Treatment Study. Controlled Clinical Trials1999;20(1):52‐63. ">RTS 2000</a> was the only trial with a 95% CI for the SMD which unequivocally suggested a beneficial effect of treatment (the interval did not span zero). Accordingly, the meta‐analysis was repeated with <a href="./references#CD002069-bbs2-0004" title="MaricqHR , JenningsJR , ValterI , FrederickM , ThompsonB , SmithEA , et al. Evaluation of treatment efficacy of Raynaud phenomenon by digital blood pressure response to cooling. Raynaud's Treatment Study Investigators. Vascular Medicine2000;5(3):135‐40. MiddaughSJ , HaythornthwaiteJA , ThompsonB , HillR , BrownKM , FreedmanRR , et al. The Raynaud's Treatment Study: biofeedback protocols and acquisition of temperature biofeedback skills. Applied Psychophysiology and Biofeedback2001;26(4):251‐78. Raynaud's Treatment Study Investigators. Comparison of sustained‐release nifedipine and temperature biofeedback for treatment of primary Raynaud phenomenon. Results from a randomized clinical trial with 1‐year follow‐up. Archives of Internal Medicine2000;160(8):1101‐8. ThompsonB , GellerNL , HunsbergerS , FrederickM , HillR , JacobRG , et al. Behavioral and pharmacologic interventions: the Raynaud's Treatment Study. Controlled Clinical Trials1999;20(1):52‐63. ">RTS 2000</a> removed. The effect was a reduction of the point estimate and confidence limits of the overall estimate of treatment effect. We no longer observed a statistically significant treatment effect (<a href="#CD002069-fig-0004">Figure 4</a>; <a href="./references#CD002069-fig-0009" title="">Analysis 1.3</a>). </p> <div class="figure" id="CD002069-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="Comparison: 1 Calcium channel blockers versus placebo, Outcome: 1.5 Number of attacks ‐ without RTS 2000 (sensitivity analysis)." data-id="CD002069-fig-0004" src="/cdsr/doi/10.1002/14651858.CD002069.pub5/media/CDSR/CD002069/image_n/nCD002069-AFig-FIG04.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison: 1 Calcium channel blockers versus placebo, Outcome: 1.5 Number of attacks ‐ without RTS 2000 (sensitivity analysis). </p> </div> </div> </div> <p>The results are also presented for each drug separately.</p> <section id="CD002069-sec-0074"> <h5 class="title">Nifedipine</h5> <p>(<a href="./references#CD002069-bbs2-0073" title="ATC2013 . Anatomical Therapeutical Chemical Classification. WHO. http://www.whocc.no/atcddd (accessed 21 February 2013). ">ATC classification</a> code C08CA05: Selective calcium channel blocker with mainly vascular effects; dihydropyridine derivatives) </p> <p>Four trials were included (<a href="./references#CD002069-bbs2-0003" title="RodehefferRJ , RommerJA , WigleyF , SmithCR . Controlled double‐blind trial of nifedipine in the treatment of Raynaud's phenomenon. New England Journal of Medicine1983;308(15):880‐3. ">Rodeheffer 1983</a>; <a href="./references#CD002069-bbs2-0001" title="EttingerWH , WiseRA , SchaffhauserD , WigleyFM . Controlled double‐blind trial of dazoxiben and nifedipine in the treatment of Raynaud's phenomenon. American Journal of Medicine1984;77(3):451‐6. MalametR , WiseRA , EttingerEH , WigleyFM . Nifedipine in the treatment of Raynaud's phenomenon. Evidence for inhibition of platelet activation. American Journal of Medicine1985;78(4):602‐8. WigleyFM , MalametR , WiseRA . Reproducibility of cold provocation in patients with Raynaud's phenomenon. Journal of Rheumatology1987;14(4):751‐5. ">Ettinger 1984</a>; <a href="./references#CD002069-bbs2-0005" title="SarkoziJ , BookmanAA , MahonW , RamsayC , DetskyAS , KeystoneEC . Nifedipine in the treatment of idiopathic Raynaud's syndrome. Journal of Rheumatology1986;13(2):331‐6. ">Sarkozi 1986</a>; <a href="./references#CD002069-bbs2-0004" title="MaricqHR , JenningsJR , ValterI , FrederickM , ThompsonB , SmithEA , et al. Evaluation of treatment efficacy of Raynaud phenomenon by digital blood pressure response to cooling. Raynaud's Treatment Study Investigators. Vascular Medicine2000;5(3):135‐40. MiddaughSJ , HaythornthwaiteJA , ThompsonB , HillR , BrownKM , FreedmanRR , et al. The Raynaud's Treatment Study: biofeedback protocols and acquisition of temperature biofeedback skills. Applied Psychophysiology and Biofeedback2001;26(4):251‐78. Raynaud's Treatment Study Investigators. Comparison of sustained‐release nifedipine and temperature biofeedback for treatment of primary Raynaud phenomenon. Results from a randomized clinical trial with 1‐year follow‐up. Archives of Internal Medicine2000;160(8):1101‐8. ThompsonB , GellerNL , HunsbergerS , FrederickM , HillR , JacobRG , et al. Behavioral and pharmacologic interventions: the Raynaud's Treatment Study. Controlled Clinical Trials1999;20(1):52‐63. ">RTS 2000</a>): two were parallel (<a href="./references#CD002069-bbs2-0005" title="SarkoziJ , BookmanAA , MahonW , RamsayC , DetskyAS , KeystoneEC . Nifedipine in the treatment of idiopathic Raynaud's syndrome. Journal of Rheumatology1986;13(2):331‐6. ">Sarkozi 1986</a>; <a href="./references#CD002069-bbs2-0004" title="MaricqHR , JenningsJR , ValterI , FrederickM , ThompsonB , SmithEA , et al. Evaluation of treatment efficacy of Raynaud phenomenon by digital blood pressure response to cooling. Raynaud's Treatment Study Investigators. Vascular Medicine2000;5(3):135‐40. MiddaughSJ , HaythornthwaiteJA , ThompsonB , HillR , BrownKM , FreedmanRR , et al. The Raynaud's Treatment Study: biofeedback protocols and acquisition of temperature biofeedback skills. Applied Psychophysiology and Biofeedback2001;26(4):251‐78. Raynaud's Treatment Study Investigators. Comparison of sustained‐release nifedipine and temperature biofeedback for treatment of primary Raynaud phenomenon. Results from a randomized clinical trial with 1‐year follow‐up. Archives of Internal Medicine2000;160(8):1101‐8. ThompsonB , GellerNL , HunsbergerS , FrederickM , HillR , JacobRG , et al. Behavioral and pharmacologic interventions: the Raynaud's Treatment Study. Controlled Clinical Trials1999;20(1):52‐63. ">RTS 2000</a>) and two were cross‐over (<a href="./references#CD002069-bbs2-0003" title="RodehefferRJ , RommerJA , WigleyF , SmithCR . Controlled double‐blind trial of nifedipine in the treatment of Raynaud's phenomenon. New England Journal of Medicine1983;308(15):880‐3. ">Rodeheffer 1983</a>; <a href="./references#CD002069-bbs2-0001" title="EttingerWH , WiseRA , SchaffhauserD , WigleyFM . Controlled double‐blind trial of dazoxiben and nifedipine in the treatment of Raynaud's phenomenon. American Journal of Medicine1984;77(3):451‐6. MalametR , WiseRA , EttingerEH , WigleyFM . Nifedipine in the treatment of Raynaud's phenomenon. Evidence for inhibition of platelet activation. American Journal of Medicine1985;78(4):602‐8. WigleyFM , MalametR , WiseRA . Reproducibility of cold provocation in patients with Raynaud's phenomenon. Journal of Rheumatology1987;14(4):751‐5. ">Ettinger 1984</a>). One parallel trial compared 10 mg nifedipine three times a day rising to 20 mg three times a day if no improvement shown at five weeks (<a href="./references#CD002069-bbs2-0005" title="SarkoziJ , BookmanAA , MahonW , RamsayC , DetskyAS , KeystoneEC . Nifedipine in the treatment of idiopathic Raynaud's syndrome. Journal of Rheumatology1986;13(2):331‐6. ">Sarkozi 1986</a>) with placebo for a total of 10 weeks. The other parallel trial compared 30 mg sustained‐release nifedipine once a day rising to 60 mg if well tolerated for a period of one year (<a href="./references#CD002069-bbs2-0004" title="MaricqHR , JenningsJR , ValterI , FrederickM , ThompsonB , SmithEA , et al. Evaluation of treatment efficacy of Raynaud phenomenon by digital blood pressure response to cooling. Raynaud's Treatment Study Investigators. Vascular Medicine2000;5(3):135‐40. MiddaughSJ , HaythornthwaiteJA , ThompsonB , HillR , BrownKM , FreedmanRR , et al. The Raynaud's Treatment Study: biofeedback protocols and acquisition of temperature biofeedback skills. Applied Psychophysiology and Biofeedback2001;26(4):251‐78. Raynaud's Treatment Study Investigators. Comparison of sustained‐release nifedipine and temperature biofeedback for treatment of primary Raynaud phenomenon. Results from a randomized clinical trial with 1‐year follow‐up. Archives of Internal Medicine2000;160(8):1101‐8. ThompsonB , GellerNL , HunsbergerS , FrederickM , HillR , JacobRG , et al. Behavioral and pharmacologic interventions: the Raynaud's Treatment Study. Controlled Clinical Trials1999;20(1):52‐63. ">RTS 2000</a>). One cross‐over trial compared 20 mg nifedipine three times a day with placebo for a period of two weeks (<a href="./references#CD002069-bbs2-0001" title="EttingerWH , WiseRA , SchaffhauserD , WigleyFM . Controlled double‐blind trial of dazoxiben and nifedipine in the treatment of Raynaud's phenomenon. American Journal of Medicine1984;77(3):451‐6. MalametR , WiseRA , EttingerEH , WigleyFM . Nifedipine in the treatment of Raynaud's phenomenon. Evidence for inhibition of platelet activation. American Journal of Medicine1985;78(4):602‐8. WigleyFM , MalametR , WiseRA . Reproducibility of cold provocation in patients with Raynaud's phenomenon. Journal of Rheumatology1987;14(4):751‐5. ">Ettinger 1984</a>), while the other cross‐over trial compared 10 mg nifedipine three times a day rising to 20 mg if well tolerated with placebo for a period of two weeks (<a href="./references#CD002069-bbs2-0003" title="RodehefferRJ , RommerJA , WigleyF , SmithCR . Controlled double‐blind trial of nifedipine in the treatment of Raynaud's phenomenon. New England Journal of Medicine1983;308(15):880‐3. ">Rodeheffer 1983</a>). </p> <p>The effect of excluding the three nicardipine trials was to increase the point estimate and confidence intervals for the size of the treatment effect (<a href="#CD002069-fig-0005">Figure 5</a>; <a href="./references#CD002069-fig-0010" title="">Analysis 1.4</a>). A significant treatment effect was found at the 5% level (P = 0.004). A pooled SD of 7.51 was calculated for the nifedipine trials to give a difference in means of 2.41; 95% CI 0.75 to 4.06. </p> <div class="figure" id="CD002069-fig-0005"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 5</div> </div> <hr class="top"/><img alt="Comparison 1: Calcium channel blockers versus placebo, Outcome: 1.2 Number of attacks ‐ Nifedipine trials only." data-id="CD002069-fig-0005" src="/cdsr/doi/10.1002/14651858.CD002069.pub5/media/CDSR/CD002069/image_n/nCD002069-AFig-FIG05.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 1: Calcium channel blockers versus placebo, Outcome: 1.2 Number of attacks ‐ Nifedipine trials only. </p> </div> </div> </div> <p>Nifedipine therefore could reduce the weekly number of attacks by as few as 0.8, or by as many as 4.1. There was a considerable amount of statistical heterogeneity in the meta‐analysis of nifedipine trials alone (I² = 48%). We performed a random‐effects analysis to investigate whether the results were robust to heterogeneity and, while this had a negligible effect on the point estimate of treatment effect, the confidence interval was wider and the estimate of treatment effect was no longer statistically significant at the 5% level (<a href="./references#CD002069-fig-0011" title="">Analysis 1.5</a>). The difference in means was 2.33 (95% CI ‐0.38 to 5.11). </p> </section> <section id="CD002069-sec-0075"> <h5 class="title">Nicardipine</h5> <p>(<a href="./references#CD002069-bbs2-0073" title="ATC2013 . Anatomical Therapeutical Chemical Classification. WHO. http://www.whocc.no/atcddd (accessed 21 February 2013). ">ATC classification</a> code C08CA04: Selective calcium channel blocker with mainly vascular effects; dihydropyridine derivatives) </p> <p>Three cross‐over trials were included (<a href="./references#CD002069-bbs2-0002" title="KahanA , AmorB , MenkesCJ . Nicardipine in the treatment of Raynaud's phenomenon. Revue du Rhumatisme et des Maladies Osteo‐Articulaires1987;54(6):487‐90. KahanA , AmorB , MenkesCJ , WeberS , GuerinF , DegeorgesM . Nicardipine in the treatment of Raynaud's phenomenon: A randomized double‐blind trial. Angiology1987;38(4):333‐7. ">Kahan 1987</a>; <a href="./references#CD002069-bbs2-0006" title="VayssairatM , BoccalonH , GinestetMC , PriolletP , FrancoA , CarpentierP , et al. Controlled multicenter double‐blind trial of nicardipine in the treatment of primary Raynaud phenomenon. American Heart Journal1991;122(1 Suppl 2):352‐5. ">Vayssairat 1991</a>; <a href="./references#CD002069-bbs2-0007" title="WollersheimH , ThienT . Double‐blind placebo‐controlled crossover study of oral nicardipine in the treatment of Raynaud's phenomenon. Journal of Cardiovascular Pharmacology1991;18(6):813‐8. ">Wollersheim 1991</a>): one compared 30 mg nicardipine three times a day with placebo for three weeks (<a href="./references#CD002069-bbs2-0007" title="WollersheimH , ThienT . Double‐blind placebo‐controlled crossover study of oral nicardipine in the treatment of Raynaud's phenomenon. Journal of Cardiovascular Pharmacology1991;18(6):813‐8. ">Wollersheim 1991</a>), one compared 50 mg long‐acting nicardipine twice a day with placebo for two weeks (<a href="./references#CD002069-bbs2-0006" title="VayssairatM , BoccalonH , GinestetMC , PriolletP , FrancoA , CarpentierP , et al. Controlled multicenter double‐blind trial of nicardipine in the treatment of primary Raynaud phenomenon. American Heart Journal1991;122(1 Suppl 2):352‐5. ">Vayssairat 1991</a>) and one compared 20 mg nicardipine three times a day with placebo for two weeks (<a href="./references#CD002069-bbs2-0002" title="KahanA , AmorB , MenkesCJ . Nicardipine in the treatment of Raynaud's phenomenon. Revue du Rhumatisme et des Maladies Osteo‐Articulaires1987;54(6):487‐90. KahanA , AmorB , MenkesCJ , WeberS , GuerinF , DegeorgesM . Nicardipine in the treatment of Raynaud's phenomenon: A randomized double‐blind trial. Angiology1987;38(4):333‐7. ">Kahan 1987</a>). Two trials included participants with both primary and secondary Raynaud's phenomenon, and only one was restricted to primary Raynaud's only. </p> <p>We found no overall effect of nicardipine (<a href="#CD002069-fig-0006">Figure 6</a>; <a href="./references#CD002069-fig-0012" title="">Analysis 1.6</a>). Multiplying the estimate and CI by the baseline SD reported in <a href="./references#CD002069-bbs2-0006" title="VayssairatM , BoccalonH , GinestetMC , PriolletP , FrancoA , CarpentierP , et al. Controlled multicenter double‐blind trial of nicardipine in the treatment of primary Raynaud phenomenon. American Heart Journal1991;122(1 Suppl 2):352‐5. ">Vayssairat 1991</a> gave a result of 1.11 (95% CI ‐0.44 to 2.59). Nicardipine therefore could increase the weekly number of attacks by as much as 0.4, could decrease the weekly number of attacks by as much as 2.6 or have no effect whatsoever. </p> <div class="figure" id="CD002069-fig-0006"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 6</div> </div> <hr class="top"/><img alt="Comparison 1: Calcium channel blockers versus placebo, Outcome: 1.3 Number of attacks ‐ Nicardipine trials only." data-id="CD002069-fig-0006" src="/cdsr/doi/10.1002/14651858.CD002069.pub5/media/CDSR/CD002069/image_n/nCD002069-AFig-FIG06.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 1: Calcium channel blockers versus placebo, Outcome: 1.3 Number of attacks ‐ Nicardipine trials only. </p> </div> </div> </div> </section> </section> <section id="CD002069-sec-0076"> <h4 class="title">Duration of attacks</h4> <p>Duration of attacks was recorded in only one trial (<a href="./references#CD002069-bbs2-0007" title="WollersheimH , ThienT . Double‐blind placebo‐controlled crossover study of oral nicardipine in the treatment of Raynaud's phenomenon. Journal of Cardiovascular Pharmacology1991;18(6):813‐8. ">Wollersheim 1991</a>): the average duration of attacks was 11 minutes in participants in the placebo group and 13 minutes in the nicardipine group but this difference was not statistically significant. Insufficient information was available to reproduce this analysis, and no P values or confidence intervals were provided. </p> </section> <section id="CD002069-sec-0077"> <h4 class="title">Severity scores</h4> <p>Severity of Raynaud's attacks was recorded in six of the seven trials (<a href="./references#CD002069-bbs2-0001" title="EttingerWH , WiseRA , SchaffhauserD , WigleyFM . Controlled double‐blind trial of dazoxiben and nifedipine in the treatment of Raynaud's phenomenon. American Journal of Medicine1984;77(3):451‐6. MalametR , WiseRA , EttingerEH , WigleyFM . Nifedipine in the treatment of Raynaud's phenomenon. Evidence for inhibition of platelet activation. American Journal of Medicine1985;78(4):602‐8. WigleyFM , MalametR , WiseRA . Reproducibility of cold provocation in patients with Raynaud's phenomenon. Journal of Rheumatology1987;14(4):751‐5. ">Ettinger 1984</a>; <a href="./references#CD002069-bbs2-0005" title="SarkoziJ , BookmanAA , MahonW , RamsayC , DetskyAS , KeystoneEC . Nifedipine in the treatment of idiopathic Raynaud's syndrome. Journal of Rheumatology1986;13(2):331‐6. ">Sarkozi 1986</a>; <a href="./references#CD002069-bbs2-0002" title="KahanA , AmorB , MenkesCJ . Nicardipine in the treatment of Raynaud's phenomenon. Revue du Rhumatisme et des Maladies Osteo‐Articulaires1987;54(6):487‐90. KahanA , AmorB , MenkesCJ , WeberS , GuerinF , DegeorgesM . Nicardipine in the treatment of Raynaud's phenomenon: A randomized double‐blind trial. Angiology1987;38(4):333‐7. ">Kahan 1987</a>; <a href="./references#CD002069-bbs2-0006" title="VayssairatM , BoccalonH , GinestetMC , PriolletP , FrancoA , CarpentierP , et al. Controlled multicenter double‐blind trial of nicardipine in the treatment of primary Raynaud phenomenon. American Heart Journal1991;122(1 Suppl 2):352‐5. ">Vayssairat 1991</a>; <a href="./references#CD002069-bbs2-0007" title="WollersheimH , ThienT . Double‐blind placebo‐controlled crossover study of oral nicardipine in the treatment of Raynaud's phenomenon. Journal of Cardiovascular Pharmacology1991;18(6):813‐8. ">Wollersheim 1991</a>; <a href="./references#CD002069-bbs2-0004" title="MaricqHR , JenningsJR , ValterI , FrederickM , ThompsonB , SmithEA , et al. Evaluation of treatment efficacy of Raynaud phenomenon by digital blood pressure response to cooling. Raynaud's Treatment Study Investigators. Vascular Medicine2000;5(3):135‐40. MiddaughSJ , HaythornthwaiteJA , ThompsonB , HillR , BrownKM , FreedmanRR , et al. The Raynaud's Treatment Study: biofeedback protocols and acquisition of temperature biofeedback skills. Applied Psychophysiology and Biofeedback2001;26(4):251‐78. Raynaud's Treatment Study Investigators. Comparison of sustained‐release nifedipine and temperature biofeedback for treatment of primary Raynaud phenomenon. Results from a randomized clinical trial with 1‐year follow‐up. Archives of Internal Medicine2000;160(8):1101‐8. ThompsonB , GellerNL , HunsbergerS , FrederickM , HillR , JacobRG , et al. Behavioral and pharmacologic interventions: the Raynaud's Treatment Study. Controlled Clinical Trials1999;20(1):52‐63. ">RTS 2000</a>). In one trial (<a href="./references#CD002069-bbs2-0001" title="EttingerWH , WiseRA , SchaffhauserD , WigleyFM . Controlled double‐blind trial of dazoxiben and nifedipine in the treatment of Raynaud's phenomenon. American Journal of Medicine1984;77(3):451‐6. MalametR , WiseRA , EttingerEH , WigleyFM . Nifedipine in the treatment of Raynaud's phenomenon. Evidence for inhibition of platelet activation. American Journal of Medicine1985;78(4):602‐8. WigleyFM , MalametR , WiseRA . Reproducibility of cold provocation in patients with Raynaud's phenomenon. Journal of Rheumatology1987;14(4):751‐5. ">Ettinger 1984</a>), severity scores were not reported specifically for participants with primary Raynaud's and no results were provided in another trial (<a href="./references#CD002069-bbs2-0004" title="MaricqHR , JenningsJR , ValterI , FrederickM , ThompsonB , SmithEA , et al. Evaluation of treatment efficacy of Raynaud phenomenon by digital blood pressure response to cooling. Raynaud's Treatment Study Investigators. Vascular Medicine2000;5(3):135‐40. MiddaughSJ , HaythornthwaiteJA , ThompsonB , HillR , BrownKM , FreedmanRR , et al. The Raynaud's Treatment Study: biofeedback protocols and acquisition of temperature biofeedback skills. Applied Psychophysiology and Biofeedback2001;26(4):251‐78. Raynaud's Treatment Study Investigators. Comparison of sustained‐release nifedipine and temperature biofeedback for treatment of primary Raynaud phenomenon. Results from a randomized clinical trial with 1‐year follow‐up. Archives of Internal Medicine2000;160(8):1101‐8. ThompsonB , GellerNL , HunsbergerS , FrederickM , HillR , JacobRG , et al. Behavioral and pharmacologic interventions: the Raynaud's Treatment Study. Controlled Clinical Trials1999;20(1):52‐63. ">RTS 2000</a>). <a href="./references#CD002069-bbs2-0007" title="WollersheimH , ThienT . Double‐blind placebo‐controlled crossover study of oral nicardipine in the treatment of Raynaud's phenomenon. Journal of Cardiovascular Pharmacology1991;18(6):813‐8. ">Wollersheim 1991</a> reported no significant difference between placebo and treatment although insufficient information was available to reproduce the analysis, and no P values or confidence intervals were reported. <a href="./references#CD002069-bbs2-0006" title="VayssairatM , BoccalonH , GinestetMC , PriolletP , FrancoA , CarpentierP , et al. Controlled multicenter double‐blind trial of nicardipine in the treatment of primary Raynaud phenomenon. American Heart Journal1991;122(1 Suppl 2):352‐5. ">Vayssairat 1991</a> reported no significant difference between 60 participants receiving placebo and nicardipine in a cross‐over design (mean score ± SD: 1.55 ± 0.7 in placebo versus 1.36 ± 0.8 in nicardipine; difference 0.2 (95% CI of difference 0 to 0.4)). No P value was reported and it was not possible to reproduce the Wilcoxon signed rank test due to a lack of participant‐level data. One trial (<a href="./references#CD002069-bbs2-0005" title="SarkoziJ , BookmanAA , MahonW , RamsayC , DetskyAS , KeystoneEC . Nifedipine in the treatment of idiopathic Raynaud's syndrome. Journal of Rheumatology1986;13(2):331‐6. ">Sarkozi 1986</a>) reported average percentage change in number of attacks, broken down by severity. A reduction in the average number of mild, moderate and severe attacks was reported for participants on nifedipine, although no statistical comparison was made with the placebo group. In one trial (<a href="./references#CD002069-bbs2-0002" title="KahanA , AmorB , MenkesCJ . Nicardipine in the treatment of Raynaud's phenomenon. Revue du Rhumatisme et des Maladies Osteo‐Articulaires1987;54(6):487‐90. KahanA , AmorB , MenkesCJ , WeberS , GuerinF , DegeorgesM . Nicardipine in the treatment of Raynaud's phenomenon: A randomized double‐blind trial. Angiology1987;38(4):333‐7. ">Kahan 1987</a>) a comparison of severity scores in primary Raynaud's participants was not made, but the authors of this review were able to make a comparison using reported participant‐level data with a median score of 2 for three participants while on placebo versus 2 while on nicardipine (Wilcoxon signed rank test, P &gt; 0.9999). We did not pool severity data for meta‐analysis for the following reasons: scales were generally described and unvalidated, the timing of assessment differed in one trial (<a href="./references#CD002069-bbs2-0002" title="KahanA , AmorB , MenkesCJ . Nicardipine in the treatment of Raynaud's phenomenon. Revue du Rhumatisme et des Maladies Osteo‐Articulaires1987;54(6):487‐90. KahanA , AmorB , MenkesCJ , WeberS , GuerinF , DegeorgesM . Nicardipine in the treatment of Raynaud's phenomenon: A randomized double‐blind trial. Angiology1987;38(4):333‐7. ">Kahan 1987</a>), and no data on severity were reported in one trial (<a href="./references#CD002069-bbs2-0004" title="MaricqHR , JenningsJR , ValterI , FrederickM , ThompsonB , SmithEA , et al. Evaluation of treatment efficacy of Raynaud phenomenon by digital blood pressure response to cooling. Raynaud's Treatment Study Investigators. Vascular Medicine2000;5(3):135‐40. MiddaughSJ , HaythornthwaiteJA , ThompsonB , HillR , BrownKM , FreedmanRR , et al. The Raynaud's Treatment Study: biofeedback protocols and acquisition of temperature biofeedback skills. Applied Psychophysiology and Biofeedback2001;26(4):251‐78. Raynaud's Treatment Study Investigators. Comparison of sustained‐release nifedipine and temperature biofeedback for treatment of primary Raynaud phenomenon. Results from a randomized clinical trial with 1‐year follow‐up. Archives of Internal Medicine2000;160(8):1101‐8. ThompsonB , GellerNL , HunsbergerS , FrederickM , HillR , JacobRG , et al. Behavioral and pharmacologic interventions: the Raynaud's Treatment Study. Controlled Clinical Trials1999;20(1):52‐63. ">RTS 2000</a>). </p> </section> <section id="CD002069-sec-0078"> <h4 class="title">Participant‐preference scores</h4> <p>Four trials (<a href="./references#CD002069-bbs2-0003" title="RodehefferRJ , RommerJA , WigleyF , SmithCR . Controlled double‐blind trial of nifedipine in the treatment of Raynaud's phenomenon. New England Journal of Medicine1983;308(15):880‐3. ">Rodeheffer 1983</a>; <a href="./references#CD002069-bbs2-0001" title="EttingerWH , WiseRA , SchaffhauserD , WigleyFM . Controlled double‐blind trial of dazoxiben and nifedipine in the treatment of Raynaud's phenomenon. American Journal of Medicine1984;77(3):451‐6. MalametR , WiseRA , EttingerEH , WigleyFM . Nifedipine in the treatment of Raynaud's phenomenon. Evidence for inhibition of platelet activation. American Journal of Medicine1985;78(4):602‐8. WigleyFM , MalametR , WiseRA . Reproducibility of cold provocation in patients with Raynaud's phenomenon. Journal of Rheumatology1987;14(4):751‐5. ">Ettinger 1984</a>; <a href="./references#CD002069-bbs2-0007" title="WollersheimH , ThienT . Double‐blind placebo‐controlled crossover study of oral nicardipine in the treatment of Raynaud's phenomenon. Journal of Cardiovascular Pharmacology1991;18(6):813‐8. ">Wollersheim 1991</a>; <a href="./references#CD002069-bbs2-0004" title="MaricqHR , JenningsJR , ValterI , FrederickM , ThompsonB , SmithEA , et al. Evaluation of treatment efficacy of Raynaud phenomenon by digital blood pressure response to cooling. Raynaud's Treatment Study Investigators. Vascular Medicine2000;5(3):135‐40. MiddaughSJ , HaythornthwaiteJA , ThompsonB , HillR , BrownKM , FreedmanRR , et al. The Raynaud's Treatment Study: biofeedback protocols and acquisition of temperature biofeedback skills. Applied Psychophysiology and Biofeedback2001;26(4):251‐78. Raynaud's Treatment Study Investigators. Comparison of sustained‐release nifedipine and temperature biofeedback for treatment of primary Raynaud phenomenon. Results from a randomized clinical trial with 1‐year follow‐up. Archives of Internal Medicine2000;160(8):1101‐8. ThompsonB , GellerNL , HunsbergerS , FrederickM , HillR , JacobRG , et al. Behavioral and pharmacologic interventions: the Raynaud's Treatment Study. Controlled Clinical Trials1999;20(1):52‐63. ">RTS 2000</a>) used some form of participant‐preference scores although scales used differed substantially across trials. <a href="./references#CD002069-bbs2-0003" title="RodehefferRJ , RommerJA , WigleyF , SmithCR . Controlled double‐blind trial of nifedipine in the treatment of Raynaud's phenomenon. New England Journal of Medicine1983;308(15):880‐3. ">Rodeheffer 1983</a> asked participants to rate the overall effectiveness of treatment at the end of each treatment period on a five‐point scale (marked improvement, moderate improvement, minimal improvement, no change, worse) with no significant difference between placebo and nifedipine (mean score of 0.6 in placebo group versus 2.2 in nifedipine group, P = 0.25 by Wilcoxon signed rank test). <a href="./references#CD002069-bbs2-0001" title="EttingerWH , WiseRA , SchaffhauserD , WigleyFM . Controlled double‐blind trial of dazoxiben and nifedipine in the treatment of Raynaud's phenomenon. American Journal of Medicine1984;77(3):451‐6. MalametR , WiseRA , EttingerEH , WigleyFM . Nifedipine in the treatment of Raynaud's phenomenon. Evidence for inhibition of platelet activation. American Journal of Medicine1985;78(4):602‐8. WigleyFM , MalametR , WiseRA . Reproducibility of cold provocation in patients with Raynaud's phenomenon. Journal of Rheumatology1987;14(4):751‐5. ">Ettinger 1984</a> asked participants to rate overall response to treatment and side effects at the end of each treatment period on a four‐point scale (worse or no change, slight change, moderate change, marked change) and found no significant difference between nicardipine and placebo although no breakdown was available for participants with primary Raynaud's phenomenon. <a href="./references#CD002069-bbs2-0007" title="WollersheimH , ThienT . Double‐blind placebo‐controlled crossover study of oral nicardipine in the treatment of Raynaud's phenomenon. Journal of Cardiovascular Pharmacology1991;18(6):813‐8. ">Wollersheim 1991</a> asked participants to rate drug effectiveness relative to baseline at the end of each treatment period on a five‐point scale (much worse, worse, no difference, better, much better) and found no preference for nicardipine over placebo, although again no breakdown was available for participants with primary Raynaud's phenomenon. Finally, <a href="./references#CD002069-bbs2-0004" title="MaricqHR , JenningsJR , ValterI , FrederickM , ThompsonB , SmithEA , et al. Evaluation of treatment efficacy of Raynaud phenomenon by digital blood pressure response to cooling. Raynaud's Treatment Study Investigators. Vascular Medicine2000;5(3):135‐40. MiddaughSJ , HaythornthwaiteJA , ThompsonB , HillR , BrownKM , FreedmanRR , et al. The Raynaud's Treatment Study: biofeedback protocols and acquisition of temperature biofeedback skills. Applied Psychophysiology and Biofeedback2001;26(4):251‐78. Raynaud's Treatment Study Investigators. Comparison of sustained‐release nifedipine and temperature biofeedback for treatment of primary Raynaud phenomenon. Results from a randomized clinical trial with 1‐year follow‐up. Archives of Internal Medicine2000;160(8):1101‐8. ThompsonB , GellerNL , HunsbergerS , FrederickM , HillR , JacobRG , et al. Behavioral and pharmacologic interventions: the Raynaud's Treatment Study. Controlled Clinical Trials1999;20(1):52‐63. ">RTS 2000</a> asked participants to rate improvement compared to baseline at quarterly visits and found participants rated symptoms as better on nifedipine in comparison to placebo (33% in placebo group versus 73% in nifedipine group, P &lt; 0.001). We did not pool participant‐preference data for meta‐analysis for the following reasons: scales were generally described and unvalidated, definitions of participant‐preference differed slightly across all four trials, and one trial (<a href="./references#CD002069-bbs2-0004" title="MaricqHR , JenningsJR , ValterI , FrederickM , ThompsonB , SmithEA , et al. Evaluation of treatment efficacy of Raynaud phenomenon by digital blood pressure response to cooling. Raynaud's Treatment Study Investigators. Vascular Medicine2000;5(3):135‐40. MiddaughSJ , HaythornthwaiteJA , ThompsonB , HillR , BrownKM , FreedmanRR , et al. The Raynaud's Treatment Study: biofeedback protocols and acquisition of temperature biofeedback skills. Applied Psychophysiology and Biofeedback2001;26(4):251‐78. Raynaud's Treatment Study Investigators. Comparison of sustained‐release nifedipine and temperature biofeedback for treatment of primary Raynaud phenomenon. Results from a randomized clinical trial with 1‐year follow‐up. Archives of Internal Medicine2000;160(8):1101‐8. ThompsonB , GellerNL , HunsbergerS , FrederickM , HillR , JacobRG , et al. Behavioral and pharmacologic interventions: the Raynaud's Treatment Study. Controlled Clinical Trials1999;20(1):52‐63. ">RTS 2000</a>) collected data at a different time point. </p> <p>Two trials (<a href="./references#CD002069-bbs2-0006" title="VayssairatM , BoccalonH , GinestetMC , PriolletP , FrancoA , CarpentierP , et al. Controlled multicenter double‐blind trial of nicardipine in the treatment of primary Raynaud phenomenon. American Heart Journal1991;122(1 Suppl 2):352‐5. ">Vayssairat 1991</a>; <a href="./references#CD002069-bbs2-0004" title="MaricqHR , JenningsJR , ValterI , FrederickM , ThompsonB , SmithEA , et al. Evaluation of treatment efficacy of Raynaud phenomenon by digital blood pressure response to cooling. Raynaud's Treatment Study Investigators. Vascular Medicine2000;5(3):135‐40. MiddaughSJ , HaythornthwaiteJA , ThompsonB , HillR , BrownKM , FreedmanRR , et al. The Raynaud's Treatment Study: biofeedback protocols and acquisition of temperature biofeedback skills. Applied Psychophysiology and Biofeedback2001;26(4):251‐78. Raynaud's Treatment Study Investigators. Comparison of sustained‐release nifedipine and temperature biofeedback for treatment of primary Raynaud phenomenon. Results from a randomized clinical trial with 1‐year follow‐up. Archives of Internal Medicine2000;160(8):1101‐8. ThompsonB , GellerNL , HunsbergerS , FrederickM , HillR , JacobRG , et al. Behavioral and pharmacologic interventions: the Raynaud's Treatment Study. Controlled Clinical Trials1999;20(1):52‐63. ">RTS 2000</a>) included quality of life measures, although data were reported only in one (<a href="./references#CD002069-bbs2-0006" title="VayssairatM , BoccalonH , GinestetMC , PriolletP , FrancoA , CarpentierP , et al. Controlled multicenter double‐blind trial of nicardipine in the treatment of primary Raynaud phenomenon. American Heart Journal1991;122(1 Suppl 2):352‐5. ">Vayssairat 1991</a>). </p> </section> <section id="CD002069-sec-0079"> <h4 class="title">Physiological measurements (including digital temperature and blood flow response to hand cooling) </h4> <p>Physiological measurements were used in five trials (<a href="./references#CD002069-bbs2-0003" title="RodehefferRJ , RommerJA , WigleyF , SmithCR . Controlled double‐blind trial of nifedipine in the treatment of Raynaud's phenomenon. New England Journal of Medicine1983;308(15):880‐3. ">Rodeheffer 1983</a>; <a href="./references#CD002069-bbs2-0001" title="EttingerWH , WiseRA , SchaffhauserD , WigleyFM . Controlled double‐blind trial of dazoxiben and nifedipine in the treatment of Raynaud's phenomenon. American Journal of Medicine1984;77(3):451‐6. MalametR , WiseRA , EttingerEH , WigleyFM . Nifedipine in the treatment of Raynaud's phenomenon. Evidence for inhibition of platelet activation. American Journal of Medicine1985;78(4):602‐8. WigleyFM , MalametR , WiseRA . Reproducibility of cold provocation in patients with Raynaud's phenomenon. Journal of Rheumatology1987;14(4):751‐5. ">Ettinger 1984</a>; <a href="./references#CD002069-bbs2-0005" title="SarkoziJ , BookmanAA , MahonW , RamsayC , DetskyAS , KeystoneEC . Nifedipine in the treatment of idiopathic Raynaud's syndrome. Journal of Rheumatology1986;13(2):331‐6. ">Sarkozi 1986</a>; <a href="./references#CD002069-bbs2-0006" title="VayssairatM , BoccalonH , GinestetMC , PriolletP , FrancoA , CarpentierP , et al. Controlled multicenter double‐blind trial of nicardipine in the treatment of primary Raynaud phenomenon. American Heart Journal1991;122(1 Suppl 2):352‐5. ">Vayssairat 1991</a>; <a href="./references#CD002069-bbs2-0007" title="WollersheimH , ThienT . Double‐blind placebo‐controlled crossover study of oral nicardipine in the treatment of Raynaud's phenomenon. Journal of Cardiovascular Pharmacology1991;18(6):813‐8. ">Wollersheim 1991</a>). <a href="./references#CD002069-bbs2-0001" title="EttingerWH , WiseRA , SchaffhauserD , WigleyFM . Controlled double‐blind trial of dazoxiben and nifedipine in the treatment of Raynaud's phenomenon. American Journal of Medicine1984;77(3):451‐6. MalametR , WiseRA , EttingerEH , WigleyFM . Nifedipine in the treatment of Raynaud's phenomenon. Evidence for inhibition of platelet activation. American Journal of Medicine1985;78(4):602‐8. WigleyFM , MalametR , WiseRA . Reproducibility of cold provocation in patients with Raynaud's phenomenon. Journal of Rheumatology1987;14(4):751‐5. ">Ettinger 1984</a> examined finger systolic pressure after local cooling at the end of each treatment period but no data were available specifically for participants with primary Raynaud's phenomenon. <a href="./references#CD002069-bbs2-0003" title="RodehefferRJ , RommerJA , WigleyF , SmithCR . Controlled double‐blind trial of nifedipine in the treatment of Raynaud's phenomenon. New England Journal of Medicine1983;308(15):880‐3. ">Rodeheffer 1983</a> assessed digital‐artery systolic pressure at 30 and 15 degrees C and found no significant change in the mean cold‐induced fall in digital artery systolic blood pressure between nifedipine and placebo (P = 0.625 and P &gt; 0.999 respectively, from Wilcoxon signed rank test conducted by the review authors). <a href="./references#CD002069-bbs2-0005" title="SarkoziJ , BookmanAA , MahonW , RamsayC , DetskyAS , KeystoneEC . Nifedipine in the treatment of idiopathic Raynaud's syndrome. Journal of Rheumatology1986;13(2):331‐6. ">Sarkozi 1986</a> assessed pulse amplitude of digital blood flow (assessed by photoplethysmography) and time to return to baseline pulse amplitude following cold pressor challenge at baseline and on the last day of treatment. No significant differences were found between baseline and at the end of treatment in either the nifedipine or placebo groups. Between‐group comparisons of physiological measurements after 10 weeks of treatment conducted by the authors of this review found no significant differences for pulse amplitudes (P = 0.896 and P = 0.815 by unpaired t‐tests, right and left hands respectively) or for responses to the cold pressor test (P = 0.542 and P = 0.066) for right index and middle fingers respectively). <a href="./references#CD002069-bbs2-0006" title="VayssairatM , BoccalonH , GinestetMC , PriolletP , FrancoA , CarpentierP , et al. Controlled multicenter double‐blind trial of nicardipine in the treatment of primary Raynaud phenomenon. American Heart Journal1991;122(1 Suppl 2):352‐5. ">Vayssairat 1991</a> assessed cold‐reactive hyperaemia as measured by skin temperature using cold challenge tests at each visit with the exception of the 'wash‐out' period but found no significant increase in reactive hyperaemia between the nicardipine and placebo groups (mean of 0.49 ± ‐2.4 in placebo versus 0.77 ± ‐1.6 in treatment group, difference of ‐0.3 ± ‐3, 95% CI ‐1.0 to 0.5, but no P value given and insufficient information to reproduce the analysis). <a href="./references#CD002069-bbs2-0007" title="WollersheimH , ThienT . Double‐blind placebo‐controlled crossover study of oral nicardipine in the treatment of Raynaud's phenomenon. Journal of Cardiovascular Pharmacology1991;18(6):813‐8. ">Wollersheim 1991</a> examined response to a finger cooling test as measured by finger skin temperature, laser Doppler flux and transcutaneous oxygen tension. No effects of nicardipine were found for any of these three parameters, nor were there any differences between participants with primary and secondary Raynaud's phenomenon. P values were not reported but were calculated by the review authors using unpaired t‐tests, as insufficient data were available to calculate the standard error of the mean difference required for paired t‐tests (finger skin temperature P = 0.830, laser Doppler flux P = 0.570, transcutaneous oxygen tension P = 0.812). Accordingly, we acknowledge that these tests will have reduced power. We did not pool physiological data for meta‐analysis because the methodology used varied substantially and the results could not be synthesised. </p> </section> <section id="CD002069-sec-0080"> <h4 class="title">Adverse reactions</h4> <p>Adverse reactions for participants with primary Raynaud's phenomenon were reported differently across the seven trials. <a href="./references#CD002069-bbs2-0003" title="RodehefferRJ , RommerJA , WigleyF , SmithCR . Controlled double‐blind trial of nifedipine in the treatment of Raynaud's phenomenon. New England Journal of Medicine1983;308(15):880‐3. ">Rodeheffer 1983</a> reported a significantly higher incidence of mild transient headaches in the nifedipine group versus the placebo group but no breakdown was available for participants with primary Raynaud's phenomenon. <a href="./references#CD002069-bbs2-0001" title="EttingerWH , WiseRA , SchaffhauserD , WigleyFM . Controlled double‐blind trial of dazoxiben and nifedipine in the treatment of Raynaud's phenomenon. American Journal of Medicine1984;77(3):451‐6. MalametR , WiseRA , EttingerEH , WigleyFM . Nifedipine in the treatment of Raynaud's phenomenon. Evidence for inhibition of platelet activation. American Journal of Medicine1985;78(4):602‐8. WigleyFM , MalametR , WiseRA . Reproducibility of cold provocation in patients with Raynaud's phenomenon. Journal of Rheumatology1987;14(4):751‐5. ">Ettinger 1984</a> provided no adverse event breakdown but (as above) referred to three withdrawals in the nifedipine group due to hypotension. <a href="./references#CD002069-bbs2-0005" title="SarkoziJ , BookmanAA , MahonW , RamsayC , DetskyAS , KeystoneEC . Nifedipine in the treatment of idiopathic Raynaud's syndrome. Journal of Rheumatology1986;13(2):331‐6. ">Sarkozi 1986</a> indicated that all participants on nifedipine reported side effects and, in addition, there was a significantly higher incidence of palpitations in the nifedipine group versus the placebo group (1/18 in placebo and 7/18 in treatment group, P = 0.020) as well as flushing (0/18 in placebo and 6/18 in treatment group, P = 0.010). <a href="./references#CD002069-bbs2-0002" title="KahanA , AmorB , MenkesCJ . Nicardipine in the treatment of Raynaud's phenomenon. Revue du Rhumatisme et des Maladies Osteo‐Articulaires1987;54(6):487‐90. KahanA , AmorB , MenkesCJ , WeberS , GuerinF , DegeorgesM . Nicardipine in the treatment of Raynaud's phenomenon: A randomized double‐blind trial. Angiology1987;38(4):333‐7. ">Kahan 1987</a> did not provide a breakdown by treatment group. <a href="./references#CD002069-bbs2-0007" title="WollersheimH , ThienT . Double‐blind placebo‐controlled crossover study of oral nicardipine in the treatment of Raynaud's phenomenon. Journal of Cardiovascular Pharmacology1991;18(6):813‐8. ">Wollersheim 1991</a> did not provide a breakdown but flushing, palpitations and headaches were referred to as common adverse events – 39 adverse events/16 participants in placebo group and 50 adverse events/16 participants in treatment group plus 1 discontinued therapy/16 participants in placebo group and 2 discontinued therapy/16 participants in treatment group. <a href="./references#CD002069-bbs2-0006" title="VayssairatM , BoccalonH , GinestetMC , PriolletP , FrancoA , CarpentierP , et al. Controlled multicenter double‐blind trial of nicardipine in the treatment of primary Raynaud phenomenon. American Heart Journal1991;122(1 Suppl 2):352‐5. ">Vayssairat 1991</a> reported that the number of participants with at least one side effect was significantly higher in the nifedipine group versus placebo (19 versus 7, P &lt; 0.05) with headaches (12 versus 1, P &lt; 0.05) and oedema (9 versus 2, P &lt; 0.05) listed as occurring significantly more often when taking nifedipine compared to placebo. They reported no significant differences in occurrence of flushing and/or erythema, vertigo, nausea, cutaneous rash, 'various' and withdrawal from the trial (no P values reported from McNemar's test, with insufficient detail to reproduce the analysis). <a href="./references#CD002069-bbs2-0004" title="MaricqHR , JenningsJR , ValterI , FrederickM , ThompsonB , SmithEA , et al. Evaluation of treatment efficacy of Raynaud phenomenon by digital blood pressure response to cooling. Raynaud's Treatment Study Investigators. Vascular Medicine2000;5(3):135‐40. MiddaughSJ , HaythornthwaiteJA , ThompsonB , HillR , BrownKM , FreedmanRR , et al. The Raynaud's Treatment Study: biofeedback protocols and acquisition of temperature biofeedback skills. Applied Psychophysiology and Biofeedback2001;26(4):251‐78. Raynaud's Treatment Study Investigators. Comparison of sustained‐release nifedipine and temperature biofeedback for treatment of primary Raynaud phenomenon. Results from a randomized clinical trial with 1‐year follow‐up. Archives of Internal Medicine2000;160(8):1101‐8. ThompsonB , GellerNL , HunsbergerS , FrederickM , HillR , JacobRG , et al. Behavioral and pharmacologic interventions: the Raynaud's Treatment Study. Controlled Clinical Trials1999;20(1):52‐63. ">RTS 2000</a> reported a higher incidence of oedema, flushing and headaches (8/77 headaches in placebo group versus 13/77 in treatment group, P &lt; 0.001) in the nifedipine group compared to the placebo group, and two participants in the nifedipine group reported tachycardia. </p> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD002069-sec-0081" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD002069-sec-0081"></div> <section id="CD002069-sec-0082"> <h3 class="title" id="CD002069-sec-0082">Summary of main results</h3> <p>This review summarises the evidence for the use of calcium channel blockers in the treatment of primary Raynaud's phenomenon. Of the 69 studies identified by the search (which examined 11 different calcium channel blockers), seven trials with a total of 296 participants were included in the review. The remaining 62 studies did not match the inclusion criteria of this review. Four of the seven included trials investigated nifedipine, and three investigated nicardipine. </p> <p>Only two trials (<a href="./references#CD002069-bbs2-0002" title="KahanA , AmorB , MenkesCJ . Nicardipine in the treatment of Raynaud's phenomenon. Revue du Rhumatisme et des Maladies Osteo‐Articulaires1987;54(6):487‐90. KahanA , AmorB , MenkesCJ , WeberS , GuerinF , DegeorgesM . Nicardipine in the treatment of Raynaud's phenomenon: A randomized double‐blind trial. Angiology1987;38(4):333‐7. ">Kahan 1987</a>; <a href="./references#CD002069-bbs2-0006" title="VayssairatM , BoccalonH , GinestetMC , PriolletP , FrancoA , CarpentierP , et al. Controlled multicenter double‐blind trial of nicardipine in the treatment of primary Raynaud phenomenon. American Heart Journal1991;122(1 Suppl 2):352‐5. ">Vayssairat 1991</a>), provided any detail of statistical comparisons of (unvalidated) severity scores between treatment groups: one of these trials (60 participants) reported a mean severity score of 1.55 on placebo and 1.36 on nicardipine, difference 0.2 (95% CI of difference 0 to 0.4, no P value reported) and the other trial (three participants only with primary Raynaud's phenomenon) reported a median severity score of 2 on both nicardipine and placebo treatment (P &gt; 0.999). The contrasting results may be partially explained by differences in how severity was quantified across the trials, using unvalidated scales. Participant‐preference scores were included in four trials, but in only two were results specific to participants with primary Raynaud's phenomenon, and scoring systems differed between trials: scores differed between treatments in only one trial, in which 33% of participants on placebo and 73% on nifedipine reported improvement in symptoms (P &lt; 0.001). Physiological measurements were included as outcome measures in five trials (different methodologies were used in each): in none of these trials were any between‐treatment group differences found. Treatment with calcium channel blockers was associated with a number of adverse reactions including headaches, flushing and oedema. </p> <p>The meta‐analysis of the seven trials indicated a statistically significant advantage of treatment with calcium channel blockers compared to placebo as measured by the number of Raynaud's attacks per week. However, this significant treatment effect was no longer observed when the analysis was repeated without <a href="./references#CD002069-bbs2-0004" title="MaricqHR , JenningsJR , ValterI , FrederickM , ThompsonB , SmithEA , et al. Evaluation of treatment efficacy of Raynaud phenomenon by digital blood pressure response to cooling. Raynaud's Treatment Study Investigators. Vascular Medicine2000;5(3):135‐40. MiddaughSJ , HaythornthwaiteJA , ThompsonB , HillR , BrownKM , FreedmanRR , et al. The Raynaud's Treatment Study: biofeedback protocols and acquisition of temperature biofeedback skills. Applied Psychophysiology and Biofeedback2001;26(4):251‐78. Raynaud's Treatment Study Investigators. Comparison of sustained‐release nifedipine and temperature biofeedback for treatment of primary Raynaud phenomenon. Results from a randomized clinical trial with 1‐year follow‐up. Archives of Internal Medicine2000;160(8):1101‐8. ThompsonB , GellerNL , HunsbergerS , FrederickM , HillR , JacobRG , et al. Behavioral and pharmacologic interventions: the Raynaud's Treatment Study. Controlled Clinical Trials1999;20(1):52‐63. ">RTS 2000</a>. This trial included the largest number of participants (158), was conducted over a longer period and was the one which suggested most benefit from a calcium channel blocker. It is possible that the larger effect size was attributable to the longer follow‐up period. The use of multiple imputation and the number of participants within the treatment arm who received 0 mg of nifedipine may contribute to the different findings in <a href="./references#CD002069-bbs2-0004" title="MaricqHR , JenningsJR , ValterI , FrederickM , ThompsonB , SmithEA , et al. Evaluation of treatment efficacy of Raynaud phenomenon by digital blood pressure response to cooling. Raynaud's Treatment Study Investigators. Vascular Medicine2000;5(3):135‐40. MiddaughSJ , HaythornthwaiteJA , ThompsonB , HillR , BrownKM , FreedmanRR , et al. The Raynaud's Treatment Study: biofeedback protocols and acquisition of temperature biofeedback skills. Applied Psychophysiology and Biofeedback2001;26(4):251‐78. Raynaud's Treatment Study Investigators. Comparison of sustained‐release nifedipine and temperature biofeedback for treatment of primary Raynaud phenomenon. Results from a randomized clinical trial with 1‐year follow‐up. Archives of Internal Medicine2000;160(8):1101‐8. ThompsonB , GellerNL , HunsbergerS , FrederickM , HillR , JacobRG , et al. Behavioral and pharmacologic interventions: the Raynaud's Treatment Study. Controlled Clinical Trials1999;20(1):52‐63. ">RTS 2000</a>, although these factors would be expected to decrease rather than increase the estimate of effect. </p> <p>When the meta‐analysis was repeated for each of the two calcium channel blockers individually, the estimate of treatment effect was statistically significant for the four nifedipine trials but this result was not robust to a secondary analysis using a random‐effects method. No overall effect of nicardipine was found. </p> <p>All the studies reported adverse events although it was not always possible within studies including participants with both primary and secondary Raynaud's phenomenon to determine the adverse reactions for the primary Raynaud's group alone. </p> </section> <section id="CD002069-sec-0083"> <h3 class="title" id="CD002069-sec-0083">Overall completeness and applicability of evidence</h3> <p>This meta‐analysis highlighted several difficulties inherent in the existing clinical trials of calcium channel blockers in primary Raynaud's phenomenon: </p> <p>a) The overall quality of the data was very variable with the result that the only outcome measure that could be compared using a meta‐analysis across all seven included trials was the frequency of Raynaud's attacks. This meta‐analysis therefore emphasises the need for validated outcome measures for Raynaud's phenomenon. </p> <p>b) A large number of trials were excluded because it was not possible to separate out participants with primary and secondary Raynaud's phenomenon, or because of inadequate wash‐out periods within cross‐over trial designs. </p> <p>c) Sample size was small, resulting from the small number of trials which could be included, and the small numbers of participants included in most of these seven trials. </p> <p>d) The dose of calcium channel blockers used may not reflect maximum doses used in current clinical practice: for example, many clinicians increase the nifedipine dose to 80 mg daily. Also, in only one study was treatment duration longer than 10 weeks, with most studies having much shorter treatment periods. </p> <p>e) The categorisation and assessment of some of the participants classed as having primary Raynaud's phenomenon was sometimes unsatisfactory with reports of digital gangrene and positive ANA titres suggesting that some participants had secondary rather than primary Raynaud's phenomenon. However, this has to be set against the 'real‐world' background in which the distinction between primary and secondary Raynaud's phenomenon can be difficult; around 1% to 2% per year of those who present with what initially seems to be primary Raynaud's phenomenon go on to develop a systemic sclerosis spectrum disorder or some other underlying disease (<a href="./references#CD002069-bbs2-0084" title="HirschlM , HirschlK , LenzM , KatzenschlagerR , HutterHP , KundiM . Transition from primary Raynaud's phenomenon to secondary Raynaud's phenomenon identified by diagnosis of an associated disease; results of ten years of prospective surveillance. Arthritis and Rheumatism2006;54(6):1974‐81. ">Hirschl 2006</a>). </p> </section> <section id="CD002069-sec-0084"> <h3 class="title" id="CD002069-sec-0084">Quality of the evidence</h3> <p>We conducted an assessment of overall quality of the evidence according to the GRADE approach (<a href="./references#CD002069-bbs2-0077" title="GRADE Working Group. Grading quality of evidence and strength of recommendations. British Medical Journal2004;328:1490‐4. ">GRADE Working Group 2004</a>; <a href="./references#CD002069-bbs2-0094" title="SchunemannHJ , JaeschkeR , CookDJ , BriaWF , El‐SolhAA , ErnstA , et al. ATS Documents Development and Implementation Committee. An official ATS statement: grading the quality of evidence and strength of recommendations in ATS guidelines and recommendations. American Journal of Respiratory and Critical Care Medicine2006;174(5):605‐14. ">Schunemann 2006</a>; <a href="./references#CD002069-bbs2-0078" title="GuyattGH , OxmanAD , KunzR , VistGE , Falck‐YtterY , SchunemannHJ , GRADE Working Group. What is 'quality of evidence' and why is it so important to clinicians?. British Medical Journal2008;336(7651):995‐8. ">Guyatt 2008a</a>; <a href="./references#CD002069-bbs2-0079" title="GuyattGH , OxmanAD , VistGE , KunzR , Falck‐YtterY , Alonso‐CoelloP , et al. GRADE Working Group. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. British Medical Journal2008;336(7650):924‐6. ">Guyatt 2008b</a>; <a href="./references#CD002069-bbs2-0083" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>). All seven trials included in the review were described as randomised, double‐blind, placebo‐controlled trials and were judged to be sound in terms of design. Allocation concealment was not fully described in six out of the seven trials, and although described as 'double‐blinded', details of how blinding was ensured were not provided. Although detail was lacking in this regard, the review authors did not feel that there was a high likelihood of bias as a result. </p> <p>Our population of interest was people with primary Raynaud's phenomenon and as such we excluded trials where results for primary Raynaud's participants were not identifiable. Although the demographic information reported across the seven included trials was relatively limited, the sample was broadly representative in terms of gender balance and age range. It should be noted, however, that this sample was predominantly hospital‐based and all seven trials recruited from hospital clinics, with the exception of <a href="./references#CD002069-bbs2-0004" title="MaricqHR , JenningsJR , ValterI , FrederickM , ThompsonB , SmithEA , et al. Evaluation of treatment efficacy of Raynaud phenomenon by digital blood pressure response to cooling. Raynaud's Treatment Study Investigators. Vascular Medicine2000;5(3):135‐40. MiddaughSJ , HaythornthwaiteJA , ThompsonB , HillR , BrownKM , FreedmanRR , et al. The Raynaud's Treatment Study: biofeedback protocols and acquisition of temperature biofeedback skills. Applied Psychophysiology and Biofeedback2001;26(4):251‐78. Raynaud's Treatment Study Investigators. Comparison of sustained‐release nifedipine and temperature biofeedback for treatment of primary Raynaud phenomenon. Results from a randomized clinical trial with 1‐year follow‐up. Archives of Internal Medicine2000;160(8):1101‐8. ThompsonB , GellerNL , HunsbergerS , FrederickM , HillR , JacobRG , et al. Behavioral and pharmacologic interventions: the Raynaud's Treatment Study. Controlled Clinical Trials1999;20(1):52‐63. ">RTS 2000</a> where participants were also recruited via advertisement. A significant proportion of people with primary Raynaud's phenomenon are not referred to hospital for evaluation and treatment: it is likely that those who are may be more severely affected or may not have responded to conservative measures, or both, and these are the participants mainly presented in this meta‐analysis. Another potential concern (highlighted above) is that the doses of calcium channel blockers used within the seven trials are lower than the maximum doses administered in clinical practice. The estimates of treatment effect observed in these seven trials may therefore underestimate the effect of calcium channel blockers. </p> <p>Further comments regarding quality of the evidence relating to specific outcomes considered in the review follow: </p> <section id="CD002069-sec-0085"> <h4 class="title">Number of attacks</h4> <p>With the exception of <a href="./references#CD002069-bbs2-0004" title="MaricqHR , JenningsJR , ValterI , FrederickM , ThompsonB , SmithEA , et al. Evaluation of treatment efficacy of Raynaud phenomenon by digital blood pressure response to cooling. Raynaud's Treatment Study Investigators. Vascular Medicine2000;5(3):135‐40. MiddaughSJ , HaythornthwaiteJA , ThompsonB , HillR , BrownKM , FreedmanRR , et al. The Raynaud's Treatment Study: biofeedback protocols and acquisition of temperature biofeedback skills. Applied Psychophysiology and Biofeedback2001;26(4):251‐78. Raynaud's Treatment Study Investigators. Comparison of sustained‐release nifedipine and temperature biofeedback for treatment of primary Raynaud phenomenon. Results from a randomized clinical trial with 1‐year follow‐up. Archives of Internal Medicine2000;160(8):1101‐8. ThompsonB , GellerNL , HunsbergerS , FrederickM , HillR , JacobRG , et al. Behavioral and pharmacologic interventions: the Raynaud's Treatment Study. Controlled Clinical Trials1999;20(1):52‐63. ">RTS 2000</a>, which had a higher 95% lower confidence limit for the standardised mean difference in the number of Raynaud's attacks, the 95% CIs were generally consistent across the trials. A sensitivity analysis with <a href="./references#CD002069-bbs2-0004" title="MaricqHR , JenningsJR , ValterI , FrederickM , ThompsonB , SmithEA , et al. Evaluation of treatment efficacy of Raynaud phenomenon by digital blood pressure response to cooling. Raynaud's Treatment Study Investigators. Vascular Medicine2000;5(3):135‐40. MiddaughSJ , HaythornthwaiteJA , ThompsonB , HillR , BrownKM , FreedmanRR , et al. The Raynaud's Treatment Study: biofeedback protocols and acquisition of temperature biofeedback skills. Applied Psychophysiology and Biofeedback2001;26(4):251‐78. Raynaud's Treatment Study Investigators. Comparison of sustained‐release nifedipine and temperature biofeedback for treatment of primary Raynaud phenomenon. Results from a randomized clinical trial with 1‐year follow‐up. Archives of Internal Medicine2000;160(8):1101‐8. ThompsonB , GellerNL , HunsbergerS , FrederickM , HillR , JacobRG , et al. Behavioral and pharmacologic interventions: the Raynaud's Treatment Study. Controlled Clinical Trials1999;20(1):52‐63. ">RTS 2000</a> excluded failed to reproduce the significant treatment difference observed in the meta‐analysis of all seven trials. In this review, the longer follow‐up time of <a href="./references#CD002069-bbs2-0004" title="MaricqHR , JenningsJR , ValterI , FrederickM , ThompsonB , SmithEA , et al. Evaluation of treatment efficacy of Raynaud phenomenon by digital blood pressure response to cooling. Raynaud's Treatment Study Investigators. Vascular Medicine2000;5(3):135‐40. MiddaughSJ , HaythornthwaiteJA , ThompsonB , HillR , BrownKM , FreedmanRR , et al. The Raynaud's Treatment Study: biofeedback protocols and acquisition of temperature biofeedback skills. Applied Psychophysiology and Biofeedback2001;26(4):251‐78. Raynaud's Treatment Study Investigators. Comparison of sustained‐release nifedipine and temperature biofeedback for treatment of primary Raynaud phenomenon. Results from a randomized clinical trial with 1‐year follow‐up. Archives of Internal Medicine2000;160(8):1101‐8. ThompsonB , GellerNL , HunsbergerS , FrederickM , HillR , JacobRG , et al. Behavioral and pharmacologic interventions: the Raynaud's Treatment Study. Controlled Clinical Trials1999;20(1):52‐63. ">RTS 2000</a> has been proposed as a possible explanation for this potentially discordant interval (the difference is not so severe that the intervals do not overlap). Small numbers of participants with primary Raynaud's phenomenon were included in several trials (<a href="./references#CD002069-bbs2-0003" title="RodehefferRJ , RommerJA , WigleyF , SmithCR . Controlled double‐blind trial of nifedipine in the treatment of Raynaud's phenomenon. New England Journal of Medicine1983;308(15):880‐3. ">Rodeheffer 1983</a>; <a href="./references#CD002069-bbs2-0001" title="EttingerWH , WiseRA , SchaffhauserD , WigleyFM . Controlled double‐blind trial of dazoxiben and nifedipine in the treatment of Raynaud's phenomenon. American Journal of Medicine1984;77(3):451‐6. MalametR , WiseRA , EttingerEH , WigleyFM . Nifedipine in the treatment of Raynaud's phenomenon. Evidence for inhibition of platelet activation. American Journal of Medicine1985;78(4):602‐8. WigleyFM , MalametR , WiseRA . Reproducibility of cold provocation in patients with Raynaud's phenomenon. Journal of Rheumatology1987;14(4):751‐5. ">Ettinger 1984</a>; <a href="./references#CD002069-bbs2-0002" title="KahanA , AmorB , MenkesCJ . Nicardipine in the treatment of Raynaud's phenomenon. Revue du Rhumatisme et des Maladies Osteo‐Articulaires1987;54(6):487‐90. KahanA , AmorB , MenkesCJ , WeberS , GuerinF , DegeorgesM . Nicardipine in the treatment of Raynaud's phenomenon: A randomized double‐blind trial. Angiology1987;38(4):333‐7. ">Kahan 1987</a>). The 95% confidence intervals for the standardised mean difference in the number of Raynaud's attacks in both <a href="./references#CD002069-bbs2-0003" title="RodehefferRJ , RommerJA , WigleyF , SmithCR . Controlled double‐blind trial of nifedipine in the treatment of Raynaud's phenomenon. New England Journal of Medicine1983;308(15):880‐3. ">Rodeheffer 1983</a> and <a href="./references#CD002069-bbs2-0002" title="KahanA , AmorB , MenkesCJ . Nicardipine in the treatment of Raynaud's phenomenon. Revue du Rhumatisme et des Maladies Osteo‐Articulaires1987;54(6):487‐90. KahanA , AmorB , MenkesCJ , WeberS , GuerinF , DegeorgesM . Nicardipine in the treatment of Raynaud's phenomenon: A randomized double‐blind trial. Angiology1987;38(4):333‐7. ">Kahan 1987</a> were wide, corresponding to a lack of precision in the estimates of treatment effect. The standard error for the estimate of treatment effect in <a href="./references#CD002069-bbs2-0001" title="EttingerWH , WiseRA , SchaffhauserD , WigleyFM . Controlled double‐blind trial of dazoxiben and nifedipine in the treatment of Raynaud's phenomenon. American Journal of Medicine1984;77(3):451‐6. MalametR , WiseRA , EttingerEH , WigleyFM . Nifedipine in the treatment of Raynaud's phenomenon. Evidence for inhibition of platelet activation. American Journal of Medicine1985;78(4):602‐8. WigleyFM , MalametR , WiseRA . Reproducibility of cold provocation in patients with Raynaud's phenomenon. Journal of Rheumatology1987;14(4):751‐5. ">Ettinger 1984</a>, however, was small due to the high within‐participant correlation (ρ = 0.953) and the 95% confidence interval calculated from this study was not too wide. Although <a href="./references#CD002069-bbs2-0003" title="RodehefferRJ , RommerJA , WigleyF , SmithCR . Controlled double‐blind trial of nifedipine in the treatment of Raynaud's phenomenon. New England Journal of Medicine1983;308(15):880‐3. ">Rodeheffer 1983</a> and <a href="./references#CD002069-bbs2-0002" title="KahanA , AmorB , MenkesCJ . Nicardipine in the treatment of Raynaud's phenomenon. Revue du Rhumatisme et des Maladies Osteo‐Articulaires1987;54(6):487‐90. KahanA , AmorB , MenkesCJ , WeberS , GuerinF , DegeorgesM . Nicardipine in the treatment of Raynaud's phenomenon: A randomized double‐blind trial. Angiology1987;38(4):333‐7. ">Kahan 1987</a> received a very low weighting in the meta‐analysis on account of their large standard errors, the presence of studies with small samples constitutes a limiting feature of these trials as a body of evidence. On account of this, the review authors revised their assessment of the quality of evidence provided by these trials to 'moderate' for number of attacks. </p> </section> <section id="CD002069-sec-0086"> <h4 class="title">Duration of attacks</h4> <p>The quality of evidence for the outcome duration of attacks was considered to be very low due to the fact that only information on 13 participants in one trial was provided (<a href="./references#CD002069-bbs2-0007" title="WollersheimH , ThienT . Double‐blind placebo‐controlled crossover study of oral nicardipine in the treatment of Raynaud's phenomenon. Journal of Cardiovascular Pharmacology1991;18(6):813‐8. ">Wollersheim 1991</a>), and no information on variation in response (precision) was available. </p> </section> <section id="CD002069-sec-0087"> <h4 class="title">Severity scores</h4> <p>While six trials reported on severity scores, only one trial reported on this outcome in a manner that allowed for robust conclusions to be drawn (<a href="./references#CD002069-bbs2-0006" title="VayssairatM , BoccalonH , GinestetMC , PriolletP , FrancoA , CarpentierP , et al. Controlled multicenter double‐blind trial of nicardipine in the treatment of primary Raynaud phenomenon. American Heart Journal1991;122(1 Suppl 2):352‐5. ">Vayssairat 1991</a>). This was a well‐designed cross‐over study of 60 participants and the evidence arising from this study was consistent with the limited information provided by the remainder. As such, we believe the quality of evidence in relation to the outcome severity scores to be high. </p> </section> <section id="CD002069-sec-0088"> <h4 class="title">Patient preference scores</h4> <p>We considered the quality of evidence in relation to patient preference scores to be low. No information on variation in response was available, incommensurate scales were used between studies and two studies did not report results separately for primary Raynaud's phenomenon participants. Accordingly, it is difficult to comment on the effect of calcium channel blockers on patient preference scores. </p> <p>Due to the small number of trials meeting the inclusion criteria of this review, a definitive assessment of publication bias using a funnel plot was not possible. However, the search strategy employed in this review was robust, including conference abstracts in addition to published papers. Furthermore, several of the studies included here contained results best described as null findings. We did not deem the risk of publication bias to be substantial enough to downgrade our assessment of the quality of this body of evidence. </p> </section> </section> <section id="CD002069-sec-0089"> <h3 class="title" id="CD002069-sec-0089">Potential biases in the review process</h3> <p>None of the review authors was involved in any of the included or excluded studies, and none of us has any relevant commercial or other conflicts of interest. The Trial Search Co‐ordinator conducted extensive searches for relevant articles and for details of ongoing studies, to reduce the risk of publication bias. Three review authors independently assessed all studies. As described in the review, we also attempted to deal with missing information and data by contacting authors. No further information was available, however, and missing data could introduce bias into the results of four of the seven studies where multiple imputation had not been attempted and could not be performed by the review authors. This, in turn, could introduce bias into the results of the meta‐analyses presented here. Two trials (<a href="./references#CD002069-bbs2-0001" title="EttingerWH , WiseRA , SchaffhauserD , WigleyFM . Controlled double‐blind trial of dazoxiben and nifedipine in the treatment of Raynaud's phenomenon. American Journal of Medicine1984;77(3):451‐6. MalametR , WiseRA , EttingerEH , WigleyFM . Nifedipine in the treatment of Raynaud's phenomenon. Evidence for inhibition of platelet activation. American Journal of Medicine1985;78(4):602‐8. WigleyFM , MalametR , WiseRA . Reproducibility of cold provocation in patients with Raynaud's phenomenon. Journal of Rheumatology1987;14(4):751‐5. ">Ettinger 1984</a>; <a href="./references#CD002069-bbs2-0006" title="VayssairatM , BoccalonH , GinestetMC , PriolletP , FrancoA , CarpentierP , et al. Controlled multicenter double‐blind trial of nicardipine in the treatment of primary Raynaud phenomenon. American Heart Journal1991;122(1 Suppl 2):352‐5. ">Vayssairat 1991</a>), are of concern in this respect, as both received high weighting in the meta‐analysis of all trials. </p> </section> <section id="CD002069-sec-0090"> <h3 class="title" id="CD002069-sec-0090">Agreements and disagreements with other studies or reviews</h3> <p>A previous meta‐analysis (<a href="./references#CD002069-bbs2-0098" title="ThompsonAE , PopeJE . Calcium channel blockers for primary Raynaud's phenomenon: a meta‐analysis. Rheumatology2005;44(2):145‐50. ">Thompson 2005</a>), indicated a statistically significant advantage of treatment with calcium channel blockers over placebo in primary Raynaud's phenomenon, with a decrease of between 2.8 to 5 attacks per week. The estimate of treatment effect was statistically significant for nifedipine but not significant for nicardipine or nisoldipine. Inclusion criteria, however, differed from those for this Cochrane review. Trials were included if the number of participants with primary Raynaud's phenomenon exceeded 75%, and trials with a cross‐over design but no wash‐out period were also included. As a result, the following trials were included by <a href="./references#CD002069-bbs2-0098" title="ThompsonAE , PopeJE . Calcium channel blockers for primary Raynaud's phenomenon: a meta‐analysis. Rheumatology2005;44(2):145‐50. ">Thompson 2005</a> but excluded from this review: <a href="./references#CD002069-bbs2-0035" title="KahanA , WeberS , AmorB , MenkesCJ , HodaraM , DegeorgesM . Nifedipine and Raynaud's phenomenon associated with connective tissue diseases. International Angiology1985;4(2):221‐3. KahanA , WeberS , AmorB , MenkesCJ , SaportaL , HodaraM , et al. Calcium entry blocking agents in digital vasospasm (Raynaud's phenomenon). European Heart Journal1983;4(Suppl C):123‐9. KahanA , WeberS , AmorB , SaportaL , HodaraM , DegeorgesM . Controlled study of nifedipine in the treatment of Raynaud's phenomenon. Revue du Rhumatisme et des Maladies Osteo‐Articulaires1982;49(5):337‐43. ">Kahan 1983a</a>; <a href="./references#CD002069-bbs2-0037" title="KahanA , AmorB , MenkesCJ . A randomised double‐blind trial of diltiazem in the treatment of Raynaud's phenomenon. Annals of the Rheumatic Diseases1985;44(1):30‐3. ">Kahan 1985a</a>; <a href="./references#CD002069-bbs2-0038" title="KahanA , FoultJM , WeberS , AmorB , MenkesCJ , DegeorgesM . Nifedipine and alpha1‐adrenergic blockade in Raynaud's phenomenon. European Heart Journal1985;6(8):702‐5. ">Kahan 1985b</a>; <a href="./references#CD002069-bbs2-0009" title="AldooriM , CampbellWB , DieppePA . Nifedipine in the treatment of Raynaud's syndrome. Cardiovascular Research1986;20(6):466‐70. ">Aldoori 1986</a>; <a href="./references#CD002069-bbs2-0018" title="CorbinDO , WoodDA , MacintyreCC , HousleyE . A randomized double blind cross‐over trial of nifedipine in the treatment of primary Raynaud's phenomenon. European Heart Journal1986;7(2):165‐70. CorbinDOC , WoodDA , MacintyreCCA , HousleyEl . A randomised double blind cross‐over trial of nifedipine in the treatment of primary Raynaud's phenomenon [abstract]. Clinical Science1985; Vol. 69, issue Suppl 12:21P. ">Corbin 1986</a>; <a href="./references#CD002069-bbs2-0030" title="GjorupT , KelbaekH , HartlingOJ , NielsenSL . Controlled double‐blind trial of the clinical effect of nifedipine in the treatment of idiopathic Raynaud's phenomenon. American Heart Journal1986;111(4):742‐5. ">Gjorup 1986a</a>; <a href="./references#CD002069-bbs2-0031" title="GjorupT , HartlingOJ , KelbaekH , NielsenSL . Controlled double blind trial of nisoldipine in the treatment of idiopathic Raynaud's phenomenon. European Journal of Clinical Pharmacology1986;31(4):387‐9. ">Gjorup 1986b</a>; <a href="./references#CD002069-bbs2-0053" title="Rivera RedondoJ , Noguerado AsensioA , López BoteJP , Alvaro‐Gracia AlvaroJM , Ossorio CastellanosC . Nifedipine treatment of Raynaud's phenomenon: a double blind controlled clinical study. Revista Espanola de Reumatologia1986;13:121‐3. ">Redondo 1986</a>; <a href="./references#CD002069-bbs2-0064" title="FrancisDA , WallerDG , ChallenorVF , RoathOS . Red cell deformability in patients with Raynaud's phenomenon treated with nifedipine. Clinical Hemorheology1985; Vol. 5, issue 5:742. WallerDG , ChallenorVF , FrancisDA , RoathOS . Clinical and rheological effects of nifedipine in Raynaud's phenomenon. British Journal of Clinical Pharmacology1986;22(4):449‐54. ">Waller 1986</a>; <a href="./references#CD002069-bbs2-0013" title="ChallenorVF , WallerDG , FrancisDA , FrancisJL , ManiR , RoathS . Nisoldipine in primary Raynaud's phenomenon. European Journal of Clinical Pharmacology1987;33(1):27‐30. FrancisJL , RoathOS , ChallenorVF , WallerDG . The effect of nisoldipine on whole blood platelet aggregation in patients with Raynaud's phenomenon. British Journal of Clinical Pharmacology1988;25(6):751‐4. ">Challenor 1987</a>; <a href="./references#CD002069-bbs2-0051" title="NilssonH , JonasonT , LeppertJ , RingqvistI . The effect of the calcium‐entry blocker nifedipine on cold‐induced digital vasospasm. A double‐blind crossover study versus placebo. Acta Medica Scandinavica1987;221(1):53‐60. ">Nilsson 1987</a>; <a href="./references#CD002069-bbs2-0014" title="ChallenorVF , WallerDG , HaywardRA , GriffinMJ , RoathOS . Vibrotactile sensation and response to nifedipine dose titration in primary Raynaud's phenomenon. Angiology1989;40(2):122‐8. ">Challenor 1989</a>. In one case, a trial was excluded by <a href="./references#CD002069-bbs2-0098" title="ThompsonAE , PopeJE . Calcium channel blockers for primary Raynaud's phenomenon: a meta‐analysis. Rheumatology2005;44(2):145‐50. ">Thompson 2005</a> on the grounds of insufficient data for primary Raynaud's participants but was included within this review (<a href="./references#CD002069-bbs2-0007" title="WollersheimH , ThienT . Double‐blind placebo‐controlled crossover study of oral nicardipine in the treatment of Raynaud's phenomenon. Journal of Cardiovascular Pharmacology1991;18(6):813‐8. ">Wollersheim 1991</a>). Despite these different inclusion criteria, the results presented here can be seen as consistent with the findings of <a href="./references#CD002069-bbs2-0098" title="ThompsonAE , PopeJE . Calcium channel blockers for primary Raynaud's phenomenon: a meta‐analysis. Rheumatology2005;44(2):145‐50. ">Thompson 2005</a> . </p> <p><a href="./references#CD002069-bbs2-0098" title="ThompsonAE , PopeJE . Calcium channel blockers for primary Raynaud's phenomenon: a meta‐analysis. Rheumatology2005;44(2):145‐50. ">Thompson 2005</a> also included data on the severity of Raynaud's attacks within the meta‐analysis. However, we decided not to pool these data because of variation across the seven included trials in terms of scale, description and usage. Instead, we have reported the severity results separately for each trial in which they were reported. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD002069-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002069.pub5/media/CDSR/CD002069/urn:x-wiley:14651858:media:CD002069:CD002069-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002069.pub5/media/CDSR/CD002069/image_t/tCD002069-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram." data-id="CD002069-fig-0001" src="/cdsr/doi/10.1002/14651858.CD002069.pub5/media/CDSR/CD002069/image_n/nCD002069-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002069.pub5/full#CD002069-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002069.pub5/media/CDSR/CD002069/image_n/nCD002069-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002069-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002069.pub5/media/CDSR/CD002069/urn:x-wiley:14651858:media:CD002069:CD002069-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002069.pub5/media/CDSR/CD002069/image_t/tCD002069-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD002069-fig-0002" src="/cdsr/doi/10.1002/14651858.CD002069.pub5/media/CDSR/CD002069/image_n/nCD002069-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002069.pub5/full#CD002069-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002069.pub5/media/CDSR/CD002069/image_n/nCD002069-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002069-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002069.pub5/media/CDSR/CD002069/urn:x-wiley:14651858:media:CD002069:CD002069-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002069.pub5/media/CDSR/CD002069/image_t/tCD002069-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Calcium channel blockers versus placebo, Outcome: 1 Number of attacks." data-id="CD002069-fig-0003" src="/cdsr/doi/10.1002/14651858.CD002069.pub5/media/CDSR/CD002069/image_n/nCD002069-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Comparison 1 Calcium channel blockers versus placebo, Outcome: 1 Number of attacks.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002069.pub5/full#CD002069-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002069.pub5/media/CDSR/CD002069/image_n/nCD002069-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002069-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002069.pub5/media/CDSR/CD002069/urn:x-wiley:14651858:media:CD002069:CD002069-AFig-FIG04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002069.pub5/media/CDSR/CD002069/image_t/tCD002069-AFig-FIG04.png" target="_blank"><b></b></a></p> </div><img alt="Comparison: 1 Calcium channel blockers versus placebo, Outcome: 1.5 Number of attacks ‐ without RTS 2000 (sensitivity analysis)." data-id="CD002069-fig-0004" src="/cdsr/doi/10.1002/14651858.CD002069.pub5/media/CDSR/CD002069/image_n/nCD002069-AFig-FIG04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p>Comparison: 1 Calcium channel blockers versus placebo, Outcome: 1.5 Number of attacks ‐ without RTS 2000 (sensitivity analysis). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002069.pub5/full#CD002069-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002069.pub5/media/CDSR/CD002069/image_n/nCD002069-AFig-FIG04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002069-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002069.pub5/media/CDSR/CD002069/urn:x-wiley:14651858:media:CD002069:CD002069-AFig-FIG05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002069.pub5/media/CDSR/CD002069/image_t/tCD002069-AFig-FIG05.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Calcium channel blockers versus placebo, Outcome: 1.2 Number of attacks ‐ Nifedipine trials only." data-id="CD002069-fig-0005" src="/cdsr/doi/10.1002/14651858.CD002069.pub5/media/CDSR/CD002069/image_n/nCD002069-AFig-FIG05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 5</div> <div class="figure-caption"> <p>Comparison 1: Calcium channel blockers versus placebo, Outcome: 1.2 Number of attacks ‐ Nifedipine trials only. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002069.pub5/full#CD002069-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002069.pub5/media/CDSR/CD002069/image_n/nCD002069-AFig-FIG05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002069-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002069.pub5/media/CDSR/CD002069/urn:x-wiley:14651858:media:CD002069:CD002069-AFig-FIG06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002069.pub5/media/CDSR/CD002069/image_t/tCD002069-AFig-FIG06.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Calcium channel blockers versus placebo, Outcome: 1.3 Number of attacks ‐ Nicardipine trials only." data-id="CD002069-fig-0006" src="/cdsr/doi/10.1002/14651858.CD002069.pub5/media/CDSR/CD002069/image_n/nCD002069-AFig-FIG06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 6</div> <div class="figure-caption"> <p>Comparison 1: Calcium channel blockers versus placebo, Outcome: 1.3 Number of attacks ‐ Nicardipine trials only. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002069.pub5/full#CD002069-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002069.pub5/media/CDSR/CD002069/image_n/nCD002069-AFig-FIG06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002069-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002069.pub5/media/CDSR/CD002069/urn:x-wiley:14651858:media:CD002069:CD002069-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002069.pub5/media/CDSR/CD002069/image_t/tCD002069-CMP-001-01.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Calcium channel blockers versus placebo, Outcome 1 Number of attacks ‐ Primary." data-id="CD002069-fig-0007" src="/cdsr/doi/10.1002/14651858.CD002069.pub5/media/CDSR/CD002069/image_n/nCD002069-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 Calcium channel blockers versus placebo, Outcome 1 Number of attacks ‐ Primary. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002069.pub5/references#CD002069-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002069.pub5/media/CDSR/CD002069/image_n/nCD002069-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002069-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002069.pub5/media/CDSR/CD002069/urn:x-wiley:14651858:media:CD002069:CD002069-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002069.pub5/media/CDSR/CD002069/image_t/tCD002069-CMP-001-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Calcium channel blockers versus placebo, Outcome 2 Number of attacks ‐ without Ettinger (sensitivity analysis)." data-id="CD002069-fig-0008" src="/cdsr/doi/10.1002/14651858.CD002069.pub5/media/CDSR/CD002069/image_n/nCD002069-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 Calcium channel blockers versus placebo, Outcome 2 Number of attacks ‐ without Ettinger (sensitivity analysis). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002069.pub5/references#CD002069-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002069.pub5/media/CDSR/CD002069/image_n/nCD002069-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002069-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002069.pub5/media/CDSR/CD002069/urn:x-wiley:14651858:media:CD002069:CD002069-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002069.pub5/media/CDSR/CD002069/image_t/tCD002069-CMP-001-03.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Calcium channel blockers versus placebo, Outcome 3 Number of attacks ‐ without RTS 2000 (sensitivity analysis)." data-id="CD002069-fig-0009" src="/cdsr/doi/10.1002/14651858.CD002069.pub5/media/CDSR/CD002069/image_n/nCD002069-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 Calcium channel blockers versus placebo, Outcome 3 Number of attacks ‐ without RTS 2000 (sensitivity analysis). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002069.pub5/references#CD002069-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002069.pub5/media/CDSR/CD002069/image_n/nCD002069-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002069-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002069.pub5/media/CDSR/CD002069/urn:x-wiley:14651858:media:CD002069:CD002069-CMP-001-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002069.pub5/media/CDSR/CD002069/image_t/tCD002069-CMP-001-04.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Calcium channel blockers versus placebo, Outcome 4 Number of attacks ‐ Nifedipine trials only." data-id="CD002069-fig-0010" src="/cdsr/doi/10.1002/14651858.CD002069.pub5/media/CDSR/CD002069/image_n/nCD002069-CMP-001-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1 Calcium channel blockers versus placebo, Outcome 4 Number of attacks ‐ Nifedipine trials only. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002069.pub5/references#CD002069-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002069.pub5/media/CDSR/CD002069/image_n/nCD002069-CMP-001-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002069-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002069.pub5/media/CDSR/CD002069/urn:x-wiley:14651858:media:CD002069:CD002069-CMP-001-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002069.pub5/media/CDSR/CD002069/image_t/tCD002069-CMP-001-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Calcium channel blockers versus placebo, Outcome 5 Number of attacks ‐ Nifedipine trials only (random‐effects)." data-id="CD002069-fig-0011" src="/cdsr/doi/10.1002/14651858.CD002069.pub5/media/CDSR/CD002069/image_n/nCD002069-CMP-001-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1 Calcium channel blockers versus placebo, Outcome 5 Number of attacks ‐ Nifedipine trials only (random‐effects). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002069.pub5/references#CD002069-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002069.pub5/media/CDSR/CD002069/image_n/nCD002069-CMP-001-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002069-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002069.pub5/media/CDSR/CD002069/urn:x-wiley:14651858:media:CD002069:CD002069-CMP-001-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002069.pub5/media/CDSR/CD002069/image_t/tCD002069-CMP-001-06.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Calcium channel blockers versus placebo, Outcome 6 Number of attacks ‐ Nicardipine trials only." data-id="CD002069-fig-0012" src="/cdsr/doi/10.1002/14651858.CD002069.pub5/media/CDSR/CD002069/image_n/nCD002069-CMP-001-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1 Calcium channel blockers versus placebo, Outcome 6 Number of attacks ‐ Nicardipine trials only. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002069.pub5/references#CD002069-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002069.pub5/media/CDSR/CD002069/image_n/nCD002069-CMP-001-06.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD002069-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Calcium channel blockers for primary Raynauds's phenomenon</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Calcium channel blockers for primary Raynauds's phenomenon</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> primary Raynaud's phenomenon<br/> <b>Setting:</b> hospital and hospital outpatient clinics<br/> <b>Intervention:</b> calcium channel blockers<br/> <b>Comparison:</b> placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with Calcium channel blockers</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number of attacks</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>The mean number of attacks in the intervention group was 0.23 standard deviations more (0.08 more to 0.38 more) than the placebo group. This translates to 1.72 (0.60 to 2.84) fewer attacks per week. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>296<br/> (7 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Duration of attacks</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>One study reported mean attack duration of 11 minutes in placebo group compared to 13 minutes in Nicardipine group. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16</p> <p>(1 RCT)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW <sup>2 3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Severity scores</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>One study reported difference in mean (95% CI) severity score of 0.2 (0 to 0.4) in favour of nicardipine for 60 patients in a crossover study. One study had a median score of 2 for patients taking both placebo and nicardipine. One reported 'no significant difference' with no other information. Unable to make between‐group comparisons using information reported in other studies. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>291</p> <p>(6 RCTs)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> HIGH </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Please see <a href="#CD002069-sec-0084">Quality of the evidence</a> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Patient preference scores</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>One study reported mean improvement score of 0.6 vs 2.2 in favour of nifedipine, P = 0.25. One reported that 73% of patients considered symptoms to have improved on nifedipine compared to 33% on placebo. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>185</p> <p>(4 RCTs)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>4 5</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; <b>OR:</b> Odds ratio; </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate quality:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low quality:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low quality:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Small crossover studies given high weighting due to high correlation between treatment periods. 95% CI for pooled treatment estimate consistent with negligible to moderate treatment effectiveness.<br/> <sup>2</sup> Information from one study of 13 participants.<br/> <sup>3</sup> Only group means provided. No information on variability of response, so unable to establish precision.<br/> <sup>4</sup> Information on variability missing. Substantively different methods of recording prevent pooling.<br/> <sup>5</sup> Two studies did not report separately for primary Raynaud's phenomenon participants. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Calcium channel blockers for primary Raynauds's phenomenon</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD002069.pub5/full#CD002069-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD002069-tbl-0002"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Calcium channel blockers versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Number of attacks ‐ Primary <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>358</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.23 [0.08, 0.38]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Number of attacks ‐ without Ettinger (sensitivity analysis) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>352</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.26 [0.09, 0.43]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Number of attacks ‐ without RTS 2000 (sensitivity analysis) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>200</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.14 [‐0.03, 0.31]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Number of attacks ‐ Nifedipine trials only <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>206</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.32 [0.10, 0.54]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Number of attacks ‐ Nifedipine trials only (random‐effects) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>206</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.31 [‐0.05, 0.68]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Number of attacks ‐ Nicardipine trials only <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>152</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.15 [‐0.06, 0.35]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Calcium channel blockers versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD002069.pub5/references#CD002069-tbl-0002">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD002069.pub5&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="de#CD002069-note-0001">Deutsch</a> </li> <li class="section-language"> <a class="" href="es#CD002069-note-0004">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD002069-note-0005">فارسی</a> </li> <li class="section-language"> <a class="" href="hr#CD002069-note-0003">Hrvatski</a> </li> <li class="section-language"> <a class="" href="ru#CD002069-note-0002">Русский</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD002069-note-0008">简体中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738735355000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738735355000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD002069\x2epub5\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD002069\x2epub5\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD002069\x2epub5\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD002069\x2epub5"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD002069\x2epub5\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD002069\x2epub5\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD002069\x2epub5\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD002069\x2epub5\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD002069\x2epub5\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD002069\x2epub5"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD002069\x2epub5\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD002069\x2epub5\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD002069\x2epub5\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD002069\x2epub5"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD002069\x2epub5\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD002069\x2epub5\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD002069\x2epub5\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD002069\x2epub5"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=afU96cMv&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD002069.pub5&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD002069.pub5';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD002069.pub5/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD002069.pub5/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD002069.pub5%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740715839016"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD002069.pub5/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740715839020"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD002069.pub5/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918d90e19b19f55f',t:'MTc0MDcxNTgzOS4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 